122320-73-4 | 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$11.00	$8.00
10mg	98%	in stock	$15.00	$11.00
50mg	98%	in stock	$21.00	$15.00
1g	98%	in stock	$27.00	$19.00
5g	98%	in stock	$89.00	$63.00
25g	98%	in stock	$246.00	$172.00

Description

• Catalog Number: AA55673
• Chemical Name: 5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
• CAS Number: 122320-73-4
• Molecular Formula: C18H19N3O3S
• Molecular Weight: 357.4268
• MDL Number: MFCD00871760
• SMILES: O=C1NC(=O)C(S1)Cc1ccc(cc1)OCCN(c1ccccn1)C
• NSC Number: 758698

Computed Properties

• Complexity: 469
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• Undefined Atom Stereocenter Count: 1
• XLogP3: 3.1

Upstream Synthesis Route

The compound 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione plays a crucial role in chemical synthesis as a versatile building block. Its unique molecular structure makes it a valuable intermediate in the creation of diverse organic compounds. This compound can be utilized in the synthesis of complex molecules for pharmaceuticals, agrochemicals, and materials science. The presence of the thiazolidine-2,4-dione moiety offers a reactive site for further functionalization, allowing for the introduction of various substituents to tailor the properties of the final compound. Additionally, the presence of the amino and pyridyl groups enables specific interactions and reactivity, expanding the potential applications of this compound in synthetic chemistry.

Literature

• Impairment of bisphenol F on the glucose metabolism of zebrafish larvae.

  Ecotoxicology and environmental safety 20181215

• An in vitro approach for prioritization and evaluation of chemical effects on glucocorticoid receptor mediated adipogenesis.

  Toxicology and applied pharmacology 20180915

• Involvement of insulin signalling pathway in methamphetamine-induced hyperphosphorylation of Tau.

  Toxicology 20180901

• Tributyltin induces a transcriptional response without a brite adipocyte signature in adipocyte models.

  Archives of toxicology 20180901

• Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells.

  Toxicology letters 20180701

• Inhibition of tumorigenesis by peroxisome proliferator-activated receptor (PPAR)-dependent cell cycle blocks in human skin carcinoma cells.

  Toxicology 20180701

• Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-γ and subsequent expression of HGF in colons.

  Toxicology and applied pharmacology 20180315

• Distinctive effects of licarin A on lipolysis mediated by PKA and on formation of brown adipocytes from C3H10T1/2 mesenchymal stem cells.

  Toxicology and applied pharmacology 20180201

• Neuroprotective activity of macamides on manganese-induced mitochondrial disruption in U-87 MG glioblastoma cells.

  Toxicology and applied pharmacology 20180201

• The high-production volume fungicide pyraclostrobin induces triglyceride accumulation associated with mitochondrial dysfunction, and promotes adipocyte differentiation independent of PPARγ activation, in 3T3-L1 cells.

  Toxicology 20180115

• From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate.

  Toxicological sciences : an official journal of the Society of Toxicology 20171201

• Exposure of Pregnant Mice to Triclosan Causes Insulin Resistance via Thyroxine Reduction.

  Toxicological sciences : an official journal of the Society of Toxicology 20171101

• Rosiglitazone promotes cardiac hypertrophy and alters chromatin remodeling in isolated cardiomyocytes.

  Toxicology letters 20171005

• Editor's Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis.

  Toxicological sciences : an official journal of the Society of Toxicology 20171001

• Methylparaben and butylparaben alter multipotent mesenchymal stem cell fates towards adipocyte lineage.

  Toxicology and applied pharmacology 20170815

• Curcumin inhibits adipogenesis induced by benzyl butyl phthalate in 3T3-L1 cells.

  Toxicology and applied pharmacology 20170815

• Inferring transcription factor activity from microarray data reveals novel targets for toxicological investigations.

  Toxicology 20170815

• Regulatory effects of 4-methoxychalcone on adipocyte differentiation through PPARγ activation and reverse effect on TNF-α in 3T3-L1 cells.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20170801

• Editor's Highlight: Thy1 (CD90) Expression is Reduced by the Environmental Chemical Tetrabromobisphenol-A to Promote Adipogenesis Through Induction of microRNA-103.

  Toxicological sciences : an official journal of the Society of Toxicology 20170601

• Regulation of the placental BCRP transporter by PPAR gamma.

  Journal of biochemical and molecular toxicology 20170501

• Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates.

  Archives of toxicology 20170301

• Editor's Highlight: Transgenic Zebrafish Reporter Lines as Alternative In Vivo Organ Toxicity Models.

  Toxicological sciences : an official journal of the Society of Toxicology 20170301

• Protective effect of rosiglitazone against acetaminophen-induced acute liver injury is associated with down-regulation of hepatic NADPH oxidases.

  Toxicology letters 20170104

• The unexpected teratogenicity of RXR antagonist UVI3003 via activation of PPARγ in Xenopus tropicalis.

  Toxicology and applied pharmacology 20170101

• Selective Tissue Distribution Mediates Tissue-Dependent PPARγ Activation and Insulin Sensitization by INT131, a Selective PPARγ Modulator.

  Frontiers in pharmacology 20170101

• Obesogenic and Diabetogenic Effects of High-Calorie Nutrition Require Adipocyte BK Channels.

  Diabetes 20161201

• PPAR-γ activation attenuates deltamethrin-induced apoptosis by regulating cytosolic PINK1 and inhibiting mitochondrial dysfunction.

  Toxicology letters 20161017

• Environmental Chemicals Modulate Polar Bear (Ursus maritimus) Peroxisome Proliferator-Activated Receptor Gamma (PPARG) and Adipogenesis in Vitro.

  Environmental science & technology 20161004

• Bisphenol S- and bisphenol A-induced adipogenesis of murine preadipocytes occurs through direct peroxisome proliferator-activated receptor gamma activation.

  International journal of obesity (2005) 20161001

• Thioredoxin-mimetic peptides (TXM) inhibit inflammatory pathways associated with high-glucose and oxidative stress.

  Free radical biology & medicine 20161001

• New brominated flame retardants and their metabolites as activators of the pregnane X receptor.

  Toxicology letters 20160930

• Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.

  Chemico-biological interactions 20160825

• Inhibition of Macrophage CD36 Expression and Cellular Oxidized Low Density Lipoprotein (oxLDL) Accumulation by Tamoxifen: A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)γ-DEPENDENT MECHANISM.

  The Journal of biological chemistry 20160812

• Inhibition of the acetyl lysine-binding pocket of bromodomain and extraterminal domain proteins interferes with adipogenesis.

  Biochemical and biophysical research communications 20160415

• Tungsten Promotes Sex-Specific Adipogenesis in the Bone by Altering Differentiation of Bone Marrow-Resident Mesenchymal Stromal Cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20160401

• Tributyltin induces G2/M cell cycle arrest via NAD(+)-dependent isocitrate dehydrogenase in human embryonic carcinoma cells.

  The Journal of toxicological sciences 20160401

• Effects of primary metabolites of organophosphate flame retardants on transcriptional activity via human nuclear receptors.

  Toxicology letters 20160314

• Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.

  The Journal of biological chemistry 20160205

• Effects of Crude Oil/Dispersant Mixture and Dispersant Components on PPARγ Activity in Vitro and in Vivo: Identification of Dioctyl Sodium Sulfosuccinate (DOSS; CAS #577-11-7) as a Probable Obesogen.

  Environmental health perspectives 20160101

• Ligand Activity of Group 15 Compounds Possessing Triphenyl Substituent for the RXR and PPARγ Nuclear Receptors.

  Biological & pharmaceutical bulletin 20160101

• Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period.

  Toxicology in vitro : an international journal published in association with BIBRA 20151225

• Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing.

  Toxicology in vitro : an international journal published in association with BIBRA 20151225

• Effect of diosgenin on metabolic dysfunction: Role of ERβ in the regulation of PPARγ.

  Toxicology and applied pharmacology 20151201

• Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.

  Toxicological sciences : an official journal of the Society of Toxicology 20151101

• Are zebrafish larvae suitable for assessing the hepatotoxicity potential of drug candidates?

  Journal of applied toxicology : JAT 20150901

• Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.

  Neuroscience 20150827

• Activation of Human Peroxisome Proliferator-Activated Nuclear Receptors (PPARγ1) by Semi-Volatile Compounds (SVOCs) and Chemical Mixtures in Indoor Dust.

  Environmental science & technology 20150818

• Multiparametric assay using HepaRG cells for predicting drug-induced liver injury.

  Toxicology letters 20150702

• Tributyltin engages multiple nuclear receptor pathways and suppresses osteogenesis in bone marrow multipotent stromal cells.

  Chemical research in toxicology 20150615

• Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships.

  Chemico-biological interactions 20150605

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice.

  Toxicology and applied pharmacology 20150515

• Structurally-diverse, PPARγ-activating environmental toxicants induce adipogenesis and suppress osteogenesis in bone marrow mesenchymal stromal cells.

  Toxicology 20150504

• The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-γ).

  Food & function 20150401

• Peroxisome proliferator-activated receptor γ controls ingestive behavior, agouti-related protein, and neuropeptide Y mRNA in the arcuate hypothalamus.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20150318

• Characterizing the peroxisome proliferator-activated receptor (PPARγ) ligand binding potential of several major flame retardants, their metabolites, and chemical mixtures in house dust.

  Environmental health perspectives 20150201

• Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.

  PloS one 20150101

• Rosiglitzone suppresses angiotensin II-induced production of KLF5 and cell proliferation in rat vascular smooth muscle cells.

  PloS one 20150101

• Differential effects of dexamethasone and rosiglitazone in a sephadex-induced model of lung inflammation in rats: possible role of tissue inhibitor of metalloproteinase-3.

  Indian journal of pharmacology 20150101

• Ligand binding and activation of PPARγ by Firemaster® 550: effects on adipogenesis and osteogenesis in vitro.

  Environmental health perspectives 20141101

• Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ.

  Toxicology and applied pharmacology 20140915

• Tumour necrosis factor-α promotes liver ischaemia-reperfusion injury through the PGC-1α/Mfn2 pathway.

  Journal of cellular and molecular medicine 20140901

• Toxicogenomics in the 3T3-L1 cell line, a new approach for screening of obesogenic compounds.

  Toxicological sciences : an official journal of the Society of Toxicology 20140801

• Rosiglitazone inhibits chlorpyrifos-induced apoptosis via modulation of the oxidative stress and inflammatory response in SH-SY5Y cells.

  Toxicology and applied pharmacology 20140715

• Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor α, β, γ subtypes: an in silico approach.

  Journal of applied toxicology : JAT 20140701

• Resveratrol and its metabolites bind to PPARs.

  Chembiochem : a European journal of chemical biology 20140526

• Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma.

  Antioxidants & redox signaling 20140520

• Tributyltin affects adipogenic cell fate commitment in mesenchymal stem cells by a PPARγ independent mechanism.

  Chemico-biological interactions 20140505

• Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20140401

• PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.

  Toxicology and applied pharmacology 20140401

• PPARγ activation rescues mitochondrial function from inhibition of complex I and loss of PINK1.

  Experimental neurology 20140301

• Long term intake of 0.1% ethanol decreases serum adiponectin by suppressing PPARγ expression via p38 MAPK pathway.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20140301

• The role of prolyl hydroxylase domain protein (PHD) during rosiglitazone-induced adipocyte differentiation.

  The Journal of biological chemistry 20140131

• A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.

  Toxicological sciences : an official journal of the Society of Toxicology 20140101

• CDK5-induced p-PPARγ(Ser 112) downregulates GFAP via PPREs in developing rat brain: effect of metal mixture and troglitazone in astrocytes.

  Cell death & disease 20140101

• Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.

  PloS one 20140101

• PPARγ agonists regulate tobacco smoke-induced Toll like receptor 4 expression in alveolar macrophages.

  Respiratory research 20140101

• 3,5-Dimethoxy-(4-methoxyphenyl)benzamide suppresses adipogenesis in 3T3-L1 cells.

  Acta poloniae pharmaceutica 20140101

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20131201

• A novel natural Nrf2 activator with PPARγ-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia.

  Toxicology and applied pharmacology 20131101

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Regulation of cigarette smoke-induced toll-like receptor 4 expression by peroxisome proliferator-activated receptor-gamma agonists in bronchial epithelial cells.

  Respirology (Carlton, Vic.) 20131101

• Correlation between activation of PPARγ and resistin downregulation in a mouse adipocyte cell line by a series of thiazolidinediones.

  Toxicology in vitro : an international journal published in association with BIBRA 20130801

• Perfluorooctane sulfonate induces neuronal and oligodendrocytic differentiation in neural stem cells and alters the expression of PPARγ in vitro and in vivo.

  Toxicology and applied pharmacology 20130515

• Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis.

  Molecular human reproduction 20130501

• Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.

  European journal of medicinal chemistry 20130501

• The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members.

  Basic & clinical pharmacology & toxicology 20130401

• Transgenerational inheritance of increased fat depot size, stem cell reprogramming, and hepatic steatosis elicited by prenatal exposure to the obesogen tributyltin in mice.

  Environmental health perspectives 20130301

• Rosiglitazone shows partial oncostatic effect in rat mammary carcinogenesis.

  Neoplasma 20130101

• Role of Peroxisome Proliferator-Activated Receptor β/δ and B-Cell Lymphoma-6 in Regulation of Genes Involved in Metastasis and Migration in Pancreatic Cancer Cells.

  PPAR research 20130101

• Sodium dodecyl sulfate and sodium dodecyl benzenesulfonate are ligands for peroxisome proliferator-activated receptor γ.

  The Journal of toxicological sciences 20130101

• Evaluation of a screening system for obesogenic compounds: screening of endocrine disrupting compounds and evaluation of the PPAR dependency of the effect.

  PloS one 20130101

• Wy14643 improves vascular function in the aorta of the spontaneously hypertensive rat mainly by activating peroxisome proliferator-activated receptors alpha.

  European journal of pharmacology 20121205

• Biodegradable anionic acrylic resin based hollow microspheres of moderately water soluble drug rosiglitazone maleate: preparation and in vitro characterization.

  Drug development and industrial pharmacy 20121201

• Rodent thyroid, liver, and fetal testis toxicity of the monoester metabolite of bis-(2-ethylhexyl) tetrabromophthalate (tbph), a novel brominated flame retardant present in indoor dust.

  Environmental health perspectives 20121201

• Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).

  Bioorganic & medicinal chemistry letters 20121201

• Triflumizole is an obesogen in mice that acts through peroxisome proliferator activated receptor gamma (PPARγ).

  Environmental health perspectives 20121201

• Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.

  Chinese medical journal 20121201

• PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.

  Diabetes, obesity & metabolism 20121101

• Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.

  Journal of psychiatry & neuroscience : JPN 20121101

• Entorhinal cortical neurons are the primary targets of FUS mislocalization and ubiquitin aggregation in FUS transgenic rats.

  Human molecular genetics 20121101

• The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation.

  American journal of respiratory cell and molecular biology 20121101

• Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin.

  American journal of physiology. Renal physiology 20121101

• Rosiglitazone negatively regulates c-Jun N-terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms.

  Atherosclerosis 20121101

• Quantitative whole-body MRI in familial partial lipodystrophy type 2: changes in adipose tissue distribution coincide with biochemical improvement.

  AJR. American journal of roentgenology 20121101

• Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models.

  Neuroscience letters 20121018

• An essential role for Tbx15 in the differentiation of brown and 'brite' but not white adipocytes.

  American journal of physiology. Endocrinology and metabolism 20121015

• Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents.

  Bioorganic & medicinal chemistry letters 20121015

• Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway.

  The Journal of biological chemistry 20121012

• Plakilactones from the marine sponge Plakinastrella mamillaris. Discovery of a new class of marine ligands of peroxisome proliferator-activated receptor γ.

  Journal of medicinal chemistry 20121011

• Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.

  Journal of medicinal chemistry 20121011

• The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats.

  Fundamental & clinical pharmacology 20121001

• A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study.

  Diabetes & metabolism 20121001

• Dynamic regulation of platelet-derived growth factor receptor α expression in alveolar fibroblasts during realveolarization.

  American journal of respiratory cell and molecular biology 20121001

• Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients.

  Diabetes research and clinical practice 20121001

• Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway.

  Neurochemical research 20121001

• Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?

  Diabetes technology & therapeutics 20121001

• Rosiglitazone promotes PPARγ-dependent and -independent alterations in gene expression in mouse islets.

  Endocrinology 20121001

• Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity.

  The Journal of pharmacology and experimental therapeutics 20121001

• Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial.

  Diabetologia 20121001

• Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

  Clinical therapeutics 20121001

• Effects of rosiglitazone treatment on insulin resistance and TNF-alpha levels in patients with chronic kidney disease: a prospective study.

  European review for medical and pharmacological sciences 20121001

• Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate-induced decrease in adiponectin synthesis in 3T3L1 adipocytes.

  Experimental & molecular medicine 20120930

• Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

  Journal of the National Cancer Institute 20120919

• Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.

  Toxicology letters 20120918

• Activation of PPARγ by restores mast cell numbers and reactivity in alloxan-diabetic rats by reducing the systemic glucocorticoid levels.

  European journal of pharmacology 20120915

• Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates postincisional pain by regulating macrophage polarization.

  Biochemical and biophysical research communications 20120914

• Resveratrol upregulates Nrf2 expression to attenuate methylglyoxal-induced insulin resistance in Hep G2 cells.

  Journal of agricultural and food chemistry 20120912

• Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20120904

• Rosiglitazone causes endothelial dysfunction in humans.

  Journal of cardiovascular pharmacology and therapeutics 20120901

• Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit.

  British journal of pharmacology 20120901

• Selective block of K(ATP) channels: why the anti-diabetic sulphonylureas and rosiglitazone have more in common than we thought.

  British journal of pharmacology 20120901

• Rosiglitazone protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity through inhibition of microglia activation.

  The International journal of neuroscience 20120901

• PPAR gamma activation protects the brain against microvascular dysfunction in sepsis.

  Microvascular research 20120901

• Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20120901

• Insulin sensitization with a peroxisome proliferator-activated receptor γ agonist prevents adrenocortical lipid infiltration and secretory changes induced by a high-sucrose diet.

  The Journal of endocrinology 20120901

• Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosteres as PPARγ agonists.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20120901

• Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?

  Thrombosis and haemostasis 20120901

• Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.

  Advances in therapy 20120901

• [The effects of rosiglitazone combined ceftazidime on peroxisome proliferator activated receptor γ activity and interleukin in septic rats].

  Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20120901

• Ursolic acid and rosiglitazone combination alleviates metabolic syndrome in high fat diet fed C57BL/6J mice.

  General physiology and biophysics 20120901

• Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.

  Archives of pharmacal research 20120901

• MDG-1, a polysaccharide from Ophiopogon japonicus exerts hypoglycemic effects through the PI3K/Akt pathway in a diabetic KKAy mouse model.

  Journal of ethnopharmacology 20120830

• In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.

  Chemical research in toxicology 20120820

• Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats.

  European journal of pharmacology 20120815

• Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.

  Free radical biology & medicine 20120815

• Design and synthesis of marine fungal phthalide derivatives as PPAR-γ agonists.

  Bioorganic & medicinal chemistry 20120815

• Effectiveness of rosiglitazone on bleomycin-induced lung fibrosis: Assessed by micro-computed tomography and pathologic scores.

  European journal of radiology 20120801

• Peroxisome proliferator-activated receptor α (PPARα) activation advances locomotor activity and feeding daily rhythms in mice.

  International journal of obesity (2005) 20120801

• Rosiglitazone attenuates activation of human Tenon's fibroblasts induced by transforming growth factor-β1.

  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20120801

• The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

  British journal of clinical pharmacology 20120801

• Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.

  Inflammation 20120801

• Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet.

  Clinical science (London, England : 1979) 20120801

• The role of ribosylated-BSA in regulating PC12 cell viability.

  Cell biology and toxicology 20120801

• Early induction of a brown-like phenotype by rosiglitazone in the epicardial adipose tissue of fatty Zucker rats.

  Biochimie 20120801

• Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.

  Clinical and experimental pharmacology & physiology 20120801

• Rosiglitazone treatment reduces hippocampal neuronal damage possibly through alleviating oxidative stress in chronic cerebral hypoperfusion.

  Neurochemistry international 20120801

• Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer.

  Cytokine 20120801

• Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice.

  Molecular nutrition & food research 20120801

• Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.

  European journal of medicinal chemistry 20120801

• Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease.

  Coronary artery disease 20120801

• Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation.

  Calcified tissue international 20120801

• [Reduced expression and secretion of apolipoprotein M in fat-fed, streptozotocin-diabetic rats is partially reversed by an artificial ligand of PPARγ].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20120801

• Two centuries of assessing drug risks.

  The New England journal of medicine 20120719

• Rosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells.

  American journal of physiology. Cell physiology 20120715

• Cardioprotection from oxidative stress in the newborn heart by activation of PPARγ is mediated by catalase.

  Free radical biology & medicine 20120715

• Synthesis of novel imbricatolic acid analogues via insertion of N-substituted piperazine at C-15/C-19 positions, displaying glucose uptake stimulation in L6 skeletal muscle cells.

  Bioorganic & medicinal chemistry letters 20120715

• Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.

  Archives of internal medicine 20120709

• Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.

  The Journal of biological chemistry 20120706

• A comparison of the effect of glitazones on serum sialic acid in patients with type 2 diabetes.

  Diabetes & vascular disease research 20120701

• Effects of rosiglitazone on the cardiovascular profile in postmenopausal women without diabetes mellitus: interplay of thiazolidinediones and hormone therapy.

  Menopause (New York, N.Y.) 20120701

• The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.

  Toxicologic pathology 20120701

• Stromal adipocyte PPARγ protects against breast tumorigenesis.

  Carcinogenesis 20120701

• Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.

  British journal of clinical pharmacology 20120701

• The use of the peroxisome proliferator-activated receptors γ agonist rosiglitazone to treat airway hyperreactivity.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20120701

• Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expression of fatty acid desaturases 1 and 2 and modulate response to simvastatin.

  Prostaglandins, leukotrienes, and essential fatty acids 20120701

• Bisphenol A diglycidyl ether induces adipogenic differentiation of multipotent stromal stem cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.

  Environmental health perspectives 20120701

• [Effects of ursolic acid in ameliorating insulin resistance in liver of KKAy mice via peroxisome proliferator-activated receptors α and γ].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20120701

• Formulation parameters influencing the physicochemical characteristics of rosiglitazone-loaded cationic lipid emulsion.

  Archives of pharmacal research 20120701

• Antihyperglycemic agents from Ammannia multiflora.

  Natural product communications 20120701

• Rosiglitazone suppresses lipopolysaccharide-induced matrix metalloproteinase-2 activity in rat aortic endothelial cells via Ras-MEK1/2 signaling.

  International journal of cardiology 20120628

• IOM urges FDA to be more aggressive in monitoring safety of approved drugs.

  JAMA 20120620

• Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.

  European journal of pharmacology 20120615

• Synthesis of chalcone derivatives as potential anti-diabetic agents.

  Bioorganic & medicinal chemistry letters 20120615

• Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.

  Cell cycle (Georgetown, Tex.) 20120615

• A clinical trial to maintain glycemic control in youth with type 2 diabetes.

  The New England journal of medicine 20120614

• TODAY--a stark glimpse of tomorrow.

  The New England journal of medicine 20120614

• Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.

  Journal of medicinal chemistry 20120614

• Ascofuranone stimulates expression of adiponectin and peroxisome proliferator activated receptor through the modulation of mitogen activated protein kinase family members in 3T3-L1, murine pre-adipocyte cell line.

  Biochemical and biophysical research communications 20120608

• The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20120601

• Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).

  Current molecular pharmacology 20120601

• Assessment of cardiac safety for PPARγ agonists in rodent models of heart failure: a translational medicine perspective.

  Current molecular pharmacology 20120601

• Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats: attenuation of diabetic nephropathy in rats.

  Journal of physiology and biochemistry 20120601

• Transcriptional regulation of methionine adenosyltransferase 2A by peroxisome proliferator-activated receptors in rat hepatic stellate cells.

  Hepatology (Baltimore, Md.) 20120601

• Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats.

  The Journal of pharmacology and experimental therapeutics 20120601

• Mode of peroxisome proliferator-activated receptor γ activation by luteolin.

  Molecular pharmacology 20120601

• Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.

  Experimental neurology 20120601

• Protocol for effective differentiation of 3T3-L1 cells to adipocytes.

  Analytical biochemistry 20120601

• Effects of peroxisome proliferator-activated receptor-γ agonists on the generation of microparticles by monocytes/macrophages.

  Cardiovascular research 20120601

• Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.

  Cardiovascular drugs and therapy 20120601

• Developmental programming: prenatal and postnatal contribution of androgens and insulin in the reprogramming of estradiol positive feedback disruptions in prenatal testosterone-treated sheep.

  Endocrinology 20120601

• Major involvement of mTOR in the PPARγ-induced stimulation of adipose tissue lipid uptake and fat accretion.

  Journal of lipid research 20120601

• Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle.

  Molecular endocrinology (Baltimore, Md.) 20120601

• Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

  Drug safety 20120601

• Fibrates: therapeutic potential for diabetic nephropathy?

  European journal of internal medicine 20120601

• Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study.

  Current medical research and opinion 20120601

• Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.

  Diabetes technology & therapeutics 20120601

• Flavone-based novel antidiabetic and antidyslipidemic agents.

  Journal of medicinal chemistry 20120524

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Discovery and characterization of an inhibitor of glucosylceramide synthase.

  Journal of medicinal chemistry 20120510

• Estimation of financial burden due to oversupply of medications for chronic diseases.

  Asia-Pacific journal of public health 20120501

• Not only accumulation, but also saturation status of intramuscular lipids is significantly affected by PPARγ activation.

  Acta physiologica (Oxford, England) 20120501

• Rosiglitazone reverses mitomycin C resistance in human gastric cancer cells.

  The American journal of the medical sciences 20120501

• Lipopolysaccharide represses the expression of ATP-binding cassette transporter G1 and scavenger receptor class B, type I in murine macrophages.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20120501

• Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice.

  Journal of psychopharmacology (Oxford, England) 20120501

• Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.

  American journal of physiology. Endocrinology and metabolism 20120501

• High-dose rosiglitazone is pro-atherogenic in cholesterol-fed rabbits.

  Atherosclerosis 20120501

• β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.

  The Journal of endocrinology 20120501

• Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator-activated receptor gamma (PPARγ).

  The Journal of pharmacy and pharmacology 20120501

• Study of hypoglycemic activity of Subetta and rosiglitazone on the model of streptozotocin-induced diabetes mellitus in rats.

  Bulletin of experimental biology and medicine 20120501

• Isoprenylated flavonoid and adipogenesis-promoting constituents of Dodonaea viscosa.

  Journal of natural products 20120427

• PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.

  British journal of cancer 20120424

• Bromophenols as inhibitors of protein tyrosine phosphatase 1B with antidiabetic properties.

  Bioorganic & medicinal chemistry letters 20120415

• Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells.

  Journal of endocrinological investigation 20120401

• A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20120401

• Rosiglitazone enhances learning, place cell activity, and synaptic plasticity in middle-aged rats.

  Neurobiology of aging 20120401

• Anti-inflammatory mechanism of PPARγ on LPS-induced pulp cells: role of the ROS removal activity.

  Archives of oral biology 20120401

• Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice.

  Arthritis and rheumatism 20120401

• The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial.

  Diabetes & vascular disease research 20120401

• 2-hydroxy-4'-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma.

  Journal of cardiovascular pharmacology 20120401

• Functional analysis of pig myostatin gene promoter with some adipogenesis- and myogenesis-related factors.

  Molecular and cellular biochemistry 20120401

• Comparative effectiveness of incident oral antidiabetic drugs on kidney function.

  Kidney international 20120401

• 25-Hydroxycholesterol-3-sulfate attenuates inflammatory response via PPARγ signaling in human THP-1 macrophages.

  American journal of physiology. Endocrinology and metabolism 20120401

• Metformin prevents the development of chronic heart failure in the SHHF rat model.

  Diabetes 20120401

• Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.

  Drug safety 20120401

• The design of the liraglutide clinical trial programme.

  Diabetes, obesity & metabolism 20120401

• Rosiglitazone prior authorization safety policy: a cohort study.

  Journal of managed care pharmacy : JMCP 20120401

• [Protective effect of rosiglitazone against hyperoxia-induced lung injury in neonatal rats].

  Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 20120401

• Synthesis of propiophenone derivatives as new class of antidiabetic agents reducing body weight in db/db mice.

  Bioorganic & medicinal chemistry 20120315

• Synthesis and antidiabetic performance of β-amino ketone containing nabumetone moiety.

  Bioorganic & medicinal chemistry 20120315

• PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein.

  Cell metabolism 20120307

• Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).

  The international journal of cardiovascular imaging 20120301

• Rosiglitazone improves spatial memory and decreases insoluble Aβ(1-42) in APP/PS1 mice.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120301

• Cloning, structural characterization and expression analysis of a novel lipid storage droplet protein-1 (LSD-1) gene in Chinese honeybee (Apis cerana cerana).

  Molecular biology reports 20120301

• Intermittent fasting up-regulates Fsp27/Cidec gene expression in white adipose tissue.

  Nutrition (Burbank, Los Angeles County, Calif.) 20120301

• PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.

  International journal of oncology 20120301

• Anti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway.

  Cell biology international 20120301

• Postnatal rosiglitazone administration to neonatal rat pups does not alter the young adult metabolic phenotype.

  Neonatology 20120301

• Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.

  Diabetes/metabolism research and reviews 20120301

• Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton-dependent PepT1 transporter.

  Molecular pharmacology 20120301

• Rosiglitazone ameliorates the histological parameters of the dorsal root ganglion and functional assessment after sciatic nerve injury in the rat.

  Acta neurochirurgica 20120301

• Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

  American journal of physiology. Renal physiology 20120301

• Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice.

  American journal of physiology. Gastrointestinal and liver physiology 20120301

• Peroxisome proliferator-activated receptor-γ activation induces 11β-hydroxysteroid dehydrogenase type 1 activity in human alternative macrophages.

  Arteriosclerosis, thrombosis, and vascular biology 20120301

• Physiological responses to acute psychological stress are reduced by the PPARγ agonist rosiglitazone.

  Endocrinology 20120301

• Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging.

  Clinical nuclear medicine 20120301

• Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study.

  Clinics (Sao Paulo, Brazil) 20120301

• The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption.

  Molecules and cells 20120227

• [Physicians and drug industry].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20120221

• The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats.

  Regulatory peptides 20120210

• Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

  Cell 20120203

• PPAR-gamma agonist rosiglitazone attenuates the inflammation caused by carrageenan in the mouse model of pleurisy.

  Inflammation 20120201

• Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes.

  Bone 20120201

• Autocrine activation of human monocyte/macrophages by monocyte-derived microparticles and modulation by PPARγ ligands.

  British journal of pharmacology 20120201

• PPARγ ligands regulate NADPH oxidase, eNOS, and barrier function in the lung following chronic alcohol ingestion.

  Alcoholism, clinical and experimental research 20120201

• Reduction by strontium of the bone marrow adiposity in mice and repression of the adipogenic commitment of multipotent C3H10T1/2 cells.

  Bone 20120201

• Preparation and evaluation of hepatic stellate cell selective, surface conjugated, peroxisome proliferator-activated receptor-gamma ligand loaded liposomes.

  Journal of drug targeting 20120201

• Glyceollin-containing fermented soybeans improve glucose homeostasis in diabetic mice.

  Nutrition (Burbank, Los Angeles County, Calif.) 20120201

• Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype.

  Journal of molecular and cellular cardiology 20120201

• Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.

  Diabetes, obesity & metabolism 20120201

• Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120201

• The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment.

  The international journal of neuropsychopharmacology 20120201

• Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.

  Bioorganic & medicinal chemistry letters 20120201

• Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.

  The Annals of pharmacotherapy 20120201

• Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China.

  Biomedical and environmental sciences : BES 20120201

• The intervention effect of Rosiglitozone in ovarian fibrosis of PCOS rats.

  Biomedical and environmental sciences : BES 20120201

• Hypoglycemic effect and mechanism of a proteoglycan from ganoderma lucidum on streptozotocin-induced type 2 diabetic rats.

  European review for medical and pharmacological sciences 20120201

• Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition.

  Bioorganic & medicinal chemistry 20120115

• An alternative synthetic route for an antidiabetic drug, rosiglitazone.

  Bioorganic & medicinal chemistry letters 20120115

• Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.

  Journal of medicinal chemistry 20120112

• Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.

  ACS medicinal chemistry letters 20120112

• Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.

  Structure (London, England : 1993) 20120111

• Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP.

  Neurobiology of aging 20120101

• Multi-objective optimization strategy based on desirability functions used for electrophoratic separation and quantification of rosiglitazone and glimepiride in plasma and formulations.

  Drug testing and analysis 20120101

• Rosiglitazone attenuates tumor necrosis factor-α-induced protein-tyrosine phosphatase-1B production in HepG2 cells.

  Journal of endocrinological investigation 20120101

• Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist.

  British journal of pharmacology 20120101

• Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.

  Research in social & administrative pharmacy : RSAP 20120101

• Rosiglitazone increases fatty acid Δ9-desaturation and decreases elongase activity index in human skeletal muscle in vivo.

  Metabolism: clinical and experimental 20120101

• Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-γ ligands via Wnt signaling pathway.

  Cell biochemistry and biophysics 20120101

• PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.

  Neurobiology of disease 20120101

• Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20120101

• Rosiglitazone reverses increased duodenal inhibitory response in spontaneously hypertensive rats.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20120101

• Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice.

  Planta medica 20120101

• Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.

  Diabetologia 20120101

• TGF-β mediates suppression of adipogenesis by estradiol through connective tissue growth factor induction.

  Endocrinology 20120101

• The influence of peroxisome proliferator-activated receptor γ(1) during differentiation of mouse embryonic stem cells to neural cells.

  Differentiation; research in biological diversity 20120101

• PPARγ agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets.

  Endocrinology 20120101

• Regulation of LYRM1 gene expression by free fatty acids, adipokines, and rosiglitazone in 3T3-L1 adipocytes.

  Experimental diabetes research 20120101

• PPAR-γ agonists, mainly 15d-PGJ(2), reduce eosinophil recruitment following allergen challenge.

  Cellular immunology 20120101

• Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.

  International journal of clinical pharmacology and therapeutics 20120101

• AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.

  Acta pharmacologica Sinica 20120101

• A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.

  Biological & pharmaceutical bulletin 20120101

• State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning.

  Health affairs (Project Hope) 20120101

• Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.

  Current topics in medicinal chemistry 20120101

• Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ.

  PloS one 20120101

• Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis.

  PloS one 20120101

• HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes.

  Antiviral therapy 20120101

• [Puerarin combined with avandia for diabetic nephropathy].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20120101

• Activation of protein kinase A and exchange protein directly activated by cAMP promotes adipocyte differentiation of human mesenchymal stem cells.

  PloS one 20120101

• Activation of peroxisome proliferator-activated receptor-gamma by glitazones reduces the expression and release of monocyte chemoattractant protein-1 in human mesothelial cells.

  Mediators of inflammation 20120101

• Regulation of chemokine and chemokine receptor expression by PPARγ in adipocytes and macrophages.

  PloS one 20120101

• The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes.

  PloS one 20120101

• Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.

  PloS one 20120101

• Rosiglitazone modulates the behaviors of diabetic host-derived fibroblasts in a carboxymethyllysine-modified collagen model.

  Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 20120101

• The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model.

  Journal of cardiothoracic surgery 20120101

• Peroxisome proliferator-activated receptor gamma modulation and lipogenic response in adipocytes of small-for-gestational age offspring.

  Nutrition & metabolism 20120101

• Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.

  Revista da Associacao Medica Brasileira (1992) 20120101

• After avandia: the use of antidiabetic drugs in patients with heart failure.

  Texas Heart Institute journal 20120101

• The rosiglitazone decision process at FDA and EMA. What should we learn?

  The International journal of risk & safety in medicine 20120101

• Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells.

  PloS one 20120101

• Higher levels of ATGL are associated with exercise-induced enhancement of lipolysis in rat epididymal adipocytes.

  PloS one 20120101

• Rosiglitazone improves survival and hastens recovery from pancreatic inflammation in obese mice.

  PloS one 20120101

• Effects of rosiglitazone with insulin combination therapy on oxidative stress and lipid profile in left ventricular muscles of diabetic rats.

  Experimental diabetes research 20120101

• Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy.

  HIV clinical trials 20120101

• Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.

  Journal of medical economics 20120101

• Preservation of metabolic flexibility in skeletal muscle by a combined use of n-3 PUFA and rosiglitazone in dietary obese mice.

  PloS one 20120101

• PPAR-γ regulates carnitine homeostasis and mitochondrial function in a lamb model of increased pulmonary blood flow.

  PloS one 20120101

• Negative regulation of adipogenesis by kaempferol, a component of Rhizoma Polygonati falcatum in 3T3-L1 cells.

  Biological & pharmaceutical bulletin 20120101

• [Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus].

  Terapevticheskii arkhiv 20120101

• The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells.

  Nature communications 20120101

• In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist.

  PPAR research 20120101

• Human BAT possesses molecular signatures that resemble beige/brite cells.

  PloS one 20120101

• Decreased hepatic peroxisome proliferator-activated receptor-γ contributes to increased sensitivity to endotoxin in obstructive jaundice.

  World journal of gastroenterology 20111228

• Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

  Journal of medicinal chemistry 20111222

• [Investigation of amylin level changes among obese patients at different glucose metabolic states and effects of rosiglitazone intervention].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20111218

• N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.

  The Journal of biological chemistry 20111202

• The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus.

  Acta diabetologica 20111201

• Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.

  British journal of pharmacology 20111201

• Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients.

  Basic & clinical pharmacology & toxicology 20111201

• Is rosiglitazone use associated with an increase in intensive eye treatment in diabetic patients? A community based study.

  The European journal of general practice 20111201

• PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells.

  Cardiovascular research 20111201

• The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo.

  American journal of physiology. Lung cellular and molecular physiology 20111201

• Pioglitazone is a valid alternative to rosiglitazone.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20111201

• Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice.

  Biochimica et biophysica acta 20111201

• Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis.

  Diabetes 20111201

• Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

  The Journal of clinical investigation 20111201

• Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia.

  Cancer biology & therapy 20111201

• Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

  Clinical therapeutics 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• [PPARgamma agonists against respiratory syncytial virus infection in vitro study].

  Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology 20111201

• GlaxoSmithKline pays $3bn to settle dispute over rosiglitazone and other drugs.

  BMJ (Clinical research ed.) 20111107

• Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111101

• Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.

  Hepatology (Baltimore, Md.) 20111101

• PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice.

  Thrombosis research 20111101

• Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation.

  American journal of physiology. Endocrinology and metabolism 20111101

• Rosiglitazone protects diabetic rats from liver destruction.

  Journal of endocrinological investigation 20111101

• Effect of synthetic ligands of PPAR α, β/δ, γ, RAR, RXR and LXR on the fatty acid composition of phospholipids in mice.

  Lipids 20111101

• Elevated circulating vaspin levels were decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone.

  Cytokine 20111101

• Opposing actions of rosiglitazone and resveratrol on mineralization in human vascular smooth muscle cells.

  Journal of molecular and cellular cardiology 20111101

• Neuroprotection by rosiglitazone in transient focal cerebral ischemia might not be mediated by glutamate transporter-1.

  Journal of neuroscience research 20111101

• Decreased STAMP2 expression in association with visceral adipose tissue dysfunction.

  The Journal of clinical endocrinology and metabolism 20111101

• Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?

  Hepatology (Baltimore, Md.) 20111101

• Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease.

  The Annals of pharmacotherapy 20111101

• Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

  Health technology assessment (Winchester, England) 20111101

• Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.

  Neuroscience 20111027

• Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCl3.

  The Journal of organic chemistry 20111021

• Stabilization of superoxide dismutase by acetyl-l-carnitine in human brain endothelium during alcohol exposure: novel protective approach.

  Free radical biology & medicine 20111015

• Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats.

  European journal of pharmacology 20111015

• Early atheroma-derived agonists of peroxisome proliferator-activated receptor-γ trigger intramedial angiogenesis in a smooth muscle cell-dependent manner.

  Circulation research 20111014

• Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury.

  Neuroscience letters 20111010

• Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.

  Breast cancer research and treatment 20111001

• Curcumin inhibits adipocyte differentiation through modulation of mitotic clonal expansion.

  The Journal of nutritional biochemistry 20111001

• The environmental obesogen tributyltin chloride acts via peroxisome proliferator activated receptor gamma to induce adipogenesis in murine 3T3-L1 preadipocytes.

  The Journal of steroid biochemistry and molecular biology 20111001

• Nrf2-dependent gene expression is affected by the proatherogenic apoE4 genotype-studies in targeted gene replacement mice.

  Journal of molecular medicine (Berlin, Germany) 20111001

• Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells.

  American journal of physiology. Gastrointestinal and liver physiology 20111001

• Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome.

  Endocrine 20111001

• Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones.

  American journal of physiology. Heart and circulatory physiology 20111001

• 11-Hydroxy-β-steroid dehydrogenase gene expression in canine adipose tissue and adipocytes: stimulation by lipopolysaccharide and tumor necrosis factor α.

  Domestic animal endocrinology 20111001

• Trans-10, cis-12 conjugated linoleic acid and the PPAR-γ agonist rosiglitazone attenuate lipopolysaccharide-induced TNF-α production by bovine immune cells.

  Domestic animal endocrinology 20111001

• Fixed dose combination diabetes medicines - usage in the Australian veteran population.

  Australian family physician 20111001

• Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients.

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20111001

• [Effects of rosiglitazone on peroxisome proliferator activated receptor-γ pathway in patients with chronic obstructive pulmonary disease].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20111001

• Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats.

  Neuroscience 20110929

• Synthesis of a new [6]-gingerol analogue and its protective effect with respect to the development of metabolic syndrome in mice fed a high-fat diet.

  Journal of medicinal chemistry 20110922

• Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

  Nature 20110922

• A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET.

  Bioorganic & medicinal chemistry letters 20110915

• SAR studies of acidic dual γ-secretase/PPARγ modulators.

  Bioorganic & medicinal chemistry 20110915

• Development and validation of a UPLC-MS/MS method for quantification of SKLB010, an investigational anti-inflammatory compound, and its application to pharmacokinetic studies in beagle dogs.

  Journal of pharmaceutical and biomedical analysis 20110910

• Protective effect of the peroxisome proliferator-activated receptor (PPAR)-γ, ligand rosiglitazone on tert-butyl hydroperoxide-induced QZG cell injury.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20110901

• In vitro characterization of rosiglitazone metabolites and determination of the kinetic parameters employing rat liver microsomal fraction.

  European journal of drug metabolism and pharmacokinetics 20110901

• Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20110901

• Anti-stroke profile of thiazolidin-4-one derivatives in focal cerebral ischemia model in rat.

  Chemical biology & drug design 20110901

• Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice.

  American journal of physiology. Heart and circulatory physiology 20110901

• Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.

  The Journal of endocrinology 20110901

• Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.

  Drug metabolism and disposition: the biological fate of chemicals 20110901

• PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway.

  Cytokine 20110901

• Selenium levels affect the IL-4-induced expression of alternative activation markers in murine macrophages.

  The Journal of nutrition 20110901

• Immunopathogenesis of falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria.

  Expert review of anti-infective therapy 20110901

• Kaiyuqingre formula improves insulin secretion via regulating uncoupling protein-2 and KATP channel.

  Chinese medical journal 20110901

• The DLK gene is a transcriptional target of PPARγ.

  The Biochemical journal 20110815

• Selenoprotein-dependent up-regulation of hematopoietic prostaglandin D2 synthase in macrophages is mediated through the activation of peroxisome proliferator-activated receptor (PPAR) gamma.

  The Journal of biological chemistry 20110805

• The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development.

  Anesthesia and analgesia 20110801

• Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ.

  British journal of pharmacology 20110801

• Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies.

  Current Alzheimer research 20110801

• Characterization of novel ligands of ERα, Erβ, and PPARγ: the case of halogenated bisphenol A and their conjugated metabolites.

  Toxicological sciences : an official journal of the Society of Toxicology 20110801

• Organotins are potent activators of PPARγ and adipocyte differentiation in bone marrow multipotent mesenchymal stromal cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20110801

• Effect of rosiglitazone on cardiac electrophysiology, infarct size and mitochondrial function in ischaemia and reperfusion of swine and rat heart.

  Experimental physiology 20110801

• Neuroprotective efficacy of the peroxisome proliferator-activated receptor-γ ligand in chronic cerebral hypoperfusion.

  Current neurovascular research 20110801

• The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis.

  Fertility and sterility 20110801

• Peroxisome proliferator-activated receptor-γ as a potential therapeutic target in the treatment of preeclampsia.

  Hypertension (Dallas, Tex. : 1979) 20110801

• Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients.

  Current medical research and opinion 20110801

• The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome--a double-blind randomized placebo-controlled study.

  Fertility and sterility 20110801

• New isoprenylated flavonoids and adipogenesis-promoting constituents from Morus notabilis.

  Bioorganic & medicinal chemistry letters 20110801

• Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury.

  Acta pharmacologica Sinica 20110801

• Bid as a potential target of apoptotic effects exerted by low doses of PPARγ and RXR ligands in breast cancer cells.

  Cell cycle (Georgetown, Tex.) 20110715

• The long Avandia endgame.

  Lancet (London, England) 20110709

• Adiponectin is required for PPARγ-mediated improvement of endothelial function in diabetic mice.

  Cell metabolism 20110706

• Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells.

  American journal of respiratory cell and molecular biology 20110701

• PPARγ agonist suppresses TLR4 expression and TNF-α production in LPS stimulated monocyte leukemia cells.

  Cell biochemistry and biophysics 20110701

• Stable reporter cell lines for peroxisome proliferator-activated receptor γ (PPARγ)-mediated modulation of gene expression.

  Analytical biochemistry 20110701

• Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.

  Diabetes research and clinical practice 20110701

• Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.

  Drug metabolism and disposition: the biological fate of chemicals 20110701

• 15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma.

  Molecular pharmacology 20110701

• Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.

  Toxicology and applied pharmacology 20110701

• Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes.

  Diabetes research and clinical practice 20110701

• Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone.

  American journal of physiology. Lung cellular and molecular physiology 20110701

• Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin.

  Diabetes & vascular disease research 20110701

• Protective effects of rosiglitazone on retinal neuronal damage in diabetic rats.

  Current eye research 20110701

• Rosiglitazone REMS arrives in November.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110701

• Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.

  Diabetes care 20110701

• What's next for diabetes prevention?

  Diabetes care 20110701

• Effect of silybin on high-fat-induced fatty liver in rats.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20110701

• A study comparing the effects of rosiglitazone and/or insulin treatments on streptozotocin induced diabetic (type I diabetes) rat aorta and cavernous tissues.

  European journal of pharmacology 20110625

• Therapeutic potential of peroxisome proliferator-activated receptor γ agonist rosiglitazone in cerebral vasospasm after a rat experimental subarachnoid hemorrhage model.

  Journal of the neurological sciences 20110615

• Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.

  Cancer biology & therapy 20110615

• Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells.

  Experimental cell research 20110610

• Intensive glucose lowering and cardiovascular outcomes.

  The New England journal of medicine 20110609

• Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study.

  Metabolism: clinical and experimental 20110601

• Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.

  Metabolism: clinical and experimental 20110601

• Role of NF-kappaB and PPAR-gamma in lung inflammation induced by monocyte-derived microparticles.

  The European respiratory journal 20110601

• Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation.

  British journal of pharmacology 20110601

• Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells.

  British journal of pharmacology 20110601

• Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes.

  Clinical and experimental pharmacology & physiology 20110601

• Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte.

  Toxicology in vitro : an international journal published in association with BIBRA 20110601

• Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels.

  Molecular pharmacology 20110601

• Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease.

  European journal of medicinal chemistry 20110601

• Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity.

  American journal of physiology. Renal physiology 20110601

• PPAR-γ signaling and IL-5 inhibition together prevent chronic rejection of MHC Class II-mismatched cardiac grafts.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20110601

• Incidence of diabetes following ramipril or rosiglitazone withdrawal.

  Diabetes care 20110601

• Novel ligands that target the mitochondrial membrane protein mitoNEET.

  Journal of molecular graphics & modelling 20110601

• Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone.

  British journal of pharmacology 20110601

• Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.

  Diabetes care 20110601

• Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?

  Clinical pharmacology and therapeutics 20110601

• Rosiglitazone and the risk of adverse cardiovascular outcomes.

  Clinical pharmacology and therapeutics 20110601

• [The semi-quantitative method for evaluating lipid accumulation in pancreas of diabetic mice].

  Yao xue xue bao = Acta pharmaceutica Sinica 20110601

• Recent diabetes issues affecting the primary care clinician.

  Southern medical journal 20110601

• Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20110601

• Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.

  The Journal of biological chemistry 20110527

• Simple HPLC method for determination of rosiglitazone in sheep plasma and amniotic fluid and its application in a pregnant sheep model.

  Journal of pharmaceutical and biomedical analysis 20110515

• Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.

  Bioorganic & medicinal chemistry letters 20110515

• Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.

  Bioorganic & medicinal chemistry 20110515

• Electrophilic fatty acids regulate matrix metalloproteinase activity and expression.

  The Journal of biological chemistry 20110506

• Differential effects of advanced glycation end-products on renal tubular cell inflammation.

  Nephrology (Carlton, Vic.) 20110501

• The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-α and free fatty acids.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20110501

• Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.

  The Journal of clinical endocrinology and metabolism 20110501

• Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.

  Current medical research and opinion 20110501

• PPARγ agonist rosiglitazone prevents perinatal nicotine exposure-induced asthma in rat offspring.

  American journal of physiology. Lung cellular and molecular physiology 20110501

• The safety of thiazolidinediones.

  Expert opinion on drug safety 20110501

• Rosiglitazone decreases bone mass and bone marrow fat.

  The Journal of clinical endocrinology and metabolism 20110501

• Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure.

  Circulation. Heart failure 20110501

• Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.

  Diabetes 20110501

• Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

  Clinical journal of the American Society of Nephrology : CJASN 20110501

• Determination of rosiglitazone and metformin in human serum by CE-ESI-MS.

  Journal of separation science 20110501

• Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

  International journal of clinical practice 20110501

• A role for central nervous system PPAR-γ in the regulation of energy balance.

  Nature medicine 20110501

• Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.

  Nature medicine 20110501

• [Glycemic control and cardiovascular benefit: what do we know today?].

  Deutsche medizinische Wochenschrift (1946) 20110501

• [Expression of Galectin-9 and Tim-3 in lungs of mice with asthma].

  Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 20110501

• Wild bitter gourd extract up-regulates mRNA expression of PPARα, PPARγ and their target genes in C57BL/6J mice.

  Journal of ethnopharmacology 20110426

• Isoprenylated flavonoids and adipogenesis-promoting constituents from Morus nigra.

  Journal of natural products 20110425

• Rosiglitazone saga. Should we throw the baby out with the bathwater?

  BMJ (Clinical research ed.) 20110421

• Rosiglitazone saga. Demonisation of rosiglitazone.

  BMJ (Clinical research ed.) 20110421

• Rosiglitazone promotes pancreatic regeneration in experimental model of acute pancreatitis.

  Fundamental & clinical pharmacology 20110401

• The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.

  Journal of cellular and molecular medicine 20110401

• Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation confers functional neuroprotection in global ischemia.

  Neurotoxicity research 20110401

• Mechanism for nicotine-induced up-regulation of Wnt signaling in human alveolar interstitial fibroblasts.

  Experimental lung research 20110401

• Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice.

  Pharmacological research 20110401

• Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo.

  Drug metabolism and disposition: the biological fate of chemicals 20110401

• Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking.

  Biological psychiatry 20110401

• HL005--a new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7.

  The Journal of steroid biochemistry and molecular biology 20110401

• Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20110401

• Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study.

  Clinical pharmacology and therapeutics 20110401

• Contending mediated risk messages: a grounded theory of the physician-patient discussion of a prescription medication's changing risk.

  Patient education and counseling 20110401

• Mitochondrial function in skeletal muscle in type 2 diabetes.

  Danish medical bulletin 20110401

• Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.

  Archives of pharmacal research 20110401

• Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment.

  Diabetes & vascular disease research 20110401

• Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.

  Diabetes & vascular disease research 20110401

• HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20110401

• Identification of the target proteins of rosiglitazone in 3T3-L1 adipocytes through proteomic analysis of cytosolic and secreted proteins.

  Molecules and cells 20110331

• Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia.

  Journal of pharmaceutical and biomedical analysis 20110325

• Inhibitory effect of leptin on rosiglitazone-induced differentiation of primary adipocytes prepared from TallyHO/Jng mice.

  Biochemical and biophysical research communications 20110325

• What have we learnt from the rosiglitazone saga?

  BMJ (Clinical research ed.) 20110317

• Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone.

  Toxicology letters 20110305

• Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood.

  Journal of applied toxicology : JAT 20110301

• Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.

  Fitoterapia 20110301

• Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo.

  AIDS research and human retroviruses 20110301

• Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice.

  Scandinavian journal of gastroenterology 20110301

• Effect of combining rosiglitazone with either metformin or insulin on β-cell mass and function in an animal model of Type 2 diabetes characterized by reduced β-cell mass at birth.

  Journal of diabetes 20110301

• Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.

  Clinical endocrinology 20110301

• PPARG regulates gonadotropin-releasing hormone signaling in LbetaT2 cells in vitro and pituitary gonadotroph function in vivo in mice.

  Biology of reproduction 20110301

• Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.

  Diabetologia 20110301

• Pharmacological treatment of hyperinsulineamia in rats depends on coping style.

  European journal of pharmacology 20110301

• Rosiglitazone attenuates myocardial remodeling in spontaneously hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20110301

• Synthesis, glucose uptake activity and structure-activity relationships of some novel glitazones incorporated with glycine, aromatic and alicyclic amine moieties via two carbon acyl linker.

  European journal of medicinal chemistry 20110301

• Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007.

  Clinical pharmacology and therapeutics 20110301

• Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.

  Clinical pharmacology and therapeutics 20110301

• Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells.

  Journal of cardiovascular pharmacology 20110301

• Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease.

  Polskie Archiwum Medycyny Wewnetrznej 20110301

• [Detection of glimepiride and rosiglitazone from Chinese dietary supplements].

  Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology 20110301

• Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.

  Chinese medical journal 20110301

• [Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?].

  Revue medicale de Liege 20110301

• [PPARγ up-regulates TGFβ/smad signal pathway repressor c-Ski].

  Sheng li xue bao : [Acta physiologica Sinica] 20110225

• Switching from rosiglitazone: thinking outside the class.

  JAMA 20110223

• Differential effects of PPARgamma ligands on oxidative stress-induced death of retinal pigmented epithelial cells.

  Investigative ophthalmology & visual science 20110222

• Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection.

  Bioorganic & medicinal chemistry letters 20110215

• Rosiglitazone balances insulin-induced exo- and endocytosis in single 3T3-L1 adipocytes.

  Molecular and cellular endocrinology 20110210

• Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.

  Journal of medicinal chemistry 20110210

• Health Canada 'passes the buck' on diabetes drug, researcher charges.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20110208

• Neuroprotective effects of KR-62980, a new PPARγ agonist, against chemical ischemia-reperfusion in SK-N-SH cells.

  Brain research 20110204

• Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

  Journal of clinical pharmacology 20110201

• Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.

  Journal of endocrinological investigation 20110201

• Effect of glucose and insulin on oxidized low-density lipoprotein phagocytosis by human monocytes: a pilot study.

  Angiology 20110201

• Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.

  Planta medica 20110201

• Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARγ-dependent manner in human adipocytes.

  Obesity (Silver Spring, Md.) 20110201

• In vitro effects of peroxisome proliferator-activated receptor-γ ligands on gene expression in lipopolysaccharide-induced endometrial and endometriotic stromal cells.

  Fertility and sterility 20110201

• Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110201

• Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20110201

• Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production.

  Journal of molecular endocrinology 20110201

• A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.

  American journal of physiology. Renal physiology 20110201

• Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.

  Pediatric nephrology (Berlin, Germany) 20110201

• Peroxisome proliferator-activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo.

  Glia 20110201

• Rosiglitazone: a European regulatory perspective.

  Diabetologia 20110201

• Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.

  International journal of oncology 20110201

• Inaccuracy in meta-analysis on rosiglitazone and myocardial infarction.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20110201

• FDA puts restrictions on use of controversial diabetes drug.

  Mayo Clinic women's healthsource 20110201

• Peroxisome proliferator-activated receptor γ-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice.

  The Journal of allergy and clinical immunology 20110201

• Inhibitory effect of rosiglitazone on the acid-induced intracellular generation of hydrogen peroxide in cultured feline esophageal epithelial cells.

  Naunyn-Schmiedeberg's archives of pharmacology 20110201

• Simultaneous determination and pharmacokinetic study of metformin and rosiglitazone in human plasma by HPLC-ESI-MS.

  Journal of chromatographic science 20110201

• Molecular mechanisms underlying the inhibition of IFN-γ-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs.

  Journal of cellular biochemistry 20110201

• Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma.

  American journal of veterinary research 20110201

• [Pravastatin and rosiglitazone combination therapy upgrades the expression of ABCA1 in THP-1 macrophages].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20110201

• Analytical issues regarding rosiglitazone meta-analysis.

  Archives of internal medicine 20110124

• Rosiglitazone: trials, tribulations and termination.

  Drugs 20110122

• The role of peroxisome proliferator-activated receptor γ, and effects of its agonist, rosiglitazone, on transient cerebral ischemic damage.

  Journal of the neurological sciences 20110115

• PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

  European journal of pharmacology 20110115

• Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.

  Bioorganic & medicinal chemistry 20110115

• The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats.

  European journal of pharmacology 20110110

• Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20110101

• Rosiglitazone ameliorates endotoxin-induced organ damage in conscious rats.

  Biological research for nursing 20110101

• What is the effect of rosiglitazone treatment on insulin secretory function in insulin-resistant individuals? It depends on how you measure it.

  Metabolism: clinical and experimental 20110101

• Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study.

  Obesity (Silver Spring, Md.) 20110101

• Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus.

  Journal of diabetes and its complications 20110101

• Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.

  Behavioural brain research 20110101

• Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.

  Journal of diabetes and its complications 20110101

• Ginkgo biloba extract enhances glucose tolerance in hyperinsulinism-induced hepatic cells.

  Journal of natural medicines 20110101

• Rosiglitazone reverses salbutamol-induced β(2) -adrenoceptor tolerance in airway smooth muscle.

  British journal of pharmacology 20110101

• Tumor suppressor Pdcd4 is a major transcript that is upregulated during in vivo pancreatic islet neogenesis and is expressed in both beta-cell and ductal cell lines.

  Pancreas 20110101

• Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study.

  Diabetes care 20110101

• FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction.

  Diabetes 20110101

• Delivery of rosiglitazone from an injectable triple interpenetrating network hydrogel composed of naturally derived materials.

  Biomaterials 20110101

• Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy.

  Arteriosclerosis, thrombosis, and vascular biology 20110101

• Hormone-sensitive lipase modulates adipose metabolism through PPARγ.

  Biochimica et biophysica acta 20110101

• Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials.

  Diabetologia 20110101

• Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.

  Journal of lipid research 20110101

• Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne?

  The British journal of dermatology 20110101

• Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.

  Atherosclerosis 20110101

• Therapy: The second time as farce: rosiglitazone and the regulators.

  Nature reviews. Endocrinology 20110101

• Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.

  Bioorganic & medicinal chemistry letters 20110101

• Comparative neuroprotective effects of methylprednisolone and rosiglitazone, a peroxisome proliferator-activated receptor-γ following spinal cord injury.

  Neurosciences (Riyadh, Saudi Arabia) 20110101

• Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats.

  The American journal of Chinese medicine 20110101

• Playing the numbers game.

  Drug and therapeutics bulletin 20110101

• Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro.

  Cardiovascular diabetology 20110101

• Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.

  PloS one 20110101

• [Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake].

  Revista espanola de medicina nuclear 20110101

• A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations.

  Acta medica Indonesiana 20110101

• Ask the doctor. Because of the recent news about Avandia, my physician has advised me to stop taking it. Is that wise?

  Harvard health letter 20110101

• Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.

  PloS one 20110101

• Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

  BMJ (Clinical research ed.) 20110101

• Dual acting and pan-PPAR activators as potential anti-diabetic therapies.

  Handbook of experimental pharmacology 20110101

• [Benefits and harms - two sides of the same medal?].

  Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 20110101

• Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance.

  Pathology research international 20110101

• Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.

  BMC clinical pharmacology 20110101

• Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.

  The Journal of international medical research 20110101

• Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes.

  PloS one 20110101

• Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver.

  Biological & pharmaceutical bulletin 20110101

• Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages.

  Current medicinal chemistry 20110101

• Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells.

  American journal of nephrology 20110101

• Red wine: a source of potent ligands for peroxisome proliferator-activated receptor γ.

  Food & function 20110101

• Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

  Current medicinal chemistry 20110101

• Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.

  BMC cancer 20110101

• Effects of a single dose of methylprednisolone versus three doses of rosiglitazone on nerve growth factor levels after spinal cord injury.

  The Journal of international medical research 20110101

• Rosiglitazone protects the dorsal root ganglion cells and sciatic nerve after crush in rat.

  Folia neuropathologica 20110101

• Effects of pioglitazone and rosiglitazone on vascular function of mesenteric resistance arteries in rat genetic hypertension.

  Pharmacology 20110101

• RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.

  PloS one 20110101

• Rosiglitazone protects against severe hemorrhagic shock-induced organ damage in rats.

  Medical science monitor : international medical journal of experimental and clinical research 20110101

• Two thiophenes compounds are partial peroxisome proliferator-activated receptor α/γ dual agonists.

  Biological & pharmaceutical bulletin 20110101

• A novel series of (S)-2,7-substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor α/γ dual agonists with protein-tyrosine phosphatase 1B inhibitory activity.

  Chemical & pharmaceutical bulletin 20110101

• Effect of PPAR-γ agonist rosiglitazone on bone mineral density and serum adipokines in C57BL/6 male mice.

  Folia biologica 20110101

• Rosiglitazone Induces Mitochondrial Biogenesis in Differentiated Murine 3T3-L1 and C3H/10T1/2 Adipocytes.

  PPAR research 20110101

• Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

• Carbon monoxide induced PPARγ SUMOylation and UCP2 block inflammatory gene expression in macrophages.

  PloS one 20110101

• Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone.

  PloS one 20110101

• [Effect of chromium enriched fermentation product of barley and brewer's yeast and its combination with rosiglitazone on experimentally induced hyperglycaemia in mice].

  Srpski arhiv za celokupno lekarstvo 20110101

• Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.

  PloS one 20110101

• Development and validation of new assay method for the simultaneous analysis of diltiazem, metformin, pioglitazone and rosiglitazone by RP-HPLC and its applications in pharmaceuticals and human serum.

  Journal of chromatographic science 20110101

• Rosiglitazone-induced mitochondrial biogenesis in white adipose tissue is independent of peroxisome proliferator-activated receptor γ coactivator-1α.

  PloS one 20110101

• Rosiglitazone attenuates endothelial progenitor cell apoptosis induced by TNF-α via ERK/MAPK and NF-κB signal pathways.

  Journal of pharmacological sciences 20110101

• Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion.

  PloS one 20110101

• Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.

  PloS one 20110101

• Mining relational paths in integrated biomedical data.

  PloS one 20110101

• Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.

  PloS one 20110101

• Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells.

  PloS one 20110101

• Acute mitochondrial actions of glitazones on the liver: a crucial parameter for their antidiabetic properties.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20110101

• Rosiglitazone, PPARγ, and type 2 diabetes.

  The New England journal of medicine 20101230

• European drug regulators publish their evaluation of rosiglitazone.

  BMJ (Clinical research ed.) 20101217

• The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.

  Experimental cell research 20101210

• DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.

  Investigational new drugs 20101201

• Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

  Current osteoporosis reports 20101201

• Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin.

  Journal of hepatology 20101201

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• The Avandia debate: an unhappy conclusion.

  Journal of diabetes 20101201

• The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis.

  Diabetes research and clinical practice 20101201

• hCG-induced down-regulation of PPARγ and liver X receptors promotes periovulatory progesterone synthesis by macaque granulosa cells.

  Endocrinology 20101201

• Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.

  Hepatology (Baltimore, Md.) 20101201

• Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?

  Diabetes, obesity & metabolism 20101201

• Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.

  Annales d'endocrinologie 20101201

• Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.

  Diabetes research and clinical practice 20101201

• 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists.

  Bioorganic & medicinal chemistry 20101201

• Electrochemical characterization of repaglinide and its determination in human plasma using liquid chromatography with dual-channel coulometric detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101201

• Serum sialic acid changes in type 2 diabetic patients on metformin or rosiglitazone treatment.

  Journal of clinical pharmacy and therapeutics 20101201

• The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.

  Diabetic medicine : a journal of the British Diabetic Association 20101201

• Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.

  Nature reviews. Cardiology 20101201

• Goodbye avandia!

  Saudi medical journal 20101201

• Influence of the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, rosiglitazone and antagonist, biphenol-A-diglicydyl ether (BADGE) on the course of inflammation in the experimental model of colitis in rats.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20101201

• Responding to an FDA warning--geographic variation in the use of rosiglitazone.

  The New England journal of medicine 20101125

• Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.

  The Journal of biological chemistry 20101119

• The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways.

  The Journal of biological chemistry 20101119

• Data openness. Independent public inquiries needed to ensure drug safety.

  BMJ (Clinical research ed.) 20101116

• Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats.

  Steroids 20101101

• Inverse association of PPARγ agonists use and high grade glioma development.

  Journal of neuro-oncology 20101101

• Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.

  American journal of respiratory and critical care medicine 20101101

• Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells.

  Neurobiology of disease 20101101

• Viewing FOP through rosi-colored glasses.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20101101

• Antenatally administered PPAR-gamma agonist rosiglitazone prevents hyperoxia-induced neonatal rat lung injury.

  American journal of physiology. Lung cellular and molecular physiology 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

  Diabetic medicine : a journal of the British Diabetic Association 20101101

• Therapy: What evidence should guide the use of thiazolidinediones?

  Nature reviews. Endocrinology 20101101

• Effects of rosiglitazone, an agonist of the peroxisome proliferator-activated receptor γ, on intestinal damage induced by Escherichia coli lipopolysaccharide in weaned pigs.

  American journal of veterinary research 20101101

• [The history of rosiglitazone: key messages].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20101101

• Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.

  Yao xue xue bao = Acta pharmaceutica Sinica 20101101

• Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.

  Neuroscience 20101027

• [PPARγ signal transduction pathway in the foam cell formation induced by visfatin].

  Sheng li xue bao : [Acta physiologica Sinica] 20101025

• Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.

  Lancet (London, England) 20101023

• Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.

  Lancet (London, England) 20101023

• Rosiglitazone plus metformin to prevent type 2 diabetes mellitus.

  Lancet (London, England) 20101023

• Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.

  Human molecular genetics 20101015

• Two different spectrofluorimetric methods for simultaneous determination of gemfibrozil and rosiglitazone in human plasma.

  Talanta 20101015

• Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.

  The New England journal of medicine 20101014

• Involvement of cholecystokinin in baseline and post-prandial whole body insulin sensitivity in rats.

  European journal of pharmacology 20101010

• Rosiglitazone and the need for a new drug safety agency.

  BMJ (Clinical research ed.) 20101006

• Abscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue: possible action of the cAMP/PKA/PPAR γ axis.

  Clinical nutrition (Edinburgh, Scotland) 20101001

• PPARγ agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats.

  Neurological research 20101001

• SLCO1B1 polymorphism and oral antidiabetic drugs.

  Basic & clinical pharmacology & toxicology 20101001

• Dynamic correlation networks in human peroxisome proliferator-activated receptor-γ nuclear receptor protein.

  European biophysics journal : EBJ 20101001

• PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.

  Laboratory investigation; a journal of technical methods and pathology 20101001

• PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B.

  American journal of physiology. Lung cellular and molecular physiology 20101001

• Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.

  Diabetes care 20101001

• Thiazolidinediones and fractures: evidence from translating research into action for diabetes.

  The Journal of clinical endocrinology and metabolism 20101001

• PPARgamma in placental angiogenesis.

  Endocrinology 20101001

• Rosiglitazone induces the unfolded protein response, but has no significant effect on cell viability, in monocytic and vascular smooth muscle cells.

  Biochemical and biophysical research communications 20101001

• Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein.

  British journal of pharmacology 20101001

• Rosiglitazone regulates IL-6-stimulated lipolysis in porcine adipocytes.

  Biochemistry and cell biology = Biochimie et biologie cellulaire 20101001

• Meta-analysis and moderation.

  Nature reviews. Drug discovery 20101001

• Why the Avandia scandal proves big pharma needs stronger ethical standards.

  Bioethics 20101001

• Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.

  Arquivos brasileiros de endocrinologia e metabologia 20101001

• [Suspension of the commercialization of sibutramine and rosiglitazone in Europe].

  Revue medicale de Liege 20101001

• Insiders criticise FDA's decision not to withdraw rosiglitazone.

  BMJ (Clinical research ed.) 20100928

• Cardiovascular risk from drugs. Editor's reply.

  BMJ (Clinical research ed.) 20100928

• Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.

  Life sciences 20100925

• FDA places greater restrictions on access to rosiglitazone.

  BMJ (Clinical research ed.) 20100924

• European regulatory body recommends suspension of rosiglitazone.

  BMJ (Clinical research ed.) 20100924

• [Rosiglitazone].

  Ugeskrift for laeger 20100920

• Rosiglitazone reverses cardiac adverse remodeling (fibrosis and vascularization) in perinatal low protein rat offspring.

  Pathology, research and practice 20100915

• Meta-analysis for rare events.

  Statistics in medicine 20100910

• FDA hearings leave doctors, patients in limbo on Avandia.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20100907

• FDA on rosiglitazone. More on advisory committee decision.

  BMJ (Clinical research ed.) 20100907

• Licensing drugs for diabetes.

  BMJ (Clinical research ed.) 20100906

• Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?

  BMJ (Clinical research ed.) 20100906

• Rosiglitazone: what went wrong?

  BMJ (Clinical research ed.) 20100906

• Rosiglitazone, peroxisome proliferator receptor-gamma agonist, ameliorates gentamicin-induced nephrotoxicity in rats.

  International urology and nephrology 20100901

• Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.

  Clinical endocrinology 20100901

• Anodic voltammetric behavior and determination of rosiglitazone in pharmaceutical dosage forms and biological fluids on solid electrode.

  Combinatorial chemistry & high throughput screening 20100901

• Systemic hyperthermia masks the neuroprotective effects of MK-801, but not rosiglitazone in brain ischaemia.

  Basic & clinical pharmacology & toxicology 20100901

• Induction of CXCL10 secretion by interferon-γ and tumour necrosis factor-α and its inhibition by peroxisome proliferator-activated receptor-γ agonists in cultured scleroderma fibroblasts.

  The British journal of dermatology 20100901

• Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus.

  Journal of clinical pharmacology 20100901

• Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.

  Diabetologia 20100901

• Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.

  The Journal of pharmacology and experimental therapeutics 20100901

• Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.

  Diabetologia 20100901

• Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.

  European heart journal 20100901

• Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20100901

• Effects of physical exercise versus rosiglitazone on endothelial function in coronary artery disease patients with prediabetes.

  Diabetes, obesity & metabolism 20100901

• Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.

  Bioorganic & medicinal chemistry letters 20100901

• Rosiglitazone and vascular injury in hypercholesterolemic rabbits: neointimal formation assessment.

  Arquivos brasileiros de cardiologia 20100901

• Simultaneous determination of rosiglitazone and its metabolites in rat liver microsomal fraction using hollow-fiber liquid-phase microextraction for sample preparation.

  Journal of separation science 20100901

• Positive correlation between PPARgamma/PGC-1alpha and gamma-GCS in lungs of rats and patients with chronic obstructive pulmonary disease.

  Acta biochimica et biophysica Sinica 20100901

• Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

  Dementia and geriatric cognitive disorders 20100901

• Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population.

  Circulation. Cardiovascular quality and outcomes 20100901

• Improving drug safety surveillance: lessons from rosiglitazone.

  Circulation. Cardiovascular quality and outcomes 20100901

• Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells.

  Phytotherapy research : PTR 20100901

• Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria.

  Expert review of anti-infective therapy 20100901

• Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?

  The Journal of family practice 20100901

• [Wrong choice of antidiabetics can be disastrous].

  Lakartidningen 20100901

• Rosiglitazone reduces fatty acid translocase and increases AMPK in skeletal muscle in aged rats: a possible mechanism to prevent high-fat-induced insulin resistance.

  Chinese medical journal 20100901

• [Transparency in biomedical research: about the risks associated with the use of Avandia].

  Revista medica de Chile 20100901

• Revisiting the rosiglitazone story--lessons learned.

  The New England journal of medicine 20100826

• Is the FDA on drugs?

  Time 20100823

• Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

  International journal of cardiology 20100820

• Rosiglitazone inhibits monocyte/macrophage adhesion through de novo adiponectin production in human monocytes.

  Journal of cellular biochemistry 20100815

• FDA advisers recommend new controls on rosiglitazone use.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100815

• Drug safety crackdown revs up.

  Nature 20100805

• Avandia panel member may be investigated for possible conflicts of interest.

  BMJ (Clinical research ed.) 20100803

• Rosiglitazone and cardiovascular disease revisited.

  The Medical journal of Australia 20100802

• Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.

  Investigational new drugs 20100801

• Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.

  Metabolism: clinical and experimental 20100801

• Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury.

  Cardiovascular research 20100801

• Hepatic effects of rosiglitazone in rats with the metabolic syndrome.

  Basic & clinical pharmacology & toxicology 20100801

• Thiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution.

  Aging cell 20100801

• Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment.

  Diabetes care 20100801

• Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes.

  Angiology 20100801

• Adipokine expression and secretion by canine adipocytes: stimulation of inflammatory adipokine production by LPS and TNFalpha.

  Pflugers Archiv : European journal of physiology 20100801

• Endocrine control of oleic acid and glucose metabolism in rainbow trout (Oncorhynchus mykiss) muscle cells in culture.

  American journal of physiology. Regulatory, integrative and comparative physiology 20100801

• Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep.

  Endocrinology 20100801

• Rosiglitazone, thiazolidinediones and atherosclerosis.

  Atherosclerosis 20100801

• Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.

  Diabetes, obesity & metabolism 20100801

• Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial.

  Atherosclerosis 20100801

• Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.

  Chinese journal of cancer 20100801

• After Avandia, some seek split in drug approval and monitoring.

  Nature medicine 20100801

• Bioethics and post-approval research in translational science.

  The American journal of bioethics : AJOB 20100801

• Stimulation of ENaC activity by rosiglitazone is PPARγ-dependent and correlates with SGK1 expression increase.

  The Journal of membrane biology 20100801

• Concurrently using rosiglitazone prevents glucosamine-induced islet beta-cell apoptosis and dysfunction.

  Cell biochemistry and function 20100801

• [Effect of lovastatin and rosiglitazone on cholesterol reverse transportation in foam cell].

  Zhonghua nei ke za zhi 20100801

• The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.

  Life sciences 20100731

• Don't mess with the DSMB.

  The New England journal of medicine 20100729

• Rosiglitazone and the case for safety over certainty.

  JAMA 20100728

• Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

  JAMA 20100728

• Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

  Archives of internal medicine 20100726

• FDA puts rosiglitazone post-marketing trial on hold.

  BMJ (Clinical research ed.) 20100726

• Drug safety. Planned study of Avandia in doubt after FDA review.

  Science (New York, N.Y.) 20100723

• Effective approach.

  Nature 20100722

• Diabetes drugs offered fresh start.

  Nature 20100722

• Obesity: New life for antidiabetic drugs.

  Nature 20100722

• Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

  Nature 20100722

• Intracellular Ca2+ can compensate for the lack of NADPH oxidase-derived ROS in endothelial cells.

  FEBS letters 20100716

• FDA committee urges tight restrictions on rosiglitazone.

  BMJ (Clinical research ed.) 20100716

• Researcher urges Health Canada to suspend 'unethical' diabetes drug trial.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20100713

• Health Canada named in class action lawsuit.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20100713

• Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.

  Lancet (London, England) 20100710

• Preventing type 2 diabetes with low-dose combinations.

  Lancet (London, England) 20100710

• Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.

  Clinical science (London, England : 1979) 20100709

• Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.

  Journal of medicinal chemistry 20100708

• Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.

  Current drug safety 20100702

• A randomised controlled trial on melatonin and rosiglitazone for prevention of adhesion formation in a rat uterine horn model.

  Archives of gynecology and obstetrics 20100701

• 15-deoxy-Delta12,14 prostaglandin GJ2 but not rosiglitazone regulates metalloproteinase 9, NOS-2, and cyclooxygenase 2 expression and functions by peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms in cardiac cells.

  Shock (Augusta, Ga.) 20100701

• Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity.

  The American journal of gastroenterology 20100701

• Ameliorative role of rosiglitazone in hyperhomocysteinemia-induced experimental cardiac hypertrophy.

  Journal of cardiovascular pharmacology 20100701

• Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats.

  Bone 20100701

• Basal adrenergic tone is required for maximal stimulation of rat brown adipose tissue UCP1 expression by chronic PPAR-gamma activation.

  American journal of physiology. Regulatory, integrative and comparative physiology 20100701

• Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.

  Diabetologia 20100701

• Regulation of adipogenesis by natural and synthetic REV-ERB ligands.

  Endocrinology 20100701

• Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.

  Diabetes & vascular disease research 20100701

• Peroxisome proliferator-activated receptor gamma activation inhibits progesterone-stimulated human MUC1 expression.

  Molecular endocrinology (Baltimore, Md.) 20100701

• Peroxisome proliferator-activated receptor-gamma increases adiponectin secretion via transcriptional repression of endoplasmic reticulum chaperone protein ERp44.

  Endocrinology 20100701

• Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor.

  Hypertension (Dallas, Tex. : 1979) 20100701

• Diabetes: making sense of the rosiglitazone controversy.

  Nature reviews. Cardiology 20100701

• Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).

  Pharmacoepidemiology and drug safety 20100701

• Preparation of rosiglitazone maleate sustained-release floating microspheres for improved bioavailability.

  Die Pharmazie 20100701

• [Macular oedema due to rosiglitazone treatment in diabetes mellitus].

  Archivos de la Sociedad Espanola de Oftalmologia 20100701

• The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.

  European journal of pharmacology 20100625

• Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues.

  JAMA 20100616

• Adiponectin deficiency promotes the production of inflammatory mediators while severely exacerbating hepatic injury in mice with polymicrobial sepsis.

  The Journal of surgical research 20100615

• Rosiglitazone reduces a wide range of proinflammatory profiles in synovial fibroblast SW982 under spheroid culture.

  Immunology letters 20100615

• Structural insight into peroxisome proliferator-activated receptor gamma binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis.

  Journal of medicinal chemistry 20100610

• Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).

  Journal of medicinal chemistry 20100610

• PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss.

  Cell metabolism 20100609

• GlaxoSmithKline denies it has settled thousands of lawsuits over rosiglitazone (Avandia).

  BMJ (Clinical research ed.) 20100607

• Hollow fiber liquid-phase microextraction for the determination of trace amounts of rosiglitazone (anti-diabetic drug) in biological fluids using capillary electrophoresis and high performance liquid chromatographic methods.

  Journal of chromatography. A 20100604

• Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.

  Blood 20100603

• PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells.

  Journal of cellular and molecular medicine 20100601

• Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressiva.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100601

• Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1.

  Shock (Augusta, Ga.) 20100601

• Anti-apoptotic actions of PPAR-gamma against ischemic stroke.

  Molecular neurobiology 20100601

• Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.

  Journal of cardiovascular pharmacology and therapeutics 20100601

• Factors influencing the differentiation of bovine preadipocytes in vitro.

  Journal of animal science 20100601

• Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.

  Basic & clinical pharmacology & toxicology 20100601

• PPARgamma agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells.

  Pharmacological research 20100601

• Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists.

  Cytokine 20100601

• Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100601

• Stimulators of AMP-activated kinase (AMPK) inhibit seawater- but not cAMP-induced oocyte maturation in a marine worm: Implications for interactions between cAMP and AMPK signaling.

  Molecular reproduction and development 20100601

• Toluene diisocyanate (TDI) regulates haem oxygenase-1/ferritin expression: implications for toluene diisocyanate-induced asthma.

  Clinical and experimental immunology 20100601

• PPARgamma is essential for protection against nonalcoholic steatohepatitis.

  Gene therapy 20100601

• PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats.

  Stroke 20100601

• Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats.

  Hypertension (Dallas, Tex. : 1979) 20100601

• Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma).

  Bioorganic & medicinal chemistry letters 20100601

• Insulinomimetic activity of two new gallotannins from the fruits of Capparis moonii.

  Bioorganic & medicinal chemistry 20100601

• Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens.

  AIDS (London, England) 20100601

• Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.

  Bioorganic & medicinal chemistry 20100601

• Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPARgamma ligands.

  Bioorganic & medicinal chemistry 20100601

• Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.

  Hepatology (Baltimore, Md.) 20100601

• Avandia outcome may signal change in epidemiologists' sway.

  Nature medicine 20100601

• Diabetes drug woes spell trouble for the entire drug family.

  Nature medicine 20100601

• Diabetes drug safety update: Avandia and your heart.

  The Johns Hopkins medical letter health after 50 20100601

• Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20100601

• Macular oedema linked to latanoprost and rosiglitazone.

  Prescrire international 20100601

• Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone.

  Biochemical and biophysical research communications 20100528

• GSK is accused of trying to suppress editorial on rosiglitazone.

  BMJ (Clinical research ed.) 20100519

• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, decreases immunoreactivity of markers for cell proliferation and neuronal differentiation in the mouse hippocampus.

  Brain research 20100506

• Composite end points in clinical trials.

  JAMA 20100505

• Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans.

  The Journal of clinical investigation 20100503

• Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.

  Basic research in cardiology 20100501

• Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial.

  Respiratory medicine 20100501

• A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate.

  Archives of gynecology and obstetrics 20100501

• Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling.

  Biochemical pharmacology 20100501

• PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium.

  Cardiovascular research 20100501

• Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.

  Diabetes care 20100501

• Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20100501

• Thiazolidinediones prevent PDGF-BB-induced CREB depletion in pulmonary artery smooth muscle cells by preventing upregulation of casein kinase 2 alpha' catalytic subunit.

  Journal of cardiovascular pharmacology 20100501

• Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-γ and MAPK activation, in mouse M1 cortical collecting duct cells.

  American journal of physiology. Renal physiology 20100501

• A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.

  Circulation. Cardiovascular quality and outcomes 20100501

• The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.

  Calcified tissue international 20100501

• Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage.

  The American journal of pathology 20100501

• Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.

  The Annals of pharmacotherapy 20100501

• Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study.

  Echocardiography (Mount Kisco, N.Y.) 20100501

• The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.

  Diabetes, obesity & metabolism 20100501

• The painful truth.

  European heart journal 20100501

• Clinical consequences of disseminating the rosiglitazone FDA safety warning.

  The American journal of managed care 20100501

• The rise and fall of rosiglitazone: reply.

  European heart journal 20100501

• Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.

  Diabetes/metabolism research and reviews 20100501

• Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats.

  Respirology (Carlton, Vic.) 20100501

• [Effects of rosiglitazone on the expression of connective tissue growth factor in the pulmonary arteries of rats suffering from fibrosis in lung].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20100501

• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

  Circulation 20100427

• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.

  Journal of the American College of Cardiology 20100427

• Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.

  The Journal of biological chemistry 20100416

• (S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl) propanoic acid compounds: synthesis and biological evaluation of dual PPARalpha/gamma agonists.

  Bioorganic & medicinal chemistry letters 20100415

• Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.

  Bioorganic & medicinal chemistry letters 20100415

• Peroxisome proliferator-activated receptor-gamma (PPARgamma) modulates hypothalamic Trh regulation in vivo.

  Molecular and cellular endocrinology 20100412

• Strengthening the credibility of clinical research.

  Lancet (London, England) 20100410

• Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells.

  Biochemical and biophysical research communications 20100409

• Rosiglitazone, marketing, and medical science.

  BMJ (Clinical research ed.) 20100407

• Rosiglitazone in the UK: down but not out.

  BMJ (Clinical research ed.) 20100407

• Development of a rapid culture method to induce adipocyte differentiation of human bone marrow-derived mesenchymal stem cells.

  Biochemical and biophysical research communications 20100402

• Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.

  American journal of respiratory cell and molecular biology 20100401

• The effect of substituted thiophene and benzothiophene derivates on PPARgamma expression and glucose metabolism.

  Journal of enzyme inhibition and medicinal chemistry 20100401

• FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.

  Journal of lipid research 20100401

• Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20100401

• Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100401

• Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment.

  Journal of molecular modeling 20100401

• Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome.

  European heart journal 20100401

• Selective binding of the fluorescent dye 1-anilinonaphthalene-8-sulfonic acid to peroxisome proliferator-activated receptor gamma allows ligand identification and characterization.

  Analytical biochemistry 20100401

• Molecular characterization and functional analysis of porcine macrophage migration inhibitory factor (MIF) gene.

  Cytokine 20100401

• Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

  European heart journal 20100401

• The rise and fall of rosiglitazone.

  European heart journal 20100401

• Site-specific modulation of white adipose tissue lipid metabolism by oleoyl-estrone and/or rosiglitazone in overweight rats.

  Naunyn-Schmiedeberg's archives of pharmacology 20100401

• Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.

  Bioorganic & medicinal chemistry letters 20100401

• Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin.

  American journal of obstetrics and gynecology 20100401

• IL-10 mediates rosiglitazone-induced kidney protection in cisplatin nephrotoxicity.

  Journal of Korean medical science 20100401

• [The effect of rosiglitazone on the cell proliferation and the expressions of p27 and skp2 in helicobacter pylori infected human gastric epithelial cells].

  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20100401

• Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction.

  Archives of pharmacal research 20100401

• [Effects of rosiglitazone on the Hep-2 cell proliferation, cell cycle and COX-2 expression].

  Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery 20100401

• Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis.

  Endocrine 20100401

• Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells.

  Brain research 20100331

• Setting the RECORD Straight.

  JAMA 20100324

• Ensuring integrity in industry-sponsored research: primum non nocere, revisited.

  JAMA 20100324

• Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.

  Circulation 20100316

• Seeking alternatives to Hard End Points: is imaging the best APPROACH?

  Circulation 20100316

• Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation.

  Biochemical pharmacology 20100315

• Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program.

  Chemical research in toxicology 20100315

• Novel glitazones: design, synthesis, glucose uptake and structure-activity relationships.

  Bioorganic & medicinal chemistry letters 20100315

• Rosiglitazone (Avandia) revisited.

  The Medical letter on drugs and therapeutics 20100308

• Chronic peroxisome proliferator-activated receptor gamma (PPARgamma) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes.

  The Journal of biological chemistry 20100305

• Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy.

  Journal of the American College of Cardiology 20100302

• Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease.

  Molecular psychiatry 20100301

• PPARalpha and PPARgamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium.

  Journal of applied toxicology : JAT 20100301

• Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20100301

• Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.

  Cell death and differentiation 20100301

• Selective effects of PPARgamma agonists and antagonists on human pre-adipocyte differentiation.

  Diabetes, obesity & metabolism 20100301

• Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.

  Diabetologia 20100301

• Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.

  Endocrine-related cancer 20100301

• Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice.

  American journal of physiology. Gastrointestinal and liver physiology 20100301

• Early exposure of the pregestational intrauterine and postnatal growth-restricted female offspring to a peroxisome proliferator-activated receptor-{gamma} agonist.

  American journal of physiology. Endocrinology and metabolism 20100301

• Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.

  Diabetes care 20100301

• Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta.

  Arteriosclerosis, thrombosis, and vascular biology 20100301

• Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation.

  Journal of thrombosis and haemostasis : JTH 20100301

• Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20100301

• Pseudomonas signal molecule 3-oxo-C12-homoserine lactone interferes with binding of rosiglitazone to human PPARgamma.

  Microbes and infection 20100301

• Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.

  Analytical and bioanalytical chemistry 20100301

• Acidic elements in histamine H(3) receptor antagonists.

  Bioorganic & medicinal chemistry letters 20100301

• Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.

  Diabetes, obesity & metabolism 20100301

• Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice.

  Nature medicine 20100301

• Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.

  Pharmacotherapy 20100301

• Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts.

  Experimental lung research 20100301

• Lipids control mucus production in cystic fibrosis.

  Nature medicine 20100301

• Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail.

  Neoplasia (New York, N.Y.) 20100301

• [Protective effect of fibroblast growth factors-21 and rosiglitazone sodium on palmitic acid-induced apoptosis in HIT-T15 cells].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100301

• [Application of multilevel models in the evaluation of bioequivalence (II).].

  Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 20100301

• Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.

  Arquivos brasileiros de endocrinologia e metabologia 20100301

• Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling.

  European journal of pharmacology 20100225

• Drug therapies for the primary prevention of cardiovascular events: trials and errors: 2009 Ancel Keys Memorial Lecture.

  Circulation 20100223

• In vivo effects of rosiglitazone in a human neuroblastoma xenograft.

  British journal of cancer 20100216

• Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1.

  Clinical science (London, England : 1979) 20100209

• Relaxin signaling activates peroxisome proliferator-activated receptor gamma.

  Molecular and cellular endocrinology 20100205

• Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.

  Circulation research 20100205

• A macrophage sterol-responsive network linked to atherogenesis.

  Cell metabolism 20100203

• Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.

  Clinical and experimental pharmacology & physiology 20100201

• Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway.

  Clinical and experimental pharmacology & physiology 20100201

• Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100201

• Abelmoschus moschatus (Malvaceae), an aromatic plant, suitable for medical or food uses to improve insulin sensitivity.

  Phytotherapy research : PTR 20100201

• Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice.

  International journal of cancer 20100201

• A role for TGFbeta signaling in the pathogenesis of psoriasis.

  The Journal of investigative dermatology 20100201

• Acute exposure to rosiglitazone does not affect glucose transport in intact human skeletal muscle.

  Metabolism: clinical and experimental 20100201

• Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.

  Metabolism: clinical and experimental 20100201

• Effects of rosiglitazone on intramyocellular lipid accumulation in Psammomys obesus.

  Biochimica et biophysica acta 20100201

• Rosiglitazone activation of PPARgamma suppresses fractalkine signaling.

  Journal of molecular endocrinology 20100201

• Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes.

  International journal of obesity (2005) 20100201

• Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.

  Hepatology (Baltimore, Md.) 20100201

• Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema.

  Neuropharmacology 20100201

• Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone.

  American journal of physiology. Renal physiology 20100201

• Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome.

  European journal of endocrinology 20100201

• Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts.

  Rheumatology (Oxford, England) 20100201

• Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.

  Hypertension (Dallas, Tex. : 1979) 20100201

• Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET.

  Bioorganic & medicinal chemistry letters 20100201

• Lipid metabolism.

  Current opinion in lipidology 20100201

• Effects of peroxisome proliferator-activated receptor gamma agonists on Na+ transport and activity of the kinase SGK1 in epithelial cells from lung and kidney.

  British journal of pharmacology 20100201

• [Effect of rosiglitazone on cells cycle, apoptosis and expression of Skp2 and p27Kip1 in hepatocellular carcinoma cell line].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20100201

• [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].

  The Korean journal of laboratory medicine 20100201

• Rosiglitazone reduces plasma levels of inflammatory and hemostatic biomarkers and improves global endothelial function in habitual heavy smokers without diabetes mellitus or metabolic syndrome.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20100201

• Composite end points in randomized trials: there is no free lunch.

  JAMA 20100120

• 12/15-Lipoxygenase inhibitor baicalein suppresses PPAR gamma expression and nuclear translocation induced by cerebral ischemia/reperfusion.

  Brain research 20100111

• Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.

  Journal of diabetes and its complications 20100101

• Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake.

  Obesity (Silver Spring, Md.) 20100101

• Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.

  European journal of gastroenterology & hepatology 20100101

• Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients.

  Metabolism: clinical and experimental 20100101

• Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots.

  Metabolism: clinical and experimental 20100101

• Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101

• Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

  Diabetes care 20100101

• Complement factor H is expressed in adipose tissue in association with insulin resistance.

  Diabetes 20100101

• Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20100101

• Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity.

  European journal of medicinal chemistry 20100101

• Peroxisome proliferator-activated receptor-alpha control of lipid and glucose metabolism in human white adipocytes.

  Endocrinology 20100101

• Spirulina protects against rosiglitazone induced osteoporosis in insulin resistance rats.

  Diabetes research and clinical practice 20100101

• Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.

  Arteriosclerosis, thrombosis, and vascular biology 20100101

• The effects of rosiglitazone and high glucose on protein expression in endothelial cells.

  Journal of proteome research 20100101

• Rosiglitazone may assist with glycemic control in the ICU.

  Journal of intensive care medicine 20100101

• The novel function of nesfatin-1: anti-hyperglycemia.

  Biochemical and biophysical research communications 20100101

• The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats.

  Cell biochemistry and function 20100101

• Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101

• Association of proliferative diabetic retinopathy with insulin use and microalbuminuria.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20100101

• Rosiglitazone inhibits proliferation of renal proximal tubular cells via down-regulation of ERK and Akt.

  Renal failure 20100101

• Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

  BMC nephrology 20100101

• Rosiglitazone decreases intra- to extramyocellular fat ratio in obese non-diabetic adults with metabolic syndrome.

  Diabetic medicine : a journal of the British Diabetic Association 20100101

• The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20100101

• Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole.

  BMC pharmacology 20100101

• Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studies.

  Reproductive biology and endocrinology : RB&E 20100101

• Association between rosiglitazone use and decline in renal function in patients with type 2 diabetes mellitus.

  Journal of nephrology 20100101

• Efficacy of peroxisome proliferator activated receptor agonist in the treatment of virus-associated haemophagocytic syndrome in a rabbit model.

  Antiviral therapy 20100101

• Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study.

  TheScientificWorldJournal 20100101

• Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease.

  The Journal of international medical research 20100101

• Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

  BMJ (Clinical research ed.) 20100101

• Effect of rosiglitazone on cisplatin-induced nephrotoxicity.

  Renal failure 20100101

• A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

  HIV clinical trials 20100101

• The effect of the PPAR-gamma agonist rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model.

  Oncology research 20100101

• Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats.

  Cardiovascular diabetology 20100101

• The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.

  BMC infectious diseases 20100101

• Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: Role of STAT1 inhibition and nephrin restoration.

  American journal of nephrology 20100101

• [Endpoints in clinical trials and their relevance for patients].

  Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 20100101

• The impact of rosiglitazone on nitric oxide bioavailability and endothelial function.

  Clinical hemorheology and microcirculation 20100101

• Sclerochorioretinal abnormalities in hypercholesterolemic rabbits treated with rosiglitazone.

  Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye 20100101

• Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.

  American journal of nephrology 20100101

• Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice.

  Biological & pharmaceutical bulletin 20100101

• A systems biology approach to identify effective cocktail drugs.

  BMC systems biology 20100101

• PPARγ ligands switched high fat diet-induced macrophage M2b polarization toward M2a thereby improving intestinal Candida elimination.

  PloS one 20100101

• [PPAR-gamma agonists: a role in the prevention of chronic allograft nephropathy?].

  Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20100101

• A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20100101

• Different effects of thiazolidinediones on target vessel revascularization with bare metal stents: a meta-analysis.

  Cardiovascular revascularization medicine : including molecular interventions 20100101

• The role of PPARγ for the osteoblastic differentiation.

  Journal of endocrinological investigation 20100101

• PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice.

  Cardiovascular diabetology 20100101

• Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice.

  The American journal of Chinese medicine 20100101

• Peroxisome Proliferator-Activated Receptor -β/δ, -γ Agonists and Resveratrol Modulate Hypoxia Induced Changes in Nuclear Receptor Activators of Muscle Oxidative Metabolism.

  PPAR research 20100101

• Prevention of sodium valproate-induced hepatotoxicity by curcumin, rosiglitazone and N-acetylcysteine in rats.

  Arzneimittel-Forschung 20100101

• National Diabetes Month: headlines from 2010.

  Diabetes self-management 20100101

• [Drug correction of hormonal disturbances and risk factors of cardiovascular complications in women of reproductive age with polycystic ovary syndrome].

  Kardiologiia 20100101

• Activation of PPAR gamma induces profound multilocularization of adipocytes in adult mouse white adipose tissues.

  Experimental & molecular medicine 20091231

• Rosiglitazone protects the pancreatic beta-cell death induced by cyclosporine A.

  Biochemical and biophysical research communications 20091218

• Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies.

  Journal of pharmaceutical and biomedical analysis 20091205

• Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts.

  American journal of respiratory cell and molecular biology 20091201

• Rosiglitazone reduces the inflammatory response in a model of vascular injury in rats.

  Shock (Augusta, Ga.) 20091201

• PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss.

  Neurochemistry international 20091201

• Targeting BuChE-inflammatory pathway by SK0506 to manage type 2 diabetes and Alzheimer disease.

  Neurochemical research 20091201

• The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients.

  Pharmacological research 20091201

• Case series of liver failure associated with rosiglitazone and pioglitazone.

  Pharmacoepidemiology and drug safety 20091201

• Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.

  Pharmacoepidemiology and drug safety 20091201

• Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

  Cellular signalling 20091201

• Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.

  Molecular pharmacology 20091201

• Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.

  Diabetes, obesity & metabolism 20091201

• Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.

  Metabolism: clinical and experimental 20091201

• A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.

  American journal of physiology. Endocrinology and metabolism 20091201

• Thiazolidinediones and the liver in humans.

  Current opinion in lipidology 20091201

• Spectrophotometric and HPLC determinations of anti-diabetic drugs, rosiglitazone maleate and metformin hydrochloride, in pure form and in pharmaceutical preparations.

  European journal of medicinal chemistry 20091201

• Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al.

  Pharmacoepidemiology and drug safety 20091201

• Expression and regulation by PPARgamma of hCG alpha- and beta-subunits: comparison between villous and invasive extravillous trophoblastic cells.

  Placenta 20091201

• Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model.

  Carcinogenesis 20091201

• Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.

  The Journal of clinical endocrinology and metabolism 20091201

• ADAGIO misses a beat?

  The Lancet. Neurology 20091201

• Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?

  Issues in mental health nursing 20091201

• Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products.

  British journal of pharmacology 20091201

• PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats.

  Toxicologic pathology 20091201

• [The effect of Rosiglitazone, a PPARgamma receptor agonist, on the NF-kappaB signaling pathway in acute hepatic injury induced by LPS].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20091201

• Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20091201

• Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone.

  WMJ : official publication of the State Medical Society of Wisconsin 20091201

• Liquid chromatography-tandem mass spectrometry of a new PPARalpha/gamma dual agonist PAR-5359 in rat plasma.

  Archives of pharmacal research 20091201

• [Differentiating effect of PPARgamma ligand rosiglitazone and all trans-retinoic acid on myeloma cells and its possible mechanism].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20091201

• Effects of rosiglitazone, a PPAR-gamma agonist, on the contractility of bovine uterus in vitro.

  Journal of veterinary pharmacology and therapeutics 20091201

• Recent cardiovascular trials: what are the drivers of benefit and adverse effect?

  Journal of diabetes 20091201

• Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo.

  Cancer research 20091115

• 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.

  Journal of medicinal chemistry 20091112

• Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation.

  Circulation research 20091106

• Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes.

  Journal of applied microbiology 20091101

• Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

  Diabetes, obesity & metabolism 20091101

• Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes.

  Toxicology and applied pharmacology 20091101

• Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.

  Pharmacoepidemiology and drug safety 20091101

• Peroxisome proliferator-activated receptor gamma activation alleviates postoperative ileus in mice by inhibition of Egr-1 expression and its downstream target genes.

  The Journal of pharmacology and experimental therapeutics 20091101

• A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.

  American journal of physiology. Endocrinology and metabolism 20091101

• Human multipotent adipose-derived stem cells differentiate into functional brown adipocytes.

  Stem cells (Dayton, Ohio) 20091101

• The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation.

  Diabetes, obesity & metabolism 20091101

• Peroxisome proliferator-activated receptor-gamma ligands induce heme oxygenase-1 in lung fibroblasts by a PPARgamma-independent, glutathione-dependent mechanism.

  American journal of physiology. Lung cellular and molecular physiology 20091101

• Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects.

  Bioorganic & medicinal chemistry letters 20091101

• Tobacco smoke affects expression of peroxisome proliferator-activated receptor-gamma in monocyte/macrophages of patients with coronary heart disease.

  British journal of pharmacology 20091101

• Hypoglycemic polysaccharides from the tuberous root of Liriope spicata.

  Journal of natural products 20091101

• Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome.

  Bosnian journal of basic medical sciences 20091101

• The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

  Clinical therapeutics 20091101

• Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.

  The Journal of biological chemistry 20091030

• Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension.

  Circulation research 20091023

• New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.

  Journal of medicinal chemistry 20091022

• Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.

  Bioorganic & medicinal chemistry 20091015

• Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20091001

• Salacia oblonga extract increases glucose transporter 4-mediated glucose uptake in L6 rat myotubes: role of mangiferin.

  Clinical nutrition (Edinburgh, Scotland) 20091001

• Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.

  Bone 20091001

• Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20091001

• Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.

  Molecular & cellular proteomics : MCP 20091001

• Adipocyte differentiation-related protein and OXPAT in rat and human skeletal muscle: involvement in lipid accumulation and type 2 diabetes mellitus.

  The Journal of clinical endocrinology and metabolism 20091001

• Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

  Cell proliferation 20091001

• Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model.

  Toxicology in vitro : an international journal published in association with BIBRA 20091001

• Thiazolidinediones as therapy for endometriosis: a case series.

  Gynecologic and obstetric investigation 20091001

• Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression.

  American journal of physiology. Renal physiology 20091001

• PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension.

  American journal of physiology. Heart and circulatory physiology 20091001

• Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.

  Diabetes research and clinical practice 20091001

• Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine.

  Endocrine 20091001

• Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests.

  Behavioural pharmacology 20091001

• Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?

  Current diabetes reports 20091001

• Rosiglitazone and pioglitazone. Beware fractures.

  BMJ (Clinical research ed.) 20090929

• Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81).

  The Journal of biological chemistry 20090925

• Rosiglitazone and pioglitazone. Beware macular oedema.

  BMJ (Clinical research ed.) 20090922

• Molecular cloning and characterization of olive flounder (Paralichthys olivaceus) peroxisome proliferator-activated receptor gamma.

  General and comparative endocrinology 20090915

• Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090915

• Role of renin-angiotensin system blockade in patients with diabetes mellitus.

  The American journal of cardiology 20090915

• Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma.

  FEBS letters 20090903

• Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus.

  Immunology 20090901

• A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090901

• All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.

  European journal of haematology 20090901

• Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.

  Diabetes, obesity & metabolism 20090901

• PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis.

  International immunopharmacology 20090901

• Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation.

  Endocrinology 20090901

• Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.

  European journal of endocrinology 20090901

• Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature.

  American journal of physiology. Endocrinology and metabolism 20090901

• Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment.

  American journal of physiology. Endocrinology and metabolism 20090901

• Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1.

  Diabetologia 20090901

• Multiunit floating drug delivery system of rosiglitazone maleate: development, characterization, statistical optimization of drug release and in vivo evaluation.

  AAPS PharmSciTech 20090901

• Hematopoietic stem cell origin of adipocytes.

  Experimental hematology 20090901

• Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans.

  American journal of physiology. Endocrinology and metabolism 20090901

• Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation.

  Journal of immunology (Baltimore, Md. : 1950) 20090901

• Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.

  The American journal of pathology 20090901

• Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.

  Thyroid : official journal of the American Thyroid Association 20090901

• Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.

  Acta pharmacologica Sinica 20090901

• Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.

  International journal of clinical practice 20090901

• [Relationship between insulin resistance and bone metabolism].

  Clinical calcium 20090901

• Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes.

  The Korean journal of internal medicine 20090901

• Selecting among ADA/EASD tier 1 and tier 2 treatment options.

  The Journal of family practice 20090901

• A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

  The Canadian journal of cardiology 20090901

• Slower decline of renal function after initiation of rosiglitazone in diabetics -- a pilot study.

  Clinical nephrology 20090901

• [Inhibitory effects of rosiglitazone on angiotensin II-induced toll-like receptor 4 expression and myeloperoxidase activity in RAW264.7 cells].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090901

• The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.

  PLoS medicine 20090901

• In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy.

  Circulation. Cardiovascular imaging 20090901

• Rosiglitazone or pioglitazone in type 2 diabetes?

  BMJ (Clinical research ed.) 20090818

• PPARgamma-mediated advanced glycation end products regulation of neural stem cells.

  Molecular and cellular endocrinology 20090813

• Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree of unsaturation.

  Journal of medicinal chemistry 20090813

• Thiazolidinediones and fractures in men and women.

  Archives of internal medicine 20090810

• Synthesis and evaluation of some novel isochroman carboxylic acid derivatives as potential anti-diabetic agents.

  European journal of medicinal chemistry 20090801

• Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents.

  Pharmacoepidemiology and drug safety 20090801

• Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy.

  Clinical immunology (Orlando, Fla.) 20090801

• PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.

  Laboratory investigation; a journal of technical methods and pathology 20090801

• Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.

  Molecular pharmacology 20090801

• Peroxisome proliferator-activated receptor-gamma agonist improves skeletal muscle insulin signaling in the pregestational intrauterine growth-restricted rat offspring.

  American journal of physiology. Endocrinology and metabolism 20090801

• The role of pioglitazone in modifying the atherogenic lipoprotein profile.

  Diabetes, obesity & metabolism 20090801

• Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.

  Bioorganic & medicinal chemistry 20090801

• Artemisia capillaris inhibits lipid accumulation in 3T3-L1 adipocytes and obesity in C57BL/6J mice fed a high fat diet.

  Journal of medicinal food 20090801

• [Effects of PPAR-gamma agonist rosiglitazone on MMP-9 and TIMP-1 expression of monocyte-derived macrophages isolated from patients with acute coronary syndrome].

  Zhonghua xin xue guan bing za zhi 20090801

• Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.

  Journal of medicinal chemistry 20090723

• Structure-dependent activation of peroxisome proliferator-activated receptor (PPAR) gamma by organotin compounds.

  Chemico-biological interactions 20090715

• Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2.

  The Journal of biological chemistry 20090710

• Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.

  Journal of medicinal chemistry 20090709

• Neferine enhances insulin sensitivity in insulin resistant rats.

  Journal of ethnopharmacology 20090706

• Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090701

• Epigenomic derangement of hepatic glucose metabolism by feeding of high fructose diet and its prevention by Rosiglitazone in rats.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20090701

• Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins.

  Journal of cellular physiology 20090701

• The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090701

• Development and in vitro evaluation of floating rosiglitazone maleate microspheres.

  Drug development and industrial pharmacy 20090701

• Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.

  British journal of pharmacology 20090701

• Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma.

  Clinical pharmacology and therapeutics 20090701

• Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia.

  Molecular pharmacology 20090701

• Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones.

  The Journal of pharmacology and experimental therapeutics 20090701

• Rosiglitazone: to be or not to be?

  Diabetologia 20090701

• Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20090701

• Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation.

  Journal of molecular and cellular cardiology 20090701

• Comparative expression analysis reveals differences in the regulation of intestinal paraoxonase family members.

  The international journal of biochemistry & cell biology 20090701

• Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21.

  Diabetes 20090701

• PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle.

  American journal of physiology. Endocrinology and metabolism 20090701

• Genistein induces adipogenesis but inhibits leptin induction in human synovial fibroblasts.

  Laboratory investigation; a journal of technical methods and pathology 20090701

• Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion.

  American journal of physiology. Gastrointestinal and liver physiology 20090701

• Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090701

• Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease.

  Anatomical record (Hoboken, N.J. : 2007) 20090701

• The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.

  Acta pharmacologica Sinica 20090701

• Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.

  Diabetes, obesity & metabolism 20090701

• Epstein-barr virus-induced gene-3 is expressed in human atheroma plaques.

  The American journal of pathology 20090701

• Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction.

  Pharmacotherapy 20090701

• Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.

  Current cardiology reports 20090701

• Type 2 diabetes, thiazolidinediones, and cardiovascular risk.

  The British journal of general practice : the journal of the Royal College of General Practitioners 20090701

• [Effects of rosiglitazone on expression patterns of the genes involved in adipogenesis during porcine preadipocytes differentiation].

  Yi chuan = Hereditas 20090701

• Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.

  Current HIV research 20090701

• [Role of histone deacetylase in inhibiting invasion of human gastric carcinoma cell line SGC-7901 by PPARgamma-mediated pathway].

  Ai zheng = Aizheng = Chinese journal of cancer 20090701

• Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes.

  British journal of clinical pharmacology 20090701

• [The effect or rosiglitazone on signal pathways of transforming growth factor-beta1 in human lung fibroblast].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20090701

• Rosiglitazone inhibits high glucose-induced apoptosis in human umbilical vein endothelial cells through the PI3K/Akt/eNOS pathway.

  Canadian journal of physiology and pharmacology 20090701

• [Study on the protective effect and related mechanisms of Rosiglitazone on acute hepatic failure in mice].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090701

• Pluronic L-81 ameliorates diabetic symptoms in db/db mice through transcriptional regulation of microsomal triglyceride transfer protein.

  World journal of gastroenterology 20090628

• Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.

  Circulation 20090623

• Insulin sensitizing activity of ethyl acetate fraction of Acorus calamus L. in vitro and in vivo.

  Journal of ethnopharmacology 20090622

• Thiazolidinediones and clinical outcomes in type 2 diabetes.

  Lancet (London, England) 20090620

• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

  Lancet (London, England) 20090620

• Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.

  Toxicology 20090616

• Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations.

  The Prostate 20090615

• Design, synthesis and insulin-sensitizing activity of indomethacin and diclofenac derivatives.

  Bioorganic & medicinal chemistry letters 20090615

• Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

  Journal of the American College of Cardiology 20090602

• Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain.

  Neurobiology of aging 20090601

• Adipose-tissue engineering: taking advantage of the properties of human adipose-derived stem/stromal cells.

  Pathologie-biologie 20090601

• Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.

  Investigational new drugs 20090601

• Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.

  Clinical endocrinology 20090601

• PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy.

  Cerebellum (London, England) 20090601

• A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

  Acta psychiatrica Scandinavica 20090601

• The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

  Acta diabetologica 20090601

• Depot-specific effects of the PPARgamma agonist rosiglitazone on adipose tissue glucose uptake and metabolism.

  Journal of lipid research 20090601

• Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20090601

• Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

  Pharmacoepidemiology and drug safety 20090601

• A peroxisome proliferator-activated receptor-gamma agonist and other constituents from Chromolaena odorata.

  Planta medica 20090601

• Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{beta} and Wnt signaling and is protected by rosiglitazone.

  American journal of physiology. Lung cellular and molecular physiology 20090601

• Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor.

  American journal of physiology. Lung cellular and molecular physiology 20090601

• Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats.

  Diabetologia 20090601

• Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid.

  Leukemia & lymphoma 20090601

• Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20090601

• A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.

  Current medical research and opinion 20090601

• Balancing risk and benefit with oral hypoglycemic drugs.

  The Mount Sinai journal of medicine, New York 20090601

• Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats.

  Pharmacological research 20090601

• Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons.

  Journal of neurochemistry 20090601

• Activation of peroxisome proliferator-activated receptor-gamma potentiates pro-inflammatory cytokine production, and adrenal and somatotropic changes of weaned pigs after Escherichia coli lipopolysaccharide challenge.

  Innate immunity 20090601

• Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20090601

• Increase in plasma glucose lowering action of rosiglitazone by electroacupuncture at bilateral Zusanli acupoints (ST.36) in rats.

  Journal of acupuncture and meridian studies 20090601

• Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice.

  The Journal of biological chemistry 20090522

• Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat.

  Brain research 20090519

• Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells.

  Cancer letters 20090518

• IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription.

  Biochemical and biophysical research communications 20090515

• 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.

  Bioorganic & medicinal chemistry letters 20090515

• Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria.

  The Journal of infectious diseases 20090515

• Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090513

• Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle.

  Life sciences 20090508

• Glucose control and vascular complications in type 2 diabetes.

  The New England journal of medicine 20090507

• Effects of advanced glycosylation end products and rosiglitazone on the expression and secretion of galectin-3 in human renal mesangial cells.

  Chinese medical journal 20090505

• Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression.

  Endocrinology 20090501

• The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake.

  American journal of physiology. Regulatory, integrative and comparative physiology 20090501

• Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.

  International journal of obesity (2005) 20090501

• Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression.

  Diabetes, obesity & metabolism 20090501

• GlaxoSmithKline responds to the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

  Diabetologia 20090501

• PPARgamma differentially regulates energy substrate handling in brown vs. white adipose: focus on 'The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake'.

  American journal of physiology. Regulatory, integrative and comparative physiology 20090501

• Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.

  The Journal of clinical endocrinology and metabolism 20090501

• n-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet.

  Diabetologia 20090501

• PPAR gamma partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK.

  Cellular and molecular life sciences : CMLS 20090501

• Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

  Bioorganic & medicinal chemistry letters 20090501

• Rosiglitazone is associated with mortality in chronic hemodialysis patients.

  Journal of the American Society of Nephrology : JASN 20090501

• Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20090501

• Thiazolidinediones: antidiabetic agents with effects on bone.

  Joint, bone, spine : revue du rhumatisme 20090501

• Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality.

  Surgery 20090501

• The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.

  Nuclear medicine and biology 20090501

• PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.

  Archives of pharmacal research 20090501

• Rosiglitazone.

  Primary care diabetes 20090501

• Cardiovascular risk and TZD: safe therapy for the elderly?

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20090501

• [Protective effect of rosiglitazone sodium on islet beta-cell of STZ induced diabetic rats through JNK pathway].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20090501

• Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids.

  Diabetic medicine : a journal of the British Diabetic Association 20090501

• Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.

  Journal of medicinal chemistry 20090423

• S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.

  European journal of pharmacology 20090417

• Thiazolidinedione use and the risk of fractures.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090414

• Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

  Journal of medicinal chemistry 20090409

• PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.

  The international journal of biochemistry & cell biology 20090401

• Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.

  Biostatistics (Oxford, England) 20090401

• Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction.

  Nephrology (Carlton, Vic.) 20090401

• Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

  Journal of the American Society of Nephrology : JASN 20090401

• Glitazone use associated with diabetic macular edema.

  American journal of ophthalmology 20090401

• Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus.

  American journal of physiology. Regulatory, integrative and comparative physiology 20090401

• New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9.

  Arteriosclerosis, thrombosis, and vascular biology 20090401

• Role of rosiglitazone in lipopolysaccharide-induced peritonitis: a rat peritoneal dialysis model.

  Nephrology (Carlton, Vic.) 20090401

• Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.

  Pancreas 20090401

• Rosiglitazone acts as a neuroprotectant in retinal cells via up-regulation of sestrin-1 and SOD-2.

  Journal of neurochemistry 20090401

• In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.

  Current medical research and opinion 20090401

• Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.

  European journal of pharmacology 20090401

• Selective, potent PPARgamma agonists with cyclopentenone core structure.

  Bioorganic & medicinal chemistry letters 20090401

• Doing more good than harm: need for a cease fire.

  The American journal of medicine 20090401

• Peroxisome proliferator-activated receptor gamma ligands isolated from adlay seed (Coix lacryma-jobi L. var. ma-yuen STAPF.).

  Biological & pharmaceutical bulletin 20090401

• Anti-inflammatory effect of peroxisome proliferator activated receptor gamma on human dental pulp cells.

  Journal of endodontics 20090401

• CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance.

  Cell metabolism 20090401

• Clinical practice effect of rosiglitazone discontinuation on glycemic control.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20090401

• Editorial: What have we lost in the wake of the rosiglitazone controversy?

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20090401

• Rosiglitazone in Canada: experience in clinical practice.

  Expert opinion on drug metabolism & toxicology 20090401

• Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090401

• [PPAR gamma agonist rosiglitazone alleviates hypoxia/reoxygenation-induced oxidative stress and apoptosis in rat cardiac myocytes].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090401

• Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.

  Singapore medical journal 20090401

• Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake.

  Nephrology (Carlton, Vic.) 20090401

• [Insulin sensitizing drugs].

  Vnitrni lekarstvi 20090401

• [Effect of peroxisome proliferators activated receptor gamma and its ligand on airway mucus hypersecretion in rats].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20090401

• [The medical management of Cushing's syndrome].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20090401

• Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.

  Journal of proteome research 20090401

• [Rosiglitazone and all-trans retinoic acid inhibit human myeloma cell proliferation via apoptosis signaling pathway modulation].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090401

• Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study.

  The Physician and sportsmedicine 20090401

• Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients.

  Diabetes & vascular disease research 20090401

• B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation.

  Experimental & molecular medicine 20090331

• Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090325

• Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.

  Cancer letters 20090318

• Anti-diabetic effects of water extract and crude polysaccharides from tuberous root of Liriope spicata var. prolifera in mice.

  Journal of ethnopharmacology 20090318

• INT131: a selective modulator of PPAR gamma.

  Journal of molecular biology 20090313

• Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins.

  The Journal of biological chemistry 20090306

• Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation.

  Circulation 20090303

• Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes.

  Acta diabetologica 20090301

• Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I.

  Endocrinology 20090301

• Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates.

  Clinica chimica acta; international journal of clinical chemistry 20090301

• Hematoma resolution as a therapeutic target: the role of microglia/macrophages.

  Stroke 20090301

• Regulation of peroxisome proliferator-activated receptor-alpha by MDM2.

  Toxicological sciences : an official journal of the Society of Toxicology 20090301

• Capillary endothelial but not lymphatic function is restored under rosiglitazone in Zucker diabetic fatty rats.

  Microvascular research 20090301

• Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways.

  Cell biology international 20090301

• A high performance liquid chromatography method for simultaneous determination of rosiglitazone and gemfibrozil in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090301

• Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone.

  Metabolism: clinical and experimental 20090301

• PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.

  The European journal of neuroscience 20090301

• Diabetes treatment.

  Diabetes care 20090301

• Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study.

  Journal of cardiac failure 20090301

• Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.

  Neuro endocrinology letters 20090301

• Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

  Diabetic medicine : a journal of the British Diabetic Association 20090301

• [Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20090301

• Limb fat wasting improves with rosiglitazone therapy.

  Project Inform perspective 20090301

• Response to 'Rosiglitazone no longer recommended'.

  Lancet (London, England) 20090214

• Pharmacodynamic interaction of Momordica charantia with rosiglitazone in rats.

  Chemico-biological interactions 20090212

• Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model.

  Biochemical and biophysical research communications 20090206

• Long-term consumption of saponins derived from Platycodi radix (22 years old) enhances hepatic insulin sensitivity and glucose-stimulated insulin secretion in 90 % pancreatectomized diabetic rats fed a high-fat diet.

  The British journal of nutrition 20090201

• Additive inhibitory effect of experimentally induced hepatic cirrhosis by agonists of peroxisome proliferator activator receptor gamma and retinoic acid receptor.

  Digestive diseases and sciences 20090201

• Regulation of adipose triglyceride lipase by rosiglitazone.

  Diabetes, obesity & metabolism 20090201

• Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats.

  The Journal of endocrinology 20090201

• Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.

  Clinica chimica acta; international journal of clinical chemistry 20090201

• Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists.

  Cardiovascular research 20090201

• Antiatherosclerotic effect of farnesoid X receptor.

  American journal of physiology. Heart and circulatory physiology 20090201

• Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice.

  International journal of obesity (2005) 20090201

• Comments on 'Rebuttal to Carpenter et al.' Comments on 'Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death' by J. J. Shuster, L. S. Jones and D. A. Salmon, Statistics in Medicine 2008; 27:3912-3914.

  Statistics in medicine 20090201

• Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

  The American journal of pathology 20090201

• Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20090201

• Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.

  American heart journal 20090201

• Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

  Diabetes/metabolism research and reviews 20090201

• Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).

  Diabetic medicine : a journal of the British Diabetic Association 20090201

• Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury.

  Archives of medical research 20090201

• Peroxisome proliferator-activated receptor gamma agonists enhance lung maturation in a neonatal rat model.

  Pediatric research 20090201

• The new rosiglitazone story: its place today in type 2 diabetes management.

  Primary care diabetes 20090201

• [The effect of rosiglitazone on the activity of STAT1 in rats with severe acute pancreatitis].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20090201

• N-3 polyunsaturated fatty acids and statins in heart failure.

  Lancet (London, England) 20090131

• [LDL concentration and particle size after treatment with rosiglitazone in patients with diabetes mellitus type 2].

  Medicina clinica 20090131

• Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.

  World journal of gastroenterology 20090128

• Retinol saturase promotes adipogenesis and is downregulated in obesity.

  Proceedings of the National Academy of Sciences of the United States of America 20090127

• The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.

  International journal of cardiology 20090124

• Differential potencies of naturally occurring regioisomers of nitrolinoleic acid in PPARgamma activation.

  Biochemistry 20090120

• Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways.

  Cell cycle (Georgetown, Tex.) 20090115

• Glucose control and vascular complications in veterans with type 2 diabetes.

  The New England journal of medicine 20090108

• Thiazolidinediones: do harms outweigh benefits?

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090106

• Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090106

• PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice.

  The Journal of clinical investigation 20090105

• Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride.

  Journal of diabetes and its complications 20090101

• Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression.

  Journal of diabetes and its complications 20090101

• Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.

  Heart (British Cardiac Society) 20090101

• Thiazolidinediones are partial agonists for the glucocorticoid receptor.

  Endocrinology 20090101

• The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090101

• The regulation of acyl-CoA dehydrogenases in adipose tissue by rosiglitazone.

  Obesity (Silver Spring, Md.) 20090101

• Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.

  Scandinavian journal of gastroenterology 20090101

• Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study.

  Diabetes research and clinical practice 20090101

• Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.

  Hepatology (Baltimore, Md.) 20090101

• Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

  Clinical journal of the American Society of Nephrology : CJASN 20090101

• Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.

  Toxicologic pathology 20090101

• The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus.

  Physiological research 20090101

• Rosiglitazone inhibits RANTES expression by human epidermal keratinocytes.

  European journal of dermatology : EJD 20090101

• The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin.

  Journal of immunology (Baltimore, Md. : 1950) 20090101

• Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma)-specific agonist, as a modulator in experimental acute pancreatitis.

  Medical science monitor : international medical journal of experimental and clinical research 20090101

• Rosiglitazone inhibits alpha4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor gamma-independent signals.

  Molecular cancer therapeutics 20090101

• Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.

  Pharmacopsychiatry 20090101

• The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.

  Diabetes & vascular disease research 20090101

• Rosiglitazone increases testosterone in hypogonadal type 2 diabetic men.

  Diabetes & vascular disease research 20090101

• Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.

  Urologic oncology 20090101

• Effect of short-term rosiglitazone therapy in peritoneal dialysis patients.

  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20090101

• Effects of thiazolidinediones beyond glycaemic control.

  Current pharmaceutical design 20090101

• [Effects of rosiglitazone on expression of collagen I and tissue inhibitor of metalloproteinase 1 in rat hepatic stellate cells].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20090101

• Acute renal failure following the use of rosiglitazone in a chronic kidney disease patient.

  Singapore medical journal 20090101

• Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFkappaB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus.

  BMC endocrine disorders 20090101

• Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.

  Cardiovascular diabetology 20090101

• Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.

  Molecular cancer 20090101

• Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.

  Nutrition (Burbank, Los Angeles County, Calif.) 20090101

• De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis.

  PloS one 20090101

• Rosiglitazone, a PPAR-gamma ligand, reduces burn progression in rats.

  Journal of burn care & research : official publication of the American Burn Association 20090101

• Luteolin inhibits adipogenic differentiation by regulating PPARgamma activation.

  BioFactors (Oxford, England) 20090101

• Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats.

  BMC cancer 20090101

• Column high-performance liquid chromatographic method for the simultaneous determination of rosiglitazone and metformin in a pharmaceutical preparation.

  Journal of AOAC International 20090101

• Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.

  Drug safety 20090101

• Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.

  Cardiovascular therapeutics 20090101

• Redefining the role of thiazolidinediones in the management of type 2 diabetes.

  Vascular health and risk management 20090101

• Safety and efficacy of rosiglitazone in the elderly diabetic patient.

  Vascular health and risk management 20090101

• Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone--induced apoptosis in leukemia k562 cells and its mechanisms of action.

  International journal of toxicology 20090101

• Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.

  Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20090101

• Psychometric evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)--a measure of symptom distress.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

• Rosiglitazone and myocardial infarction in patients previously prescribed metformin.

  PloS one 20090101

• Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.

  Drug safety 20090101

• Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells.

  Experimental diabetes research 20090101

• Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting.

  Cardiovascular diabetology 20090101

• Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20090101

• [The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus].

  Wiener klinische Wochenschrift 20090101

• Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

  BMJ (Clinical research ed.) 20090101

• Rosiglitazone effects to ameliorate Alzheimer's disease pathogenic features: insulin signaling and neurotrophic factors.

  The Journal of neuropsychiatry and clinical neurosciences 20090101

• Effects of rosiglitazone on cardiac function in CAPD patients: a tissue Doppler study.

  Renal failure 20090101

• Effects of 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) and rosiglitazone on human gammadelta2 T cells.

  PloS one 20090101

• Drug-drug noninteractions.

  Cardiovascular therapeutics 20090101

• Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.

  Cardiovascular therapeutics 20090101

• No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.

  Clinical neuropathology 20090101

• [Rosiglitazone: no increase in cardiovascular mortality].

  Nederlands tijdschrift voor geneeskunde 20090101

• PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.

  BMC cancer 20090101

• PPARgamma regulates trophoblast proliferation and promotes labyrinthine trilineage differentiation.

  PloS one 20090101

• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

  BMJ (Clinical research ed.) 20090101

• Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro.

  Chemotherapy 20090101

• Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells.

  Reproductive biology and endocrinology : RB&E 20090101

• Differential effects of thiazolidinediones on adipocyte growth and recruitment in Zucker fatty rats.

  PloS one 20090101

• Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial.

  Wiener klinische Wochenschrift 20090101

• [Diabetic edematous maculopathy associated with rosiglitazone treatment: report of a case].

  Bulletin de la Societe belge d'ophtalmologie 20090101

• Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.

  Journal of medicinal chemistry 20081225

• Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease.

  World journal of gastroenterology 20081221

• Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.

  The Journal of infectious diseases 20081215

• PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms.

  Brain research 20081209

• Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription.

  Atherosclerosis 20081201

• Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.

  Diabetes, obesity & metabolism 20081201

• Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.

  Inflammatory bowel diseases 20081201

• A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes.

  Journal of lipid research 20081201

• Effects of rosiglitazone on the proliferation of vascular smooth muscle cell induced by high glucose.

  Cardiovascular drugs and therapy 20081201

• High concentrations of phenylalanine stimulate peroxisome proliferator-activated receptor gamma: implications for the pathophysiology of phenylketonuria.

  Neurobiology of disease 20081201

• The role of rosiglitazone treatment in the modulation of islet hormones and hormone-like peptides: a combined in situ hybridization and immunohistochemical study.

  Journal of molecular histology 20081201

• Cardiovascular risk of rosiglitazone: another perspective.

  The Journal of pharmacy and pharmacology 20081201

• Rosiglitazone for nonalcoholic steatohepatitis.

  Gastroenterology 20081201

• Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.

  American heart journal 20081201

• Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1.

  Cell metabolism 20081201

• Potential hypoglycemic effect of an ethanol extract of Gynostemma pentaphyllum in C57BL/KsJ-db/db mice.

  Journal of medicinal food 20081201

• Evaluation of rosiglitazone administration on cardiovascular function in severe obesity.

  Clinical cardiology 20081201

• Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients.

  Journal of clinical pharmacy and therapeutics 20081201

• Bioequivalence and comparison of pharmacokinetic properties of 4-mg tablet formulations of rosiglitazone hydrochloride and rosiglitazone maleate: a single-dose, randomized, open-label, two-period crossover study in healthy adult male Chinese volunteers.

  Clinical therapeutics 20081201

• Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats.

  Journal of endocrinological investigation 20081201

• Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

  Archives of internal medicine 20081124

• Rescue of neurons from ischemic injury by peroxisome proliferator-activated receptor-gamma requires a novel essential cofactor LMO4.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20081119

• Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.

  International journal of cancer 20081115

• Insulin resistance and fertility in polycystic ovary syndrome.

  Journal of medicine and life 20081115

• Leptin inhibits rosiglitazone-induced adipogenesis in murine primary adipocytes.

  Molecular and cellular endocrinology 20081106

• Major US consumer group asks FDA to ban drug for diabetes.

  BMJ (Clinical research ed.) 20081105

• An improved LC-ESI-MS-MS method for simultaneous quantitation of rosiglitazone and N-desmethyl rosiglitazone in human plasma.

  Journal of pharmaceutical and biomedical analysis 20081104

• Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.

  European journal of medicinal chemistry 20081101

• A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.

  Journal of cellular physiology 20081101

• Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20081101

• Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.

  American journal of physiology. Endocrinology and metabolism 20081101

• The expression of GPIHBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by peroxisome proliferator-activated receptor-gamma.

  Molecular endocrinology (Baltimore, Md.) 20081101

• Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.

  Current medical research and opinion 20081101

• Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.

  Bioorganic & medicinal chemistry 20081101

• Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression.

  Oncology reports 20081101

• Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease.

  Diabetes & vascular disease research 20081101

• Rosiglitazone as treatment for clomiphene citrate-resistant polycystic ovary syndrome: factors associated with clinical response.

  Journal of women's health (2002) 20081101

• Rosiglitazone no longer recommended.

  Lancet (London, England) 20081101

• Angiotensin inhibition stimulates PPARgamma and the release of visfatin.

  European journal of clinical investigation 20081101

• Severe hyponatremia due to rosiglitazone use in an elderly woman with diabetes mellitus: a rare cause of syndrome of inappropriate antidiuretic hormone secretion.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20081101

• Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.

  Journal of the Indian Medical Association 20081101

• Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.

  European journal of pharmacology 20081031

• Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

  The Journal of biological chemistry 20081031

• Alzheimer's tests under fire.

  Nature 20081030

• Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.

  Journal of medicinal chemistry 20081023

• Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.

  Bioorganic & medicinal chemistry letters 20081015

• Analogues of 2-phenyl-ethenesulfonic acid phenyl ester have dual functions of inhibiting expression of inducible nitric oxide synthase and activating peroxisome proliferator-activated receptor gamma.

  Bioorganic & medicinal chemistry letters 20081015

• Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

• [Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].

  Medicina clinica 20081004

• Intensive glucose control in type 2 diabetes.

  The New England journal of medicine 20081002

• Rosiglitazone reverses tenofovir-induced nephrotoxicity.

  Kidney international 20081001

• Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice.

  Endocrinology 20081001

• Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.

  Molecular pharmacology 20081001

• Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway.

  Molecular and cellular biochemistry 20081001

• Analysis of the transcriptional regulation of the FABP2 promoter haplotypes by PPARgamma/RXRalpha and Oct-1.

  Biochimica et biophysica acta 20081001

• Methodology of internal standard selection. Comment on the work of Wang and co-workers: simultaneous determination of dipyridamole and salicylic acid in human plasma by high-performance liquid chromatograph-mass spectrometry.

  Biomedical chromatography : BMC 20081001

• Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome.

  European journal of endocrinology 20081001

• Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

  American journal of physiology. Renal physiology 20081001

• Rosiglitazone and cardiovascular risk.

  Current atherosclerosis reports 20081001

• Case series of rosiglitazone used during the first trimester of pregnancy.

  Reproductive toxicology (Elmsford, N.Y.) 20081001

• Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.

  Diabetes research and clinical practice 20081001

• Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes.

  Chemical research in toxicology 20081001

• Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081001

• Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20081001

• Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.

  The Journal of pharmacy and pharmacology 20081001

• Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.

  The American journal of medicine 20081001

• A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.

  The Canadian journal of cardiology 20081001

• Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling.

  Journal of the American College of Nutrition 20081001

• Significance of rosiglitazone inhibiting TLR4 expression in partial hepatic ischemia/reperfusion of mice.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20081001

• PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules.

  Biochemistry and cell biology = Biochimie et biologie cellulaire 20081001

• Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility.

  Cancer science 20081001

• The effects of rosiglitazione on renal artery endothelium in diabetic rats.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20081001

• Effect of folic acid and B vitamins on cardiovascular disease in women.

  JAMA 20080924

• Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.

  Bioorganic & medicinal chemistry letters 20080915

• Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.

  The Journal of biological chemistry 20080912

• The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

  Journal of the American College of Cardiology 20080902

• Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference?

  Journal of the American College of Cardiology 20080902

• Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats.

  Diabetes, obesity & metabolism 20080901

• Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth.

  Diabetes, obesity & metabolism 20080901

• Insulin-releasing activity of a series of phenylalanine derivatives.

  European journal of medicinal chemistry 20080901

• Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20080901

• Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.

  Diabetes, obesity & metabolism 20080901

• Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease.

  Clinical science (London, England : 1979) 20080901

• The Pal3 promoter sequence is critical for the regulation of human renin gene transcription by peroxisome proliferator-activated receptor-gamma.

  Endocrinology 20080901

• Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue.

  Diabetes 20080901

• Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.

  Journal of molecular graphics & modelling 20080901

• Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration.

  European journal of endocrinology 20080901

• Highly functionalized 7-azaindoles as selective PPAR gamma modulators.

  Bioorganic & medicinal chemistry letters 20080901

• The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

  Expert opinion on pharmacotherapy 20080901

• Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.

  The Journal of pharmacy and pharmacology 20080901

• The safety of rosiglitazone in the treatment of type 2 diabetes.

  Expert opinion on drug safety 20080901

• Reassessing the cardiovascular risks and benefits of thiazolidinediones.

  Clinical cardiology 20080901

• Pharmacological approaches to improve endothelial repair mechanisms.

  Expert review of cardiovascular therapy 20080901

• The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20080901

• Effect of pentoxifylline on the pharmacokinetics of rosiglitazone in Wistar rats.

  Methods and findings in experimental and clinical pharmacology 20080901

• Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.

  Obesity (Silver Spring, Md.) 20080901

• Comments on 'Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death'.

  Statistics in medicine 20080830

• The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway.

  Yonsei medical journal 20080830

• Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE-knockout mice.

  European journal of pharmacology 20080820

• Peroxisome proliferator-activated receptor-gamma activation suppresses HIV-1 replication in an animal model of encephalitis.

  AIDS (London, England) 20080820

• Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue.

  The Journal of biological chemistry 20080815

• Polychlorinated compounds with PPAR-gamma agonistic effect from the medicinal fungus Phellinus ribis.

  Bioorganic & medicinal chemistry letters 20080815

• Activation of PPARgamma negatively regulates O-GlcNAcylation of Sp1.

  Biochemical and biophysical research communications 20080808

• Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.

  Diabetes, obesity & metabolism 20080801

• Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.

  Pharmacoepidemiology and drug safety 20080801

• Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats.

  International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 20080801

• Dysglycemia and a history of reproductive risk factors.

  Diabetes care 20080801

• Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.

  Diabetes 20080801

• Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene.

  European journal of endocrinology 20080801

• The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20080801

• Thermogenically competent nonadrenergic recruitment in brown preadipocytes by a PPARgamma agonist.

  American journal of physiology. Endocrinology and metabolism 20080801

• Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.

  Endocrine journal 20080801

• Rosiglitazone improves aortic arginine transport, through inhibition of PKCalpha, in uremic rats.

  American journal of physiology. Renal physiology 20080801

• The effect of rosiglitazone on oxidative stress and insulin resistance in overweight individuals.

  Diabetes research and clinical practice 20080801

• Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test.

  Obesity (Silver Spring, Md.) 20080801

• Are prescribing patterns of antidiabetic medications influenced by fears of litigation?

  Nature clinical practice. Endocrinology & metabolism 20080801

• Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice.

  Progress in neuro-psychopharmacology & biological psychiatry 20080801

• Association between serious ischemic cardiac outcomes and medications used to treat diabetes.

  Pharmacoepidemiology and drug safety 20080801

• A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.

  Pharmacoepidemiology and drug safety 20080801

• Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.

  Bioorganic & medicinal chemistry 20080801

• A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.

  Journal of clinical pharmacology 20080801

• Cardiac safety of diabetes therapies and postmarketing requirements.

  Pharmacoepidemiology and drug safety 20080801

• The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.

  Pharmacoepidemiology and drug safety 20080801

• Exercise training but not rosiglitazone improves endothelial function in prediabetic patients with coronary disease.

  European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 20080801

• [Effect of rosiglitazone in non-alcoholic steatohepatitis associated liver fibrosis].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20080801

• [Effect of rosiglitazone on tumor necrosis factor-alpha-induced nuclear factor-kappaB and coupling factor 6 expressions in human umbilical vein endothelial cells].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080801

• The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial.

  Pediatric diabetes 20080728

• Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method.

  European journal of pharmacology 20080728

• Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats.

  European journal of pharmacology 20080728

• Tannins present in Cichorium intybus enhance glucose uptake and inhibit adipogenesis in 3T3-L1 adipocytes through PTP1B inhibition.

  Chemico-biological interactions 20080710

• When there's no room to grow.

  Nature 20080710

• Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1alpha.

  The Journal of biological chemistry 20080704

• Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.

  Atherosclerosis 20080701

• Bioinformatics analysis of targeted metabolomics--uncovering old and new tales of diabetic mice under medication.

  Endocrinology 20080701

• Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.

  Diabetes care 20080701

• Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.

  The journal of pain : official journal of the American Pain Society 20080701

• Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20080701

• Novel expression and direct effects of adiponectin in the rat testis.

  Endocrinology 20080701

• Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes.

  European journal of clinical pharmacology 20080701

• Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.

  Alimentary pharmacology & therapeutics 20080701

• The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function.

  The Journal of clinical endocrinology and metabolism 20080701

• Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors.

  Experimental neurology 20080701

• Treatment options in insulin resistance obesity-related acanthosis nigricans.

  The Annals of pharmacotherapy 20080701

• Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.

  Gastroenterology 20080701

• Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol.

  Metabolism: clinical and experimental 20080701

• Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities.

  Cellular and molecular life sciences : CMLS 20080701

• Rosiglitazone is cardioprotective in a murine model of myocardial I/R.

  Shock (Augusta, Ga.) 20080701

• Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids.

  Journal of dairy science 20080701

• Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.

  The American journal of cardiology 20080701

• Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.

  American heart journal 20080701

• The effects of peroxisome proliferator-activated receptor-gamma agonist on a murine model of experimental allergic rhinitis.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20080701

• Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20080701

• A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells.

  Molecular cancer therapeutics 20080701

• The cardiovascular safety of rosiglitazone.

  Expert opinion on drug safety 20080701

• [Effects of activated PPARgamma on the expression of PTEN gene in pancreatic cancer cells].

  Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20080701

• Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.

  Thyroid : official journal of the American Thyroid Association 20080701

• Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones.

  Diabetic medicine : a journal of the British Diabetic Association 20080701

• New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm.

  Diabetic medicine : a journal of the British Diabetic Association 20080701

• Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo.

  Biochemical and biophysical research communications 20080627

• Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents.

  Brain research 20080618

• Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo.

  International journal of cancer 20080615

• Activation of peroxisome proliferator-activated receptor-gamma during hepatic ischemia is age-dependent.

  The Journal of surgical research 20080615

• Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents.

  Journal of medicinal chemistry 20080612

• Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.

  Diabetes, obesity & metabolism 20080601

• Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.

  Diabetes 20080601

• Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.

  European journal of endocrinology 20080601

• The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats.

  Cell biochemistry and function 20080601

• The association of adiponectin allele 45T/G and -11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients.

  British journal of clinical pharmacology 20080601

• Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.

  Diabetes, obesity & metabolism 20080601

• Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

  Diabetes, obesity & metabolism 20080601

• Regulation of Alström syndrome gene expression during adipogenesis and its relationship with fat cell insulin sensitivity.

  International journal of molecular medicine 20080601

• Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.

  Endocrine-related cancer 20080601

• Database assessment of the effectiveness of brand versus generic rosiglitazone in patients with type 2 diabetes mellitus.

  Medical science monitor : international medical journal of experimental and clinical research 20080601

• Type 2 diabetes: a well-characterised but suboptimally controlled disease. Can we bridge the divide?

  Diabetes & metabolism 20080601

• The truth about rosiglitazone (avandia).

  The Nurse practitioner 20080601

• Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes.

  Diabetes & vascular disease research 20080601

• Rosiglitazone and delayed onset of proliferative diabetic retinopathy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20080601

• [Effects of peroxisome proliferators-activated receptor-gamma on the function of the vital organs in rats with pancreatitis].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080601

• [Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080601

• [Inhibitory effects of rosiglitazone against endothelin-1-induced proliferation of rat cardiac myocytes: the role of PKC-c-fos pathway].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080601

• Beneficial effect of chungkukjang on regulating blood glucose and pancreatic beta-cell functions in C75BL/KsJ-db/db mice.

  Journal of medicinal food 20080601

• [Effect of insulin plus rosiglitazone or metformin on serum N-terminal pro-brain natriuretic peptide in type 2 diabetes mellitus: a randomized-controlled study].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20080601

• Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese Zucker rats as determined by microarray analysis.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20080601

• Rosiglitazone modulates insulin-induced plasma membrane area changes in single 3T3-L1 adipocytes.

  The Journal of membrane biology 20080601

• Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway.

  Endocrine 20080601

• Evidence for multiple peroxisome proliferator-activated receptor gamma transcripts in bone: fine-tuning by hormonal regulation and mRNA stability.

  FEBS letters 20080514

• Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum.

  World journal of gastroenterology 20080514

• The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.

  Life sciences 20080507

• Response to Pokharna and Kanna: initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

  Diabetes, obesity & metabolism 20080501

• Insulin regulates the expression of adiponectin and adiponectin receptors in porcine adipocytes.

  Domestic animal endocrinology 20080501

• Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status.

  Endocrinology 20080501

• Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

  Diabetes care 20080501

• Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

  Diabetes care 20080501

• Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality.

  Endocrinology 20080501

• Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production.

  The Journal of clinical endocrinology and metabolism 20080501

• In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886).

  Molecular pharmacology 20080501

• Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.

  Archives of medical research 20080501

• An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

  The Journal of clinical investigation 20080501

• Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.

  Bioorganic & medicinal chemistry 20080501

• Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma.

  The Annals of pharmacotherapy 20080501

• Pleiotropic effects of thiazolidinediones.

  Expert opinion on pharmacotherapy 20080501

• Leak: Avandia and the integrity of the peer review process.

  Annals of emergency medicine 20080501

• Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats.

  Pharmacological research 20080501

• [Study on renoprotective effect of Xuebijing and Rosiglitazone in rats with focal segmental glomerular fibrosis].

  Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20080501

• Initiating antidiabetic drug therapy.

  Clinical therapeutics 20080501

• Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors.

  Current clinical pharmacology 20080501

• Effects of rosiglitazone (a peroxysome proliferator-activated receptor gamma agonist) on the blood pressure and aortic structure in metabolically programmed (perinatal low protein) rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20080501

• [Effect of Rosiglitazone on the proliferation and the production of transforming growth factor-beta 1 in cultured human Tenon' s capsule fibroblasts].

  [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20080501

• The effect of Chlamydia pneumoniae on the expression of peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells.

  Yonsei medical journal 20080430

• Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy.

  International journal of cardiology 20080425

• Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase.

  The Journal of biological chemistry 20080425

• Brain nuclear factor kappa B is involved in the corticotropin-releasing factor-induced central activation of sympatho-adrenomedullary outflow in rats.

  European journal of pharmacology 20080414

• A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

  European journal of pharmacology 20080414

• [Metabolic syndrome, type 1 diabetes mellitus and insulin resistance].

  Medicina clinica 20080405

• T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.

  The Journal of biological chemistry 20080404

• Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.

  Atherosclerosis 20080401

• Regulation of the PTEN promoter by statins and SREBP.

  Human molecular genetics 20080401

• Thiazolidinediones and the renal and hormonal response to water immersion-induced volume expansion in type 2 diabetes mellitus.

  American journal of physiology. Endocrinology and metabolism 20080401

• A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20080401

• Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.

  Diabetologia 20080401

• Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.

  British journal of pharmacology 20080401

• Insulin resistance and impaired functional vasodilation in obese Zucker rats.

  American journal of physiology. Heart and circulatory physiology 20080401

• The rough road for rosiglitazone.

  Current opinion in endocrinology, diabetes, and obesity 20080401

• Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.

  Metabolism: clinical and experimental 20080401

• IL-13 attenuates gastrointestinal candidiasis in normal and immunodeficient RAG-2(-/-) mice via peroxisome proliferator-activated receptor-gamma activation.

  Journal of immunology (Baltimore, Md. : 1950) 20080401

• Gene alterations by peroxisome proliferator-activated receptor gamma agonists in human colorectal cancer cells.

  International journal of oncology 20080401

• Controversy over the cardiovascular effects of thiazolidinediones.

  The American journal of medicine 20080401

• Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?

  Medical science monitor : international medical journal of experimental and clinical research 20080401

• Skeletal toxicity of thiazolidinediones.

  Annals of internal medicine 20080401

• PPARgamma agonists and coronary atherosclerosis.

  Current atherosclerosis reports 20080401

• A combination of CLA-DAG oil modifies the diabetic phenotype in male Zucker diabetic fatty rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20080401

• Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report.

  Transplantation 20080327

• Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus.

  Brain research 20080320

• [The decline of rosiglitazone].

  Ugeskrift for laeger 20080317

• Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.

  Free radical biology & medicine 20080315

• Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria.

  The Journal of physiology 20080315

• Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.

  Bioorganic & medicinal chemistry letters 20080315

• Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression.

  Biochemical and biophysical research communications 20080314

• Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity.

  Life sciences 20080312

• Letter by Thum et al regarding article, 'Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone'.

  Circulation 20080311

• Low-dose rosiglitazone in patients with type 2 diabetes mellitus requiring insulin therapy.

  Archives of internal medicine 20080310

• [The effectiveness in type 2 diabetes prevention: a forced landing to reality].

  Medicina clinica 20080308

• Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells.

  Breast cancer research and treatment 20080301

• Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.

  Bioorganic & medicinal chemistry 20080301

• The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue.

  The British journal of nutrition 20080301

• Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.

  Acta diabetologica 20080301

• 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.

  Bioorganic & medicinal chemistry letters 20080301

• Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.

  Diabetes, obesity & metabolism 20080301

• Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide.

  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 20080301

• Reduced cardiotropic response to insulin in spontaneously hypertensive rats: role of peroxisome proliferator-activated receptor-gamma-initiated signaling.

  Journal of hypertension 20080301

• Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids.

  Pharmacogenomics 20080301

• Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.

  Diabetic medicine : a journal of the British Diabetic Association 20080301

• The rosigliazone meta-analysis: lessons for the future.

  Diabetes care 20080301

• PPAR gamma: ally and foe in bone metabolism.

  Cell metabolism 20080301

• Rosiglitazone maleate 0.25-hydrate: a pseudopolymorphic form.

  Acta crystallographica. Section C, Crystal structure communications 20080301

• Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.

  Gastroenterology 20080301

• Meta-analysis of small trials: proceed with caution.

  Nature clinical practice. Nephrology 20080301

• Why should we avoid the use of rosiglitazone?

  Southern medical journal 20080301

• Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080301

• Evidence of acute pancreatitis in a patient with radioresistant-differentiated thyroid cancer.

  Journal of the National Medical Association 20080301

• Dichotomous effects of rosiglitazone in transplantation-induced systemic vasodilator dysfunction in rats.

  Transplantation 20080227

• AMP-activated protein kinase subunit interactions: beta1:gamma1 association requires beta1 Thr-263 and Tyr-267.

  The Journal of biological chemistry 20080222

• PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.

  Biochemical and biophysical research communications 20080222

• Metastability and instability of organic crystalline substances.

  The journal of physical chemistry. B 20080207

• Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.

  European journal of pharmacology 20080202

• Secretory products from human adipocytes impair endothelial function via nuclear factor kappaB.

  Atherosclerosis 20080201

• Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry.

  Biomedical chromatography : BMC 20080201

• Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

  British journal of pharmacology 20080201

• Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, PPARgamma agonists, differentially regulate cigarette smoke-mediated pro-inflammatory cytokine release in monocytes/macrophages.

  Antioxidants & redox signaling 20080201

• Effects of the ethanol extract of the roots of Brassica rapa on glucose and lipid metabolism in C57BL/KsJ-db/db mice.

  Clinical nutrition (Edinburgh, Scotland) 20080201

• Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins.

  The Journal of pharmacology and experimental therapeutics 20080201

• Rosiglitazone transiently disturbs calcium homeostasis in monocytic cells.

  Biochemical and biophysical research communications 20080201

• Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing.

  American journal of physiology. Renal physiology 20080201

• Effects of rosiglitazone on altered electrical left ventricular papillary muscle activities of diabetic rat.

  Naunyn-Schmiedeberg's archives of pharmacology 20080201

• Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.

  Hypertension (Dallas, Tex. : 1979) 20080201

• Inflammation and lipid accumulation in xanthoma disseminatum: Therapeutic considerations.

  Journal of the American Academy of Dermatology 20080201

• Reduction of proteinuria by rosiglitazone in non-diabetic renal disease.

  Nephrology (Carlton, Vic.) 20080201

• Lipoxygenase-derived metabolites are regulators of peroxisome proliferator-activated receptor gamma-2 expression in human vascular smooth muscle cells.

  American journal of hypertension 20080201

• Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes.

  Journal of immunology (Baltimore, Md. : 1950) 20080201

• Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients.

  Acta pharmacologica Sinica 20080201

• Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.

  Expert opinion on pharmacotherapy 20080201

• Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

  Expert opinion on pharmacotherapy 20080201

• [Glitazone - mailing no 4. In response to DMW 49/2007].

  Deutsche medizinische Wochenschrift (1946) 20080201

• [One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study].

  Annales d'endocrinologie 20080201

• Inappropriate prescribing in geriatric patients.

  Current psychiatry reports 20080201

• Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.

  Minerva ginecologica 20080201

• Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.

  Neuro endocrinology letters 20080201

• Pharmacogenomics of metabolic effects of rosiglitazone.

  Pharmacogenomics 20080201

• Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.

  Endocrine 20080201

• Reviewer leaked Avandia study to drug firm.

  Nature 20080131

• [Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents].

  Revue medicale suisse 20080130

• Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.

  Chinese medical journal 20080120

• Cardiovascular safety of low-dose rosiglitazone.

  Archives of internal medicine 20080114

• Investigation of racemisation of the enantiomers of glitazone drug compounds at different pH using chiral HPLC and chiral CE.

  Journal of pharmaceutical and biomedical analysis 20080107

• A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.

  World journal of gastroenterology 20080107

• No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.

  British journal of clinical pharmacology 20080101

• Bone biology and physiology: implications for novel osteoblastic osteosarcoma treatments?

  Medical hypotheses 20080101

• Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?

  Medical hypotheses 20080101

• Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment.

  Thrombosis research 20080101

• Ectopic expression of porcine peroxisome proliferator-activated receptor delta regulates adipogenesis in mouse myoblasts.

  Journal of animal science 20080101

• Rosiglitazone increases matrix production and quenches inflammation: studies in human cells.

  Diabetes/metabolism research and reviews 20080101

• Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

  The Journal of clinical endocrinology and metabolism 20080101

• Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse.

  Diabetes, obesity & metabolism 20080101

• Rosiglitazone treatment attenuates expression of inflammatory hallmarks in the remaining kidney following contralateral nephrectomy.

  American journal of nephrology 20080101

• Thiazolidinediones as anti-inflammatory and anti-atherogenic agents.

  Diabetes/metabolism research and reviews 20080101

• Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone.

  Circulation 20080101

• Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice.

  Hepatology (Baltimore, Md.) 20080101

• Augmentation of nitric oxide is crucial for the time-dependent effects of rosiglitazone on blood pressure and baroreflex function in rats.

  Journal of hypertension 20080101

• Bone marrow stromal cell lines having high potential for osteoclast-supporting activity express PPARgamma1 and show high potential for differentiation into adipocytes.

  Journal of bone and mineral metabolism 20080101

• Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20080101

• PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.

  Journal of gastroenterology and hepatology 20080101

• Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidine (TZDs).

  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20080101

• Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.

  Arthritis research & therapy 20080101

• A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.

  Archives of dermatology 20080101

• Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles.

  Thrombosis and haemostasis 20080101

• Characterization of vascular reactivity in dorsal hand veins after oral rosiglitazone treatment in healthy subjects.

  International journal of clinical pharmacology and therapeutics 20080101

• Choosing first-line therapy for management of type 2 diabetes.

  American family physician 20080101

• Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.

  BMC cancer 20080101

• The value equation for rosiglitazone and pioglitazone in older persons.

  Geriatric nursing (New York, N.Y.) 20080101

• Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.

  Cardiovascular diabetology 20080101

• Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors.

  Journal of the cardiometabolic syndrome 20080101

• Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101

• The PPARgamma agonist FMOC-L-leucine protects both mature and immature brain.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone.

  Hormones (Athens, Greece) 20080101

• Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

  Clinical trials (London, England) 20080101

• Effect of rosiglitazone on cardiac fibroblast proliferation, nitric oxide production and connective tissue growth factor expression induced by advanced glycation end-products.

  The Journal of international medical research 20080101

• Re: 'Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome', Sinha SK et al., JPEM 2007; 20: 1045-1052.

  Journal of pediatric endocrinology & metabolism : JPEM 20080101

• Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus.

  Clinical drug investigation 20080101

• Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).

  Cardiovascular diabetology 20080101

• Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.

  Molecular medicine (Cambridge, Mass.) 20080101

• Rosiglitazone-induced anasarca without heart failure: capillary leakage?

  Hormones (Athens, Greece) 20080101

• Palmitate-induced beta-cell dysfunction is associated with excessive NO production and is reversed by thiazolidinedione-mediated inhibition of GPR40 transduction mechanisms.

  PloS one 20080101

• Progeny from dedifferentiated bovine adipocytes display protracted adipogenesis.

  Cells, tissues, organs 20080101

• A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006.

  American journal of therapeutics 20080101

• Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.

  Anticancer research 20080101

• Simpson's paradox visualized: the example of the rosiglitazone meta-analysis.

  BMC medical research methodology 20080101

• Applications of proteomics to the study of adipose tissue.

  Methods in molecular biology (Clifton, N.J.) 20080101

• A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.

  Chemotherapy 20080101

• The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits.

  Thrombosis research 20080101

• Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment.

  Cardiovascular diabetology 20080101

• The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations.

  BMC developmental biology 20080101

• Rosiglitazone-enriched diet did not protect liver ischemia-reperfusion injury in a rat model.

  Acta cirurgica brasileira 20080101

• Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.

  American journal of therapeutics 20080101

• Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.

  PloS one 20080101

• Rosiglitazone attenuates allergic inflammation and inhibits expression of galectin-3 in a mouse model of allergic rhinitis.

  The Journal of international medical research 20080101

• Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis.

  Hormone research 20080101

• Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling.

  PPAR research 20080101

• Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics.

  Arzneimittel-Forschung 20080101

• LPIN1 genetic variation is associated with rosiglitazone response in type 2 diabetic patients.

  Molecular genetics and metabolism 20080101

• Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

  Journal of managed care pharmacy : JMCP 20080101

• Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.

  HIV clinical trials 20080101

• PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis.

  Angiogenesis 20080101

• Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.

  Clinical laboratory 20080101

• Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.

  Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20080101

• Does metabolic syndrome influence psoriasis?

  European review for medical and pharmacological sciences 20080101

• Cardiovascular risk and cardiometabolic protection: role of glitazones.

  Journal of nephrology 20080101

• Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.

  Arthritis research & therapy 20080101

• Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.

  Current topics in medicinal chemistry 20080101

• Role of PPAR-gamma in the modulation of CD36 and FcgammaRII induced by LDL with low and high degrees of oxidation during the differentiation of the monocytic THP-1 cell line.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20080101

• [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].

  Journal de la Societe de biologie 20080101

• [Avandia and avandamet in the treatment of patients with diabetes mellitus type 2: effects on secretion of some fat tissue hormones].

  Terapevticheskii arkhiv 20080101

• Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.

  Human genomics 20080101

• [Effects of combined treatment with rosiglitazone and intermediate-acting insulin on carbohydrate metabolism in patients with type 2 diabetes mellitus].

  Terapevticheskii arkhiv 20080101

• Effect of ciprofloxacin and ibuprofen on the in vitro metabolism of rosiglitazone and oral pharmacokinetics of rosiglitazone in healthy human volunteers.

  European journal of drug metabolism and pharmacokinetics 20080101

• Rosiglitazone and cardiovascular disease-recent controversy.

  Indian heart journal 20080101

• Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.

  The Journal of biological chemistry 20071221

• Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.

  Bioorganic & medicinal chemistry letters 20071215

• Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.

  Bioorganic & medicinal chemistry letters 20071215

• Anti-inflammatory lipid mediator 15d-PGJ2 inhibits translation through inactivation of eIF4A.

  The EMBO journal 20071212

• Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.

  JAMA 20071212

• [Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].

  Orvosi hetilap 20071209

• [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].

  MMW Fortschritte der Medizin 20071206

• Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis.

  Digestive diseases and sciences 20071201

• Pioglitazone: an anti-diabetic compound with anti-aging properties.

  Biogerontology 20071201

• Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.

  Acta diabetologica 20071201

• The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms.

  The Journal of clinical endocrinology and metabolism 20071201

• Effects of pioglitazone and rosiglitazone on aortic vascular function in rat genetic hypertension.

  European journal of pharmacology 20071201

• Rosiglitazone decreases albuminuria in type 2 diabetic patients.

  Kidney international 20071201

• Essential role of mitochondrial function in adiponectin synthesis in adipocytes.

  Diabetes 20071201

• PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.

  American journal of physiology. Endocrinology and metabolism 20071201

• Simultaneously quantitative measurement of comprehensive profiles of esterified and non-esterified fatty acid in plasma of type 2 diabetic patients.

  Chemistry and physics of lipids 20071201

• The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese mice.

  Lung 20071201

• Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism.

  Arteriosclerosis, thrombosis, and vascular biology 20071201

• Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.

  Arteriosclerosis, thrombosis, and vascular biology 20071201

• Use of insulin sensitizers in NASH.

  Endocrinology and metabolism clinics of North America 20071201

• Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?

  Kidney international 20071201

• Thiazolidinedione-induced edema in patients with heart failure.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071201

• Meta-analysis of small trials: proceed with caution.

  Nature clinical practice. Cardiovascular medicine 20071201

• Studies of diabetes, thiazolidinediones, and coronary heart disease.

  Pharmacoepidemiology and drug safety 20071201

• Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.

  Diabetes care 20071201

• Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation.

  Journal of natural products 20071201

• Effects of rosiglitazone on methionine-choline deficient diet-induced nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20071201

• Diabetes expert accuses drug company of 'intimidation'.

  BMJ (Clinical research ed.) 20071201

• [Therapy with glitazones--a risk for cardiovascular disease?].

  Deutsche medizinische Wochenschrift (1946) 20071201

• [Determining the current position regarding the value of pioglitazone for the therapy of diabetes].

  Deutsche medizinische Wochenschrift (1946) 20071201

• Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial.

  Croatian medical journal 20071201

• Cardiovascular risk in women with polycystic ovary syndrome.

  Minerva endocrinologica 20071201

• Supplementation of a novel microbial biopolymer, PGB1, from new Enterobacter sp. BL-2 delays the deterioration of type 2 diabetic mice.

  Journal of microbiology and biotechnology 20071201

• Glitazones and your heart, revisited.

  Diabetes forecast 20071201

• Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.

  Yao xue xue bao = Acta pharmaceutica Sinica 20071201

• Rosiglitazone and the thiazolidinediones: a changing context.

  Primary care diabetes 20071201

• Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients.

  AIDS (London, England) 20071130

• Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.

  Nature 20071129

• [Antidiabetic with increased risk of coronary disease].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20071115

• Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats.

  Life sciences 20071110

• Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome.

  Atherosclerosis 20071101

• Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.

  Atherosclerosis 20071101

• Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus.

  Atherosclerosis 20071101

• Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

  Diabetes, obesity & metabolism 20071101

• Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.

  International journal of obesity (2005) 20071101

• High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.

  Pharmacoepidemiology and drug safety 20071101

• PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism.

  Blood 20071101

• Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.

  Diabetic medicine : a journal of the British Diabetic Association 20071101

• Norepinephrine and rosiglitazone synergistically induce Elovl3 expression in brown adipocytes.

  American journal of physiology. Endocrinology and metabolism 20071101

• Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass.

  American journal of physiology. Endocrinology and metabolism 20071101

• Is peroxisome proliferator-activated receptor-gamma a new 'pal' of renin?

  Hypertension (Dallas, Tex. : 1979) 20071101

• A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus.

  American journal of physiology. Heart and circulatory physiology 20071101

• Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.

  Basic & clinical pharmacology & toxicology 20071101

• Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.

  Diabetes, obesity & metabolism 20071101

• Rosiglitazone: opening Pandora's black box?

  Clinical journal of the American Society of Nephrology : CJASN 20071101

• Zinc deficiency alters lipid metabolism in LDL receptor deficient mice treated with rosiglitazone.

  The Journal of nutrition 20071101

• Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus 'off-target' effectors.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071101

• The Avandia debacle: methodology and practical importance of the findings.

  Southern medical journal 20071101

• Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.

  Southern medical journal 20071101

• Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.

  Fundamental & clinical pharmacology 20071101

• Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.

  Fundamental & clinical pharmacology 20071101

• A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells.

  Clinical nephrology 20071101

• Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.

  Vascular medicine (London, England) 20071101

• Induction of circadian gene expression in human subcutaneous adipose-derived stem cells.

  Obesity (Silver Spring, Md.) 20071101

• Prolonged decrease of adipocyte size after rosiglitazone treatment in high- and low-fat-fed rats.

  Obesity (Silver Spring, Md.) 20071101

• [Rosiglitazone enhances the anti-atherosclerotic effects of peroxisome proliferator-activated receptor gamma1 gene transfer in apolipoprotein-knock out mice].

  Zhonghua xin xue guan bing za zhi 20071101

• Agonists of PPAR-alpha, PPAR-gamma, and RXR inhibit the formation of foam cells from macrophages in mice with inflammation.

  Bulletin of experimental biology and medicine 20071101

• Expression and regulation of osteoprotegerin in adipose tissue.

  Yonsei medical journal 20071031

• Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.

  Statistics in medicine 20071030

• Rosiglitazone and the FDA.

  The New England journal of medicine 20071025

• Rosiglitazone and the FDA.

  The New England journal of medicine 20071025

• [Rosiglitazone--statistics for benefits and problems].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20071018

• [Glitazones--again].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20071018

• Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.

  Annals of internal medicine 20071016

• Rosiglitazone: a thunderstorm from scarce and fragile data.

  Annals of internal medicine 20071016

• [Doubts as to the cardiovascular safety of rosiglitazone].

  Nederlands tijdschrift voor geneeskunde 20071006

• Stimulation of the peroxisome proliferator-activated receptor gamma (PPAR gamma) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy.

  Atherosclerosis 20071001

• Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities.

  European journal of medicinal chemistry 20071001

• PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study.

  Fertility and sterility 20071001

• Differential ability of a thiazolidinedione PPARgamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells.

  Journal of neurochemistry 20071001

• The anti-diabetic effects of ethanol extract from two variants of Artemisia princeps Pampanini in C57BL/KsJ-db/db mice.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20071001

• Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.

  Diabetes care 20071001

• Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones.

  Cardiovascular research 20071001

• Exercise reverses high-fat diet-induced impairments on compartmentalization and activation of components of the insulin-signaling cascade in skeletal muscle.

  American journal of physiology. Endocrinology and metabolism 20071001

• Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071001

• The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis.

  Hepatology (Baltimore, Md.) 20071001

• PPARgamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats.

  Bone 20071001

• A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.

  Pharmacoepidemiology and drug safety 20071001

• In clarification.

  Pharmacoepidemiology and drug safety 20071001

• Ginseng modifies the diabetic phenotype and genes associated with diabetes in the male ZDF rat.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20071001

• 15-Deoxy-delta(12,14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways.

  Experimental cell research 20071001

• A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.

  Oncology reports 20071001

• Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice.

  The Journal of clinical investigation 20071001

• [Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].

  Der Internist 20071001

• Reduced expression of insulin receptors in the kidneys of insulin-resistant rats.

  Journal of the American Society of Nephrology : JASN 20071001

• Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.

  Metabolism: clinical and experimental 20071001

• Weight gain may contribute to increased fracture risk in women treated with rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20071001

• The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.

  Pharmacological research 20071001

• Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes.

  The Journal of endocrinology 20071001

• 67 th annual meeting of the American Diabetes Association.

  Expert opinion on investigational drugs 20071001

• Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20071001

• Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20071001

• Avandia in perspective.

  U.S. news & world report 20071001

• Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.

  Journal of endocrinological investigation 20071001

• [Effect of rosiglitazone on NO and eNOS via PI3K/PKB signal pathways in cultured human umbilical vein endothelial cells].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20071001

• [Glitazones in type 2 diabetes--documented risks, uncertain benefits].

  Lakartidningen 20071001

• [Glitazones more than hypoglycemics in type 2 diabetes].

  Lakartidningen 20071001

• [Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy].

  Georgian medical news 20071001

• Ensuring drug safety: lessons from the thiazolidinediones.

  Lancet (London, England) 20070929

• Thiazolidinediones, deadly sins, surrogates, and elephants.

  Lancet (London, England) 20070929

• Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

  Lancet (London, England) 20070929

• MI risks linked to rosiglitazone.

  JAMA 20070912

• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  JAMA 20070912

• Cardiovascular risk and the thiazolidinediones: déjà vu all over again?

  JAMA 20070912

• [The effect of single nucleotide polymorphism SNP + 45 of the adiponectin gene on the rosiglitazone maleate response in patients with type 2 diabetes].

  Zhonghua yi xue za zhi 20070911

• [Stop selling rosiglitazone].

  Ugeskrift for laeger 20070903

• The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease.

  Digestive diseases and sciences 20070901

• Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.

  Molecular pharmacology 20070901

• Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue.

  Clinical endocrinology 20070901

• Adipocyte-derived serum amyloid A3 and hyaluronan play a role in monocyte recruitment and adhesion.

  Diabetes 20070901

• Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.

  Diabetes care 20070901

• Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women.

  The Journal of clinical endocrinology and metabolism 20070901

• Thiazolidinediones and fluid retention.

  Kidney international 20070901

• Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.

  Diabetologia 20070901

• Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene.

  International journal of oncology 20070901

• Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice.

  Basic & clinical pharmacology & toxicology 20070901

• Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone.

  Diabetes, obesity & metabolism 20070901

• Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus.

  Acta diabetologica 20070901

• Rosiglitazone and myocardial infarction: cause for concern or misleading meta-analysis?

  Diabetic medicine : a journal of the British Diabetic Association 20070901

• The Avandia debate.

  Diabetes care 20070901

• Future directions for insulin sensitizers in disease prevention.

  Current opinion in investigational drugs (London, England : 2000) 20070901

• Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase.

  The Journal of endocrinology 20070901

• Rosiglitazone: failure of oversight or demons imagined?

  The Journal of family practice 20070901

• New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.

  Journal of medical genetics 20070901

• American Diabetes Association - 67th scientific sessions.

  IDrugs : the investigational drugs journal 20070901

• Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells.

  Cytokine 20070901

• Perspective: effect of rosiglitazone on cardiovascular outcomes.

  Current cardiology reports 20070901

• Expression and secretion of the atrial natriuretic peptide in human adipose tissue and preadipocytes.

  Obesity (Silver Spring, Md.) 20070901

• [Effects of rosiglitazone on Kruppul-like factor 6 (KLF6) signaling in the livers of rats with nonalcoholic fatty liver fibrosis].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20070901

• Avandia update. Committee urges caution on heart risks.

  Diabetes forecast 20070901

• [Mechanism of rosiglitasone to improve glucose-uptake of 3T3-L1 adipocyte with insulin resistance induced by dexamethasone and insulin].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20070901

• [What about the controversy regarding rosiglitazone].

  Revue medicale de Liege 20070901

• A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

  Clinical therapeutics 20070901

• Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.

  Journal of pediatric endocrinology & metabolism : JPEM 20070901

• The rosiglitazone story--lessons from an FDA Advisory Committee meeting.

  The New England journal of medicine 20070830

• Rosiglitazone and cardiovascular risk.

  The New England journal of medicine 20070830

• Rosiglitazone and cardiovascular risk.

  The New England journal of medicine 20070830

• Rosiglitazone and cardiovascular risk.

  The New England journal of medicine 20070830

• Rosiglitazone and cardiovascular risk.

  The New England journal of medicine 20070830

• Rosiglitazone attenuates transplant arteriosclerosis after allogeneic aorta transplantation in rats.

  Transplantation 20070827

• Rosiglitazone attenuates NF-kappaB-dependent ICAM-1 and TNF-alpha production caused by homocysteine via inhibiting ERK1/2/p38MAPK activation.

  Biochemical and biophysical research communications 20070817

• Keeping science on top in drug evaluation.

  The New England journal of medicine 20070816

• Design of a partial PPARdelta agonist.

  Bioorganic & medicinal chemistry letters 20070815

• Cytosolic aspartate aminotransferase, a new partner in adipocyte glyceroneogenesis and an atypical target of thiazolidinedione.

  The Journal of biological chemistry 20070810

• FDA committees say keep rosiglitazone available but increase warnings.

  BMJ (Clinical research ed.) 20070804

• Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes.

  Diabetes research and clinical practice 20070801

• Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.

  International journal of obesity (2005) 20070801

• Comparison of mitochondrial and macrophage content between subcutaneous and visceral fat in db/db mice.

  Experimental and molecular pathology 20070801

• Ligand-activated peroxisome proliferator activated receptor gamma alters placental morphology and placental fatty acid uptake in mice.

  Endocrinology 20070801

• Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs.

  Burns : journal of the International Society for Burn Injuries 20070801

• Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts.

  Cardiovascular research 20070801

• Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20070801

• Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.

  European journal of clinical pharmacology 20070801

• Indanylacetic acids as PPAR-delta activator insulin sensitizers.

  Bioorganic & medicinal chemistry letters 20070801

• The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?

  Current opinion in lipidology 20070801

• Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model.

  The Australian & New Zealand journal of obstetrics & gynaecology 20070801

• C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes.

  The Journal of endocrinology 20070801

• Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.

  Hepatology (Baltimore, Md.) 20070801

• The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment.

  European journal of endocrinology 20070801

• The effect of rosiglitazone on orthostatic tolerance during heat exposure in individuals with type II diabetes.

  Diabetes technology & therapeutics 20070801

• Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

  Harvard heart letter : from Harvard Medical School 20070801

• By the way, doctor. First it was Vioxx and now Avandia. Why can't doctors and the government screen out unsafe medicines?

  Harvard health letter 20070801

• Heart failure risk prompts warning labels on diabetes drugs. The concern now is whether this particular class of drugs causes other cardiovascular problems.

  Harvard women's health watch 20070801

• One hundred years after the discovery of Alzheimer's disease. A turning point for therapy?

  Journal of Alzheimer's disease : JAD 20070801

• Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.

  Vascular health and risk management 20070801

• Rosiglitazone for type 2 diabetes mellitus.

  The Cochrane database of systematic reviews 20070718

• Interventions for latent autoimmune diabetes (LADA) in adults.

  The Cochrane database of systematic reviews 20070718

• Thiazolidinediones and cardiovascular disease.

  The Medical letter on drugs and therapeutics 20070716

• Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

  Circulation 20070710

• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  The New England journal of medicine 20070705

• Rosiglitazone--continued uncertainty about safety.

  The New England journal of medicine 20070705

• Rosiglitazone and cardiotoxicity--weighing the evidence.

  The New England journal of medicine 20070705

• The record on rosiglitazone and the risk of myocardial infarction.

  The New England journal of medicine 20070705

• Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

  Diabetes/metabolism research and reviews 20070701

• Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20070701

• Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.

  Diabetes 20070701

• Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.

  Diabetes 20070701

• Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone.

  Diabetes 20070701

• Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070701

• PPAR-gamma knockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone on caerulein-induced acute pancreatitis.

  American journal of physiology. Gastrointestinal and liver physiology 20070701

• Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.

  The Journal of clinical endocrinology and metabolism 20070701

• Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a single-dose hyperglycaemic clamp study.

  Diabetologia 20070701

• Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.

  Bioorganic & medicinal chemistry letters 20070701

• Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma.

  Journal of molecular and cellular cardiology 20070701

• Coronary heart disease outcomes in patients receiving antidiabetic agents.

  Pharmacoepidemiology and drug safety 20070701

• Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.

  American heart journal 20070701

• Activation of PPARgamma enhances in vitro the immunosuppressive effect of cyclosporine on T lymphocytes.

  Transplant immunology 20070701

• Faster publication isn't always better.

  Nature clinical practice. Cardiovascular medicine 20070701

• Synthesis and evaluation of 2-Nonylaminopyridine derivatives as PPAR ligands.

  Chemical & pharmaceutical bulletin 20070701

• A power surge before a short circuit.

  Nature medicine 20070701

• Straight talk from... Bruce Psaty. Interviewed by Emma Marris.

  Nature medicine 20070701

• Development and validation of a selective online dissolution method for rosiglitazone maleate.

  Journal of chromatographic science 20070701

• Preventing diabetes, Part II: an action plan.

  Harvard men's health watch 20070701

• [Rosiglitazone--under fire].

  Kardiologia polska 20070701

• Options sought after drug study. Patients who take rosiglitazone might consider pioglitazone instead.

  Heart advisor 20070701

• Avandia and your heart.

  Diabetes forecast 20070701

• Diabetes drugs under scrutiny in a post-Vioxx world.

  Nature reviews. Drug discovery 20070701

• The rosiglitazone controversy: the Indian perspective.

  The Journal of the Association of Physicians of India 20070701

• [Doubts as to the cardiovascular safety of rosiglitazone].

  Nederlands tijdschrift voor geneeskunde 20070630

• The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis.

  The Journal of biological chemistry 20070629

• [Increased risk of myocardial infarction following rosiglitazone?].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20070628

• Rosiglitazone suppresses cyclosporin-induced chronic transplant dysfunction and prolongs survival of rat cardiac allografts.

  Transplantation 20070627

• Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.

  Archives of internal medicine 20070625

• Data and safety monitoring of rosiglitazone trials.

  Lancet (London, England) 20070623

• Rosiglitazone and implications for pharmacovigilance.

  BMJ (Clinical research ed.) 20070616

• Glycaemic control is a myth.

  BMJ (Clinical research ed.) 20070616

• Cardiovascular safety of rosiglitazone.

  Lancet (London, England) 20070616

• A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.

  The Journal of infectious diseases 20070615

• Drug safety. Heart attack risk overshadows a popular diabetes therapy.

  Science (New York, N.Y.) 20070615

• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  The New England journal of medicine 20070614

• Rosiglitazone and cardiovascular risk.

  The New England journal of medicine 20070614

• Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.

  Life sciences 20070613

• Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands.

  The Journal of biological chemistry 20070608

• Heart-stopping news. The diabetes drug Avandia is under fire: what you should know. Interview by Avery Comarow.

  U.S. news & world report 20070604

• Rosiglitazone: seeking a balanced perspective.

  Lancet (London, England) 20070602

• Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070601

• Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein.

  Cell biology international 20070601

• Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.

  American journal of physiology. Gastrointestinal and liver physiology 20070601

• Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells.

  Molecular pharmacology 20070601

• Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.

  Endocrinology 20070601

• A fraction of Acorus calamus L. extract devoid of beta-asarone enhances adipocyte differentiation in 3T3-L1 cells.

  Phytotherapy research : PTR 20070601

• The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.

  Vascular pharmacology 20070601

• Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes.

  Molecular pharmacology 20070601

• Measurement of liver collagen synthesis by heavy water labeling: effects of profibrotic toxicants and antifibrotic interventions.

  American journal of physiology. Gastrointestinal and liver physiology 20070601

• Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.

  Diabetes care 20070601

• Laminar shear stress up-regulates the expression of stearoyl-CoA desaturase-1 in vascular endothelial cells.

  Cardiovascular research 20070601

• Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells.

  The Journal of clinical endocrinology and metabolism 20070601

• Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.

  Molecular pharmacology 20070601

• Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors.

  Arteriosclerosis, thrombosis, and vascular biology 20070601

• Effects of rosiglitazone on native low-density-lipoprotein-induced respiratory burst in circulating monocytes and on the leukocyte-endothelial interaction in cholesterol-fed rats.

  Naunyn-Schmiedeberg's archives of pharmacology 20070601

• IL-13 induces expression of CD36 in human monocytes through PPARgamma activation.

  European journal of immunology 20070601

• 4-Hydroxynonenal and PPARgamma ligands affect proliferation, differentiation, and apoptosis in colon cancer cells.

  Free radical biology & medicine 20070601

• Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

  Journal of clinical pharmacy and therapeutics 20070601

• Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.

  Acta pharmacologica Sinica 20070601

• Rosiglitazone RECORD study: glucose control outcomes at 18 months.

  Diabetic medicine : a journal of the British Diabetic Association 20070601

• Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?

  Diabetes care 20070601

• Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.

  Expert opinion on pharmacotherapy 20070601

• Clinical research observations with use of exubera in patients with type 1 and 2 diabetes.

  Diabetes technology & therapeutics 20070601

• [An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20070601

• COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy.

  Thyroid : official journal of the American Thyroid Association 20070601

• Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202.

  Endocrine-related cancer 20070601

• Effect of Rosiglitazone Maleate on inflammation following cerebral ischemia/reperfusion in rats.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20070601

• Rosiglitazone and cardiovascular disease: a diabetologist's perspective.

  Diabetes & vascular disease research 20070601

• Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.

  Diabetes & vascular disease research 20070601

• Rosiglitazone and cardiovascular disease: a cardiologist's perspective.

  Diabetes & vascular disease research 20070601

• Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat.

  Diabetes & vascular disease research 20070601

• [Three studies in type 2 diabetes: ADOPT Rosiglitazone monotherapy in type 2 diabetes: what indication?].

  Annales d'endocrinologie 20070601

• [Three studies in type 2 diabetes: DREAM the wash-out results].

  Annales d'endocrinologie 20070601

• Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

  Clinical therapeutics 20070601

• Time for a medical.

  Nature 20070531

• Weighing up the evidence.

  Nature 20070531

• Man on a mission.

  Nature 20070531

• Study indicates diabetes drug linked to cardiovascular death.

  BMJ (Clinical research ed.) 20070526

• Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.

  European journal of pharmacology 20070521

• 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development.

  Journal of immunology (Baltimore, Md. : 1950) 20070515

• Hospital admission associated with Medicare Part D 'doughnut hole'.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070515

• [The pharmacological prevention and treatment of diabetes mellitus; significance of 2 recent, large studies for the use of rosiglitazone].

  Nederlands tijdschrift voor geneeskunde 20070512

• Effect of glucolipotoxicity and rosiglitazone upon insulin secretion.

  Biochemical and biophysical research communications 20070511

• Beta-cell preservation with thiazolidinediones.

  Diabetes research and clinical practice 20070501

• Thiazolidinediones and the risk of edema: a meta-analysis.

  Diabetes research and clinical practice 20070501

• A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity.

  Molecular pharmacology 20070501

• Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.

  The Journal of clinical endocrinology and metabolism 20070501

• The Interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver.

  Journal of hepatology 20070501

• Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.

  The Journal of clinical endocrinology and metabolism 20070501

• Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.

  Diabetologia 20070501

• Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas.

  Stroke 20070501

• PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.

  Pharmacological research 20070501

• Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.

  International journal of oncology 20070501

• Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.

  Diabetes, obesity & metabolism 20070501

• Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.

  Cellular and molecular life sciences : CMLS 20070501

• Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.

  Metabolism: clinical and experimental 20070501

• Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.

  Diabetes 20070501

• Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.

  Diabetes 20070501

• Synergy between PPARgamma ligands and platinum-based drugs in cancer.

  Cancer cell 20070501

• The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction.

  Gastroenterology 20070501

• Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.

  British journal of clinical pharmacology 20070501

• The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis.

  Journal of clinical immunology 20070501

• Long-term treatment of central Cushing's syndrome with rosiglitazone.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20070501

• Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.

  Journal of digestive diseases 20070501

• Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070501

• [Effects of Shengqi Jiangtang Granule on rat model of insulin resistance and its mechanism].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20070501

• Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.

  Current diabetes reviews 20070501

• Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes.

  European journal of pharmacology 20070430

• Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats.

  Yonsei medical journal 20070430

• Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat.

  Yonsei medical journal 20070430

• A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

  Journal of the American College of Cardiology 20070424

• Fluid retention with thiazolidinediones: does the mechanism influence the outcome?

  Journal of the American College of Cardiology 20070424

• Diabetes drugs tied to fractures in women.

  JAMA 20070418

• Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.

  Bioorganic & medicinal chemistry letters 20070415

• [ADOPT study: Reevaluation of antidiabetic drugs. Control of diabetes].

  MMW Fortschritte der Medizin 20070412

• [Consulting Prof. Dr. Stephan Matthaei. Quakenbrück diabetes center. Prescription relevant conclusions].

  MMW Fortschritte der Medizin 20070412

• Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.

  Journal of medicinal chemistry 20070405

• Metabolic syndrome: a work in progress, but a useful construct.

  Circulation 20070403

• Expression and potential role of peroxisome proliferator-activated receptor gamma in the placenta of diabetic pregnancy.

  Placenta 20070401

• Involvement of adipose tissues in the early hypolipidemic action of PPARgamma agonism in the rat.

  American journal of physiology. Regulatory, integrative and comparative physiology 20070401

• Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.

  Journal of the American Academy of Dermatology 20070401

• Synthesis and evaluation of N-acetyl-L-tyrosine based compounds as PPARalpha selective activators.

  European journal of medicinal chemistry 20070401

• Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

  American journal of physiology. Lung cellular and molecular physiology 20070401

• Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.

  Clinical pharmacology and therapeutics 20070401

• Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages.

  Diabetes 20070401

• Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.

  Diabetes care 20070401

• Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.

  Toxicological sciences : an official journal of the Society of Toxicology 20070401

• The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.

  The Journal of clinical endocrinology and metabolism 20070401

• Involvement of PPARgamma in human trophoblast invasion.

  Placenta 20070401

• Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.

  Journal of neurochemistry 20070401

• The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.

  American journal of obstetrics and gynecology 20070401

• Larval zebrafish as a model for glucose metabolism: expression of phosphoenolpyruvate carboxykinase as a marker for exposure to anti-diabetic compounds.

  Journal of molecular endocrinology 20070401

• Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes.

  Pediatric diabetes 20070401

• The inhibitory effect of rosiglitazone on agonist-induced or spontaneous regulation of contractility.

  Archives of pharmacal research 20070401

• Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination.

  Vascular health and risk management 20070401

• Glycemic durability of monotherapy for diabetes.

  The New England journal of medicine 20070329

• Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.

  Annals of internal medicine 20070320

• Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma.

  World journal of gastroenterology 20070314

• Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.

  Circulation 20070313

• Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.

  Journal of medicinal chemistry 20070308

• [The pharmacological prevention and treatment of diabetes mellitus; significance of 2 recent, large studies for the use of rosiglitazone].

  Nederlands tijdschrift voor geneeskunde 20070303

• Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.

  British journal of clinical pharmacology 20070301

• Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.

  Molecular pharmacology 20070301

• Tetradecylselenoacetic acid, a PPAR ligand with antioxidant, antiinflammatory, and hypolipidemic properties.

  Arteriosclerosis, thrombosis, and vascular biology 20070301

• Absence of an adipogenic effect of rosiglitazone on mature 3T3-L1 adipocytes: increase of lipid catabolism and reduction of adipokine expression.

  Diabetologia 20070301

• Identification of novel human high-density lipoprotein receptor Up-regulators using a cell-based high-throughput screening assay.

  Journal of biomolecular screening 20070301

• Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.

  Journal of internal medicine 20070301

• A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.

  American heart journal 20070301

• Elevated creatine kinase and myalgia in a patient taking rosiglitazone.

  The Annals of pharmacotherapy 20070301

• Rosiglitazone induces mitochondrial biogenesis in mouse brain.

  Journal of Alzheimer's disease : JAD 20070301

• [Effect of rosiglitazone on integrin beta1 expression and apoptosis of proximal tubular cell exposed to high glucose].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20070301

• [Effect of PPAR-gamma ligand RGZ on inhibiting the cell proliferation of cholangiocarcinoma].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20070301

• [Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].

  Bulletin de l'Academie nationale de medecine 20070301

• Challenges of fragmented care in long-term management of pelvic pain.

  The Journal of family practice 20070301

• Design and synthesis of a novel class of dual PPARgamma/delta agonists.

  Bioorganic & medicinal chemistry letters 20070215

• Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.

  Bioorganic & medicinal chemistry letters 20070215

• Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.

  Bioorganic & medicinal chemistry letters 20070215

• Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production.

  Journal of the neurological sciences 20070215

• Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).

  The pharmacogenomics journal 20070201

• Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells.

  Diabetes/metabolism research and reviews 20070201

• Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis.

  American journal of physiology. Gastrointestinal and liver physiology 20070201

• Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.

  Endocrinology 20070201

• Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20070201

• Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?

  British journal of pharmacology 20070201

• Effects of rosiglitazone and high fat diet on lipase/esterase expression in adipose tissue.

  Biochimica et biophysica acta 20070201

• Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.

  Clinical endocrinology 20070201

• Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.

  Internal medicine journal 20070201

• Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.

  Journal of clinical pharmacology 20070201

• Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.

  The American journal of pathology 20070201

• DREAM and ADOPT: rosiglitazone does what it says on the packet.

  Diabetic medicine : a journal of the British Diabetic Association 20070201

• Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

  Diabetes care 20070201

• Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.

  American journal of hypertension 20070201

• Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity.

  Cell metabolism 20070201

• Leukemia inhibitory factor influences the fate choice of mesenchymal progenitor cells.

  Stem cells (Dayton, Ohio) 20070201

• Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study.

  European journal of endocrinology 20070201

• Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.

  Croatian medical journal 20070201

• [Effect of rosiglitazone on the expression of T-bet/GATA-3 in T lymphocytes in patients with acute asthma].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20070201

• The anti-atherogenic effects of thiazolidinediones.

  Current diabetes reviews 20070201

• Effect of thiazolidinediones on bile acid transport in rat liver.

  Life sciences 20070130

• Sensitive and selective liquid chromatography-mass spectrometry method for the quantification of rosiglitazone in human plasma.

  Journal of pharmaceutical and biomedical analysis 20070117

• [The DREAM of diabetes prevention].

  Revue medicale suisse 20070117

• Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis.

  Biochemical pharmacology 20070115

• Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole.

  Oncogene 20070111

• Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.

  AIDS (London, England) 20070102

• Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide.

  Basic research in cardiology 20070101

• Effects of thiazolidinediones on stroke recovery: a case-matched controlled study.

  Neurochemical research 20070101

• Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.

  Clinical chemistry 20070101

• Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.

  Journal of cellular physiology 20070101

• No functional role of plasminogen activator inhibitor-1 in murine adipogenesis or adipocyte differentiation.

  Journal of thrombosis and haemostasis : JTH 20070101

• Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study.

  Fertility and sterility 20070101

• Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.

  Physiological research 20070101

• Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes.

  Diabetologia 20070101

• Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver.

  Journal of hepatology 20070101

• Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.

  Naunyn-Schmiedeberg's archives of pharmacology 20070101

• Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

  Metabolism: clinical and experimental 20070101

• A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20070101

• Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone.

  Journal of diabetes and its complications 20070101

• A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

  PharmacoEconomics 20070101

• Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects.

  Diabetes care 20070101

• Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

  Diabetes 20070101

• Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070101

• Pharmacokinetic interactions with thiazolidinediones.

  Clinical pharmacokinetics 20070101

• Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2?

  Clinical chemistry 20070101

• Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.

  Diabetic medicine : a journal of the British Diabetic Association 20070101

• Synthesis and binding affinity of a fluorine-substituted peroxisome proliferator-activated gamma (PPARgamma) ligand as a potential positron emission tomography (PET) imaging agent.

  Bioconjugate chemistry 20070101

• Strategies for the labeling of halogen-substituted peroxisome proliferator-activated receptor gamma ligands: potential positron emission tomography and single photon emission computed tomography imaging agents.

  Bioconjugate chemistry 20070101

• Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.

  Journal of diabetes and its complications 20070101

• An optimized in vitro assay for screening compounds that stimulate liver cell glucose utilization with low cytotoxicity.

  Journal of pharmacological and toxicological methods 20070101

• [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].

  Revue medicale de Liege 20070101

• The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.

  Anticancer research 20070101

• Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat.

  Annals of nutrition & metabolism 20070101

• Reversal of nicotine-induced alveolar lipofibroblast-to-myofibroblast transdifferentiation by stimulants of parathyroid hormone-related protein signaling.

  Lung 20070101

• Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone.

  American journal of clinical dermatology 20070101

• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor-gamma, prevents contralateral testicular ischaemia-reperfusion injury in prepubertal rats.

  Clinical and experimental pharmacology & physiology 20070101

• Thiazolidinedione induced thyroid associated orbitopathy.

  BMC ophthalmology 20070101

• LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome.

  PloS one 20070101

• Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways.

  Pharmacology 20070101

• Ghrelin and insulin gene expression changes in streptozotocin-induced diabetic rats after rosiglitazone pretreatment.

  European journal of histochemistry : EJH 20070101

• Aortic preadipocyte differentiation into adipocytes induced by rosiglitazone in an in vitro model.

  In vitro cellular & developmental biology. Animal 20070101

• Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.

  Pharmacology 20070101

• Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.

  BMC medicine 20070101

• Renoprotective effects of rosiglitazone in stroke-prone spontaneously hypertensive rats.

  Kidney & blood pressure research 20070101

• Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2.

  PPAR research 20070101

• The perfect storm--drug safety and rosiglitazone.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20070101

• The rosiglitazone meta-analysis.

  Reviews in cardiovascular medicine 20070101

• Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance.

  Blood pressure 20070101

• [ADOPT study. Glitazone controls diabetes progression].

  MMW Fortschritte der Medizin 20070101

• PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats.

  Nephron. Experimental nephrology 20070101

• Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.

  American journal of nephrology 20070101

• [New rank order of antidiabetic drugs. Using glitazone before sulfonylurea drugs? (interview by Dr. Dirk Einecke)].

  MMW Fortschritte der Medizin 20070101

• Actos and Avandia in type 2 diabetes. Where do they fit?

  Diabetes self-management 20070101

• The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.

  Neuroendocrinology 20070101

• Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.

  Journal of the cardiometabolic syndrome 20070101

• Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.

  Cardiovascular diabetology 20070101

• A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

  PharmacoEconomics 20070101

• Impaired knowledge for fruits and vegetables in semantic dementia.

  The Journal of neuropsychiatry and clinical neurosciences 20070101

• [The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman--preliminary report].

  Przeglad lekarski 20070101

• Rosiglitazone and heart failure: the controversy and clinical implications.

  Congestive heart failure (Greenwich, Conn.) 20070101

• Impact of rosiglitazone on the expression of beta3-AR in the stable cell lines expressed beta3-AR gene.

  Clinical chemistry and laboratory medicine 20070101

• Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience.

  Angiology 20070101

• Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.

  Clinical therapeutics 20070101

• Rosiglitazone and cardiovascular risk: weighing recent evidence.

  Journal of the cardiometabolic syndrome 20070101

• Rosiglitazone : a review of its use in type 2 diabetes mellitus.

  Drugs 20070101

• [Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk].

  Terapevticheskii arkhiv 20070101

• Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice.

  Archives of physiology and biochemistry 20070101

• Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.

  In vivo (Athens, Greece) 20070101

• Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20070101

• [Experiences of the DREAM trial].

  Orvosi hetilap 20061231

• Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

  Bioorganic & medicinal chemistry letters 20061215

• Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.

  Bioorganic & medicinal chemistry letters 20061215

• The DREAM trial.

  Lancet (London, England) 20061209

• The DREAM trial.

  Lancet (London, England) 20061209

• Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2.

  Biochemical and biophysical research communications 20061208

• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  The New England journal of medicine 20061207

• Thiazolidinediones for initial treatment of type 2 diabetes?

  The New England journal of medicine 20061207

• Placental transfer of rosiglitazone in the ex vivo human perfusion model.

  American journal of obstetrics and gynecology 20061201

• The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.

  British journal of clinical pharmacology 20061201

• Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.

  Bioorganic & medicinal chemistry letters 20061201

• Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.

  Bioorganic & medicinal chemistry letters 20061201

• Rosiglitazone inhibits mouse liver regeneration.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061201

• Genotoxicity in rats treated with the antidiabetic agent, rosiglitazone.

  Environmental and molecular mutagenesis 20061201

• Effect of various diuretic treatments on rosiglitazone-induced fluid retention.

  Journal of the American Society of Nephrology : JASN 20061201

• A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

  Diabetic medicine : a journal of the British Diabetic Association 20061201

• Rosiglitazone-induced immune thrombocytopenia.

  Platelets 20061201

• Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance.

  Diabetes 20061201

• Search for the preadipocyte progenitor cell.

  The Journal of clinical investigation 20061201

• Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells.

  The Journal of clinical investigation 20061201

• Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis.

  The American journal of pathology 20061201

• Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.

  Diabetes & vascular disease research 20061201

• Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.

  Clinical pharmacology and therapeutics 20061201

• Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients.

  Clinical and experimental pharmacology & physiology 20061201

• A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.

  Surgery 20061201

• Synthesis and evaluation of (S)-2-ethoxy-3-phenylpropanoic acid derivatives as insulin-sensitizing agents.

  Journal of enzyme inhibition and medicinal chemistry 20061201

• [Effects of rosiglitazone on the expression connective tissue growth factor in tubulointerstitium in KKA(y) mice].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20061201

• Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones.

  The Journal of pharmacy and pharmacology 20061201

• Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).

  Bioorganic & medicinal chemistry letters 20061115

• More data needed on drug to delay the onset of diabetes.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20061107

• Free fatty acids normalize a rosiglitazone-induced visfatin release.

  American journal of physiology. Endocrinology and metabolism 20061101

• Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.

  Bioorganic & medicinal chemistry letters 20061101

• The effect of rosiglitazone in the prevention of intra-abdominal adhesion formation in a rat uterine horn model.

  Human reproduction (Oxford, England) 20061101

• Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

  Diabetes, obesity & metabolism 20061101

• Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke.

  Clinical and experimental pharmacology & physiology 20061101

• Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

  Diabetes care 20061101

• Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials.

  Current medical research and opinion 20061101

• Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.

  Hypertension research : official journal of the Japanese Society of Hypertension 20061101

• Peroxisome proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats.

  World journal of gastroenterology 20061028

• Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.

  International journal of cardiology 20061026

• Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma.

  Journal of immunology (Baltimore, Md. : 1950) 20061015

• Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.

  The American journal of cardiology 20061015

• [Diabetes manifestation. Should they be prevented with drugs?].

  MMW Fortschritte der Medizin 20061012

• [DREAM Study for prevention of diabetes. What conclusions may we draw?].

  MMW Fortschritte der Medizin 20061012

• Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells.

  British journal of cancer 20061009

• Glucose lowering and diabetes prevention: are they the same?

  Lancet (London, England) 20061007

• PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells.

  The Journal of experimental medicine 20061002

• Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay.

  Biomedical chromatography : BMC 20061001

• Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.

  Drug metabolism and disposition: the biological fate of chemicals 20061001

• Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.

  Kidney international 20061001

• Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone.

  Diabetologia 20061001

• PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control.

  Diabetologia 20061001

• An in vivo murine model of rosiglitazone use in pregnancy.

  Fertility and sterility 20061001

• Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.

  Journal of hypertension 20061001

• Porcine peroxisome proliferator-activated receptor gamma induces transdifferentiation of myocytes into adipocytes.

  Journal of animal science 20061001

• Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20061001

• The long-term effects of rosiglitazone on serum lipid concentrations and body weight.

  Clinical endocrinology 20061001

• Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.

  British journal of clinical pharmacology 20061001

• Ovarian stockpiling in polycystic ovary syndrome, infertility, and the combined use of rosiglitazone and metformin.

  Diabetes care 20061001

• Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.

  Diabetes care 20061001

• Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats.

  Diabetes 20061001

• Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.

  Investigative ophthalmology & visual science 20061001

• Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells.

  Gastroenterology 20061001

• Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.

  Journal of drugs in dermatology : JDD 20061001

• Peripheral cytokine expression in autoimmune thyroiditis: effects of in vitro modulation by rosiglitazone and dexamethasone.

  Thyroid : official journal of the American Thyroid Association 20061001

• [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].

  Revue medicale de Liege 20061001

• DREAM study and its impact on India.

  The Journal of the Association of Physicians of India 20061001

• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  Lancet (London, England) 20060923

• Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.

  Journal of medicinal chemistry 20060921

• SB-271258, a major metabolite in the dog of the thiazolidinedione, rosiglitazone, stimulates protein synthesis in re-differentiated rat cardiomyocytes in vitro.

  Toxicology in vitro : an international journal published in association with BIBRA 20060901

• Peroxisome proliferator-activated receptors increase human sebum production.

  The Journal of investigative dermatology 20060901

• PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060901

• Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.

  Vascular pharmacology 20060901

• Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.

  Endocrinology 20060901

• Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.

  Endocrinology 20060901

• Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.

  The Journal of clinical endocrinology and metabolism 20060901

• Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.

  The Annals of pharmacotherapy 20060901

• JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor gamma in vitro and in vivo.

  Diabetes, obesity & metabolism 20060901

• Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.

  Diabetes, obesity & metabolism 20060901

• PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor.

  Clinical endocrinology 20060901

• Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.

  Clinical nuclear medicine 20060901

• Exposure to rosiglitazone and fluoxetine in the first trimester of pregnancy.

  Diabetes care 20060901

• Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.

  Diabetes 20060901

• Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes.

  International journal of clinical practice 20060901

• 15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanism.

  Prostaglandins & other lipid mediators 20060901

• Insulin sensitization induced by oral cicletanine in conscious rabbits.

  Naunyn-Schmiedeberg's archives of pharmacology 20060901

• Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20060901

• Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.

  Current medical research and opinion 20060901

• Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20060901

• [Effect of rosiglitazone on metalloproteinase tissue inhibitor-1 in CCl4-induced liver fibrosis in rats].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20060901

• Altered PPARgamma expression and activation after transient focal ischemia in rats.

  The European journal of neuroscience 20060901

• Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes.

  Journal of the renin-angiotensin-aldosterone system : JRAAS 20060901

• Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.

  Cancer letters 20060828

• Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells.

  Biochemical pharmacology 20060828

• Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.

  European journal of pharmacology 20060821

• KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.

  Biochemical pharmacology 20060814

• [Glitazone treatment of type 2 diabetes mellitus].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20060810

• Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease.

  Gut 20060801

• Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK.

  American journal of physiology. Heart and circulatory physiology 20060801

• A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.

  The Journal of pharmacology and experimental therapeutics 20060801

• Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle.

  Toxicological sciences : an official journal of the Society of Toxicology 20060801

• Rosiglitazone ameliorates cisplatin-induced renal injury in mice.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060801

• Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha.

  Toxicological sciences : an official journal of the Society of Toxicology 20060801

• PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.

  Cancer biology & therapy 20060801

• Rosiglitazone modifies the adipogenic potential of human muscle satellite cells.

  Diabetologia 20060801

• Effect of rosiglitazone on embryonic growth and morphology: a study using a whole rat embryo culture model.

  Fertility and sterility 20060801

• Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.

  Protein science : a publication of the Protein Society 20060801

• Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition.

  American journal of physiology. Cell physiology 20060801

• Total cellular calcium and magnesium content of cultured human peripheral blood mononuclear cells following exposure to antidiabetic drugs.

  Acta diabetologica 20060801

• Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.

  Diabetes 20060801

• Rosiglitazone and macular edema.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060801

• Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

  Journal of clinical pharmacy and therapeutics 20060801

• PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.

  Journal of proteome research 20060801

• Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.

  Chemical research in toxicology 20060801

• Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.

  Anti-cancer drugs 20060801

• [Effects of rosiglitazone on endothelium-dependent vasodilation in patients with Type 2 diabetes].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20060801

• Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.

  Molecular diversity 20060801

• Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.

  Journal of medicinal chemistry 20060727

• Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.

  World journal of gastroenterology 20060721

• Cytotoxic mechanisms of Zn2+ and Cd2+ involve Na+/H+ exchanger (NHE) activation by ROS.

  Aquatic toxicology (Amsterdam, Netherlands) 20060720

• Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome.

  Chinese medical journal 20060720

• Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists.

  Journal of medicinal chemistry 20060713

• Peroxisome proliferator-activated receptor-gamma inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells.

  American journal of physiology. Lung cellular and molecular physiology 20060701

• Rosiglitazone as a cause of acute interstitial nephritis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701

• Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation.

  Molecular pharmacology 20060701

• Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism.

  Vascular pharmacology 20060701

• The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.

  British journal of pharmacology 20060701

• Expanding role of AMPK in endocrinology.

  Trends in endocrinology and metabolism: TEM 20060701

• The role of PPARs in the microvascular dysfunction in diabetes.

  Vascular pharmacology 20060701

• Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.

  The Journal of allergy and clinical immunology 20060701

• 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.

  Molecular cancer therapeutics 20060701

• [Effects of rosiglitazone on the expression of beta1, integrin and ICAM-1 in high glucose-induced rat glomerular mesangial cells].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20060701

• Formulation and evaluation of mucoadhesive dosage form containing rosiglitazone maleate.

  Pakistan journal of pharmaceutical sciences 20060701

• [A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis].

  Zhonghua nei ke za zhi 20060701

• Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.

  Biochemical pharmacology 20060628

• Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A.

  Biochemical and biophysical research communications 20060623

• Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment.

  Journal of the American College of Cardiology 20060620

• The synthesis of tethered ligand dimers for PPARgamma-RXR protein heterodimers.

  Organic & biomolecular chemistry 20060607

• Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia.

  Brain research 20060606

• Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study.

  Human reproduction (Oxford, England) 20060601

• Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation.

  Endocrinology 20060601

• Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice.

  Experimental neurology 20060601

• Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.

  Diabetologia 20060601

• Peroxisome proliferator-activated receptors and acute lung injury.

  Current opinion in pharmacology 20060601

• Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

  Diabetologia 20060601

• Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents hyperoxia-induced neonatal rat lung injury in vivo.

  Pediatric pulmonology 20060601

• Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060601

• Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist.

  Journal of the American Society of Nephrology : JASN 20060601

• Rosiglitazone cools down inflammation in the metabolic syndrome.

  Arteriosclerosis, thrombosis, and vascular biology 20060601

• The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes.

  Diabetes care 20060601

• Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes.

  Diabetes care 20060601

• PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease.

  Experimental neurology 20060601

• Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications.

  PLoS medicine 20060601

• Thiazolidinedione derivatives in type 2 diabetes mellitus.

  The Netherlands journal of medicine 20060601

• Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.

  Diabetes & metabolism 20060601

• Symptoms and treatments of polycystic ovary syndrome.

  British journal of nursing (Mark Allen Publishing) 20060601

• [Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed type 2 diabetic patients].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20060601

• Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone?

  Nature clinical practice. Nephrology 20060601

• Reimbursement decision-making and prescription patterns of glitazones in treatment of type 2 diabetes mellitus patients in Denmark.

  Health care analysis : HCA : journal of health philosophy and policy 20060601

• [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].

  Zhonghua yi xue za zhi 20060516

• Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone.

  International journal of cancer 20060515

• Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle.

  The Journal of physiology 20060515

• Rosiglitazone controls fatty acid cycling in human adipose tissue by means of glyceroneogenesis and glycerol phosphorylation.

  The Journal of biological chemistry 20060512

• Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells.

  The Journal of biological chemistry 20060512

• PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway.

  Oncogene 20060504

• Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes.

  Atherosclerosis 20060501

• Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.

  European journal of obstetrics, gynecology, and reproductive biology 20060501

• Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060501

• Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid.

  Acta pharmacologica Sinica 20060501

• Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.

  Diabetes care 20060501

• The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome.

  Clinical endocrinology 20060501

• Suspected suppression of the INR by thiazolidinediones: interaction between warfarin and TZDs.

  The Annals of pharmacotherapy 20060501

• Rosiglitazone-induced immune thrombocytopenia.

  Platelets 20060501

• [Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome].

  Arquivos brasileiros de cardiologia 20060501

• [Protective effect of rosiglitazone on myocardium in diabetic cardiomyopathy of rats].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20060501

• Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.

  Diabetes & vascular disease research 20060501

• Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

  Clinical therapeutics 20060501

• Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells.

  Biochemical pharmacology 20060428

• Reactive oxygen species have a causal role in multiple forms of insulin resistance.

  Nature 20060413

• [Dermatomyositis, lipodystrophy and insulin resistance].

  Medicina clinica 20060408

• Role and mechanism of rosiglitazone on the impairment of insulin secretion induced by free fatty acids on isolated rat islets.

  Chinese medical journal 20060405

• Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.

  The Journal of pharmacology and experimental therapeutics 20060401

• Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.

  The Journal of clinical endocrinology and metabolism 20060401

• Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.

  Arteriosclerosis, thrombosis, and vascular biology 20060401

• Effects of rosiglitazone and metformin on pancreatic beta cell gene expression.

  Diabetologia 20060401

• Mitochondria are impaired in the adipocytes of type 2 diabetic mice.

  Diabetologia 20060401

• Surface enhanced laser desorption ionization spectrometry reveals biomarkers for drug treatment but not dose.

  Proteomics 20060401

• Repaglinide in the management of new-onset diabetes mellitus after renal transplantation.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060401

• Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

  Journal of neurochemistry 20060401

• Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.

  Metabolism: clinical and experimental 20060401

• Optimal treatments for the metabolic syndrome.

  Arteriosclerosis, thrombosis, and vascular biology 20060401

• [Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases].

  Medecine sciences : M/S 20060401

• Re: Effects of rosiglitazone on hormonal profile and ovulatory function in Chinese women with polycystic ovary syndrome.

  The Australian & New Zealand journal of obstetrics & gynaecology 20060401

• Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.

  Infection 20060401

• AMPK regulation of mouse oocyte meiotic resumption in vitro.

  Developmental biology 20060315

• Rosiglitazone/glimepiride (Avandaryl) for diabetes.

  The Medical letter on drugs and therapeutics 20060313

• The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20060301

• Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.

  Arteriosclerosis, thrombosis, and vascular biology 20060301

• 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury.

  Arteriosclerosis, thrombosis, and vascular biology 20060301

• PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression.

  Lung cancer (Amsterdam, Netherlands) 20060301

• Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

  Diabetes, obesity & metabolism 20060301

• Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.

  Diabetes, obesity & metabolism 20060301

• Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

  The American journal of cardiology 20060301

• Type 2 diabetes, psoriasis and thiazolidinediones.

  International journal of clinical practice 20060301

• Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome.

  European journal of endocrinology 20060301

• The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.

  Diabetes 20060301

• Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue.

  Diabetes 20060301

• Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

  Diabetes care 20060301

• Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.

  Diabetes care 20060301

• Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma.

  Biological & pharmaceutical bulletin 20060301

• Effects of fatty acids on skeletal muscle cell differentiation in vitro.

  The British journal of nutrition 20060301

• Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.

  Journal of managed care pharmacy : JMCP 20060301

• The effect of rosiglitazone on overweight subjects with type 1 diabetes.

  Diabetes care 20060301

• Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes.

  Biochemical pharmacology 20060227

• Rosiglitazone (Avandia) and macular edema.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060227

• Rosiglitazone inhibits endothelial proliferation and angiogenesis.

  Life sciences 20060223

• Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.

  The Journal of biological chemistry 20060210

• Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.

  Journal of medicinal chemistry 20060209

• Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity.

  Biochemical and biophysical research communications 20060203

• Insulin and oleic acid increase PPARgamma2 expression in cultured mouse hepatocytes.

  Biochemical and biophysical research communications 20060203

• Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20060201

• Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle.

  American journal of physiology. Endocrinology and metabolism 20060201

• Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes.

  Endocrinology 20060201

• Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.

  The Journal of pharmacology and experimental therapeutics 20060201

• Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.

  Endocrinology 20060201

• Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1.

  Endocrinology 20060201

• Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.

  The Journal of clinical endocrinology and metabolism 20060201

• Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil.

  Pharmacological research 20060201

• Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease.

  Clinical endocrinology 20060201

• Rosiglitazone reduces the evolution of experimental periodontitis in the rat.

  Journal of dental research 20060201

• Improving metabolic control leads to better working memory in adults with type 2 diabetes.

  Diabetes care 20060201

• Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity.

  Cancer research 20060201

• Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.

  Pharmacotherapy 20060201

• Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways.

  Molecular cancer therapeutics 20060201

• [Rosiglitazone].

  Revue de l'infirmiere 20060201

• A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome.

  Fertility and sterility 20060201

• Substituted indanylacetic acids as PPAR-alpha-gamma activators.

  Bioorganic & medicinal chemistry letters 20060115

• Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion.

  European journal of pharmacology 20060113

• The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

  Diabetes research and clinical practice 20060101

• Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus.

  Diabetes/metabolism research and reviews 20060101

• The effect of the PPARgamma ligand rosiglitazone on energy balance regulation.

  Diabetes/metabolism research and reviews 20060101

• Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.

  Bone 20060101

• Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.

  Human reproduction (Oxford, England) 20060101

• PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1.

  American journal of physiology. Heart and circulatory physiology 20060101

• Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.

  Human reproduction (Oxford, England) 20060101

• Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats.

  Pharmacological research 20060101

• PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids.

  Nutrition (Burbank, Los Angeles County, Calif.) 20060101

• The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.

  Pulmonary pharmacology & therapeutics 20060101

• The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.

  Chembiochem : a European journal of chemical biology 20060101

• Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride.

  Metabolism: clinical and experimental 20060101

• Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo.

  Hypertension (Dallas, Tex. : 1979) 20060101

• Rosiglitazone-associated pseudotumour cerebri.

  Diabetologia 20060101

• Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes.

  American journal of physiology. Regulatory, integrative and comparative physiology 20060101

• Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

  Diabetes, obesity & metabolism 20060101

• Effects of metformin and oleic acid on adipocyte expression of resistin.

  Diabetes, obesity & metabolism 20060101

• The impact of rosiglitazone on cardiovascular responses and endurance during isometric exercise in patients with Type 2 diabetes.

  Medical science monitor : international medical journal of experimental and clinical research 20060101

• Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model.

  Journal of the Society for Gynecologic Investigation 20060101

• Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.

  Diabetes 20060101

• Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists.

  Cancer research 20060101

• A meta-analysis of the effect of thiazolidinediones on blood pressure.

  Journal of clinical hypertension (Greenwich, Conn.) 20060101

• Liver failure in a patient receiving rosiglitazone therapy.

  Diabetic medicine : a journal of the British Diabetic Association 20060101

• The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20060101

• Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

  The pharmacogenomics journal 20060101

• A preadipocyte differentiation assay as a method for screening potential anti-type II diabetes drugs from herbal extracts.

  Planta medica 20060101

• Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma.

  American journal of nephrology 20060101

• Rosiglitazone relieves acute ethanol-induced hangover in Sprague-Dawley rats.

  Alcohol and alcoholism (Oxford, Oxfordshire) 20060101

• Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening.

  International journal of toxicology 20060101

• Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.

  Journal of intensive care medicine 20060101

• Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes.

  Medicinski arhiv 20060101

• Rosiglitazone regulates ENaC and Na-K-2Cl cotransporter (NKCC2) abundance in the obese Zucker rat.

  American journal of nephrology 20060101

• Diabetic macular edema associated with glitazone use.

  Retina (Philadelphia, Pa.) 20060101

• Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

  PharmacoEconomics 20060101

• Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.

  PharmacoEconomics 20060101

• Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

  PharmacoEconomics 20060101

• Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat.

  Anticancer research 20060101

• Rosiglitazone antagonizes vascular endothelial growth factor signaling and nuclear factor of activated T cells activation in cardiac valve endothelium.

  Endothelium : journal of endothelial cell research 20060101

• The effects of thiazolidinediones on blood pressure levels - a systematic review.

  Blood pressure 20060101

• Genetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer's disease.

  The pharmacogenomics journal 20060101

• Spontaneous singleton and twin pregnancy in two patients with polycystic ovary syndrome and type 2 diabetes following treatment with metformin combined with rosiglitazone.

  Annals of Saudi medicine 20060101

• Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.

  Clinical pharmacokinetics 20060101

• [Eucaloric substitution of medium chain triglycerides for dietary long chain fatty acids improves body composition and lipid profile in a patient with human immunodeficiency virus lipodystrophy].

  Nutricion hospitalaria 20060101

• Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20060101

• Quantitative characterization of 15-deoxy-delta(12,14)-prostaglandin J2 in regulating EGFPSmad2 translocation in CHO cells through PPARgamma/TGFbeta/Smad2 pathway.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20060101

• Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes.

  PharmacoEconomics 20060101

• Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375.

  Medical oncology (Northwood, London, England) 20060101

• First-derivative spectrophotometry in the analysis of rosiglitazone in coated tablets.

  Journal of AOAC International 20060101

• New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).

  Acta medica Indonesiana 20060101

• Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution.

  Blood purification 20060101

• Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.

  The Journal of international medical research 20060101

• Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial.

  Advances in therapy 20060101

• [Stress and inflammatory bowell disease (I.B.D). Therapeutic strategies].

  Anales de la Real Academia Nacional de Medicina 20060101

• Two-year effect of rosiglitazone in chinese poorly controlled type 2 diabetic patients.

  Chang Gung medical journal 20060101

• Bioequivalence evaluation of two rosiglitazone tablet formulations.

  Arzneimittel-Forschung 20060101

• The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?

  Blood pressure 20060101

• [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].

  Akusherstvo i ginekologiia 20060101

• Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.

  Journal of medicinal chemistry 20051229

• Solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry for determination of trace rosiglitazone in urine.

  Journal of chromatography. A 20051202

• The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.

  Human reproduction (Oxford, England) 20051201

• Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat.

  The Journal of pharmacology and experimental therapeutics 20051201

• Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma.

  Molecular pharmacology 20051201

• Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes.

  Atherosclerosis 20051201

• Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.

  The Journal of clinical endocrinology and metabolism 20051201

• Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway.

  The Journal of clinical endocrinology and metabolism 20051201

• PPAR-gamma-agonists' renal effects.

  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20051201

• Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.

  Diabetes 20051201

• Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.

  Diabetes care 20051201

• FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.

  Journal of pharmacological sciences 20051201

• The impact of rosiglitazone on heat tolerance in patients with type 2 diabetes.

  Medical science monitor : international medical journal of experimental and clinical research 20051201

• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al.

  Diabetes care 20051201

• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al.

  Diabetes care 20051201

• Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.

  Current medical research and opinion 20051201

• Effect of rosiglitazone on early-morning plasma cortisol levels.

  Neuro endocrinology letters 20051201

• Derivation of adipocytes from human embryonic stem cells.

  Stem cells and development 20051201

• The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.

  Journal of endocrinological investigation 20051201

• Rosiglitazone therapy of posttransplant diabetes mellitus.

  Transplantation 20051127

• Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma.

  Biochemical and biophysical research communications 20051125

• Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARgamma.

  Biochemical and biophysical research communications 20051118

• [Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance].

  Zhonghua yi xue za zhi 20051116

• Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists.

  Bioorganic & medicinal chemistry letters 20051115

• The study of anti-metabolic syndrome effect of puerarin in vitro.

  Life sciences 20051104

• [PPARgamma agonists--antidiabetics with positive effects on cardiovascular risk?].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20051103

• PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells.

  Atherosclerosis 20051101

• Prevalence of coronary artery calcium among asymptomatic men and women in a developing country: comparison with the USA data.

  Atherosclerosis 20051101

• Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones.

  European journal of medicinal chemistry 20051101

• Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production.

  The Journal of clinical endocrinology and metabolism 20051101

• Rating the severity of the medical consequences of drug-induced liver injury.

  Regulatory toxicology and pharmacology : RTP 20051101

• Contrasting effects of insulin and cellular differentiation on expression of the novel insulin receptor substrate APS in skeletal muscle.

  Biochemical pharmacology 20051101

• Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.

  Toxicology and applied pharmacology 20051101

• Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20051101

• Creatine kinase elevation in a patient taking rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20051101

• Rb and p107 regulate preadipocyte differentiation into white versus brown fat through repression of PGC-1alpha.

  Cell metabolism 20051101

• Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20051101

• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20051101

• [Protective effects of rosiglitazone on hepatotoxicity in hepatocytes cultured with cyclosporine A].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20051101

• (+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats.

  Obesity research 20051101

• Effects of glitazones on blood pressure and vascular structure in mesenteric resistance arteries and basilar artery from genetically hypertensive rats.

  Clinical and experimental pharmacology & physiology 20051101

• [Effect of PPARgamma agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits].

  Yao xue xue bao = Acta pharmaceutica Sinica 20051101

• Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.

  Hypertension research : official journal of the Japanese Society of Hypertension 20051101

• Prevention of type 2 diabetes in the prediabetic population.

  Journal of the Indian Medical Association 20051101

• Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.

  Biochemical and biophysical research communications 20051028

• Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment.

  European journal of pharmacology 20051017

• Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation.

  Experimental cell research 20051015

• Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs.

  Bioorganic & medicinal chemistry letters 20051015

• Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions.

  Molecular endocrinology (Baltimore, Md.) 20051001

• Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.

  The Journal of pharmacology and experimental therapeutics 20051001

• Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.

  Experimental brain research 20051001

• Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.

  Diabetes research and clinical practice 20051001

• Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.

  Diabetologia 20051001

• The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats.

  Metabolism: clinical and experimental 20051001

• 'PPAR'ting ways with inflammation.

  Nature immunology 20051001

• Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes.

  International journal of clinical practice 20051001

• Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20051001

• Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.

  Pharmacotherapy 20051001

• Rational drug design and PPAR agonists.

  Current diabetes reports 20051001

• Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy.

  European journal of endocrinology 20051001

• Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats.

  Critical care medicine 20051001

• Peroxisome proliferator-activated receptor-gamma ligands protect against lung injury: potential therapeutic targets?

  Critical care medicine 20051001

• Inhibitory effect of PPAR-gamma activator on IL-6 and mPGES protein expression in PBMC induced by homocysteine.

  Hemodialysis international. International Symposium on Home Hemodialysis 20051001

• Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

  Clinical therapeutics 20051001

• Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

  Clinical therapeutics 20051001

• Leukopenia and thrombocytopenia caused by thiazolidinediones.

  Annals of internal medicine 20050920

• Summaries for patients. HIV lipodystrophy: rosiglitazone or metformin?

  Annals of internal medicine 20050906

• Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.

  Annals of internal medicine 20050906

• Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.

  European journal of pharmacology 20050905

• Induction of apoptosis in colorectal cancer cells by peroxisome proliferators-activated receptor gamma activation up-regulating PTEN and inhibiting PI3K activity.

  Chinese medical journal 20050905

• Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFkappaB signal disruption in human WISH and amnion cells.

  Biology of reproduction 20050901

• Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione.

  European journal of medicinal chemistry 20050901

• Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1.

  American journal of physiology. Lung cellular and molecular physiology 20050901

• Inhibitors of prostaglandin transport and metabolism augment protease-activated receptor-2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation in mouse isolated trachea.

  The Journal of pharmacology and experimental therapeutics 20050901

• Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment.

  The Journal of clinical endocrinology and metabolism 20050901

• PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.

  Arteriosclerosis, thrombosis, and vascular biology 20050901

• Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.

  British journal of pharmacology 20050901

• Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers.

  Arteriosclerosis, thrombosis, and vascular biology 20050901

• Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.

  Arteriosclerosis, thrombosis, and vascular biology 20050901

• Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.

  Arteriosclerosis, thrombosis, and vascular biology 20050901

• Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.

  Diabetologia 20050901

• Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.

  Analytical biochemistry 20050901

• Pharmacological profile of a novel, non-TZD PPARgamma agonist.

  Diabetes, obesity & metabolism 20050901

• Management of diabetes during Ramadan.

  Diabetic medicine : a journal of the British Diabetic Association 20050901

• Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.

  Diabetes 20050901

• Thiazolidinediones and lowered HDL cholesterol.

  Diabetes care 20050901

• Stockpiling of ovarian follicles and the response to rosiglitazone.

  Diabetes care 20050901

• The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.

  Metabolism: clinical and experimental 20050901

• Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050901

• Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20050901

• Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.

  Acta dermatovenerologica Alpina, Pannonica, et Adriatica 20050901

• Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization.

  Obesity research 20050901

• Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

  Clinical therapeutics 20050901

• The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20050901

• Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.

  Journal of medicinal chemistry 20050825

• Microarray analysis of early adipogenesis in C3H10T1/2 cells: cooperative inhibitory effects of growth factors and 2,3,7,8-tetrachlorodibenzo-p-dioxin.

  Toxicology and applied pharmacology 20050822

• Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation.

  Biochemical and biophysical research communications 20050819

• Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice.

  Circulation research 20050819

• Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells.

  World journal of gastroenterology 20050814

• Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial.

  AIDS (London, England) 20050812

• Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats.

  American journal of physiology. Renal physiology 20050801

• Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone.

  American journal of physiology. Renal physiology 20050801

• Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20050801

• The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin.

  Molecular carcinogenesis 20050801

• Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients.

  The Journal of antimicrobial chemotherapy 20050801

• Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy.

  Diabetologia 20050801

• Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050801

• Hepatic injury in a patient taking rosiglitazone.

  Journal of clinical gastroenterology 20050801

• Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.

  Journal of clinical pharmacology 20050801

• Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.

  Diabetes care 20050801

• Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.

  Diabetes 20050801

• Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes.

  Clinical pharmacology and therapeutics 20050801

• [The effect of high fat feeding and rosiglitazone intervention on pancreatic alpha cell in rats].

  Zhonghua nei ke za zhi 20050801

• The PPAR-gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium.

  Biochemical and biophysical research communications 20050729

• Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.

  Nature 20050721

• 6-Aryl-4-methylsulfanyl-2H-pyran-2-one-3-carbonitriles as PPAR-gamma activators.

  Bioorganic & medicinal chemistry letters 20050715

• Physiologic and pharmacologic factors influencing glyceroneogenic contribution to triacylglyceride glycerol measured by mass isotopomer distribution analysis.

  The Journal of biological chemistry 20050708

• Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.

  The Journal of pharmacology and experimental therapeutics 20050701

• Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones.

  International journal of obesity (2005) 20050701

• Short-term rosiglitazone treatment in renal transplant recipients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050701

• Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.

  The Journal of clinical endocrinology and metabolism 20050701

• Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.

  International journal of obesity (2005) 20050701

• The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.

  Diabetes, obesity & metabolism 20050701

• A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.

  Diabetes research and clinical practice 20050701

• Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20050701

• Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease.

  Clinical endocrinology 20050701

• Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.

  Diabetes 20050701

• Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.

  Diabetes 20050701

• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  Diabetes care 20050701

• The effect of rosiglitazone on overweight subjects with type 1 diabetes.

  Diabetes care 20050701

• Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.

  European journal of endocrinology 20050701

• A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice.

  Biological & pharmaceutical bulletin 20050701

• Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration.

  Experimental gerontology 20050701

• Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.

  Journal of medicinal chemistry 20050630

• The mouse CCR2 gene is regulated by two promoters that are responsive to plasma cholesterol and peroxisome proliferator-activated receptor gamma ligands.

  Biochemical and biophysical research communications 20050624

• [Protection of rosiglitazone against renal interstitial lesion and its mechanism].

  Zhonghua yi xue za zhi 20050622

• Rosiglitazone improves post-infarction left ventricular contractile function in rats.

  Chinese medical journal 20050620

• [Medical management of primary nonalcoholic fatty liver disease].

  Medicina clinica 20050618

• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.

  Biochemical pharmacology 20050615

• PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis.

  American journal of physiology. Lung cellular and molecular physiology 20050601

• Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone.

  The Journal of clinical endocrinology and metabolism 20050601

• Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats.

  Journal of lipid research 20050601

• PPAR-gamma modulates allergic inflammation through up-regulation of PTEN.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050601

• Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050601

• A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

  Molecular endocrinology (Baltimore, Md.) 20050601

• Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1.

  Diabetologia 20050601

• Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats.

  Diabetologia 20050601

• Gait characteristics in patients with type 2 diabetes; improvement after administration of rosiglitazone.

  Medical science monitor : international medical journal of experimental and clinical research 20050601

• Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes.

  Diabetes 20050601

• Mild, reversible pancytopenia induced by rosiglitazone.

  Diabetes care 20050601

• Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes.

  The American journal of gastroenterology 20050601

• Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.

  Endocrine-related cancer 20050601

• Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease.

  Endocrine journal 20050601

• Thiazolidinediones in type 2 diabetes--have they lived up to expectations?

  Journal of the Indian Medical Association 20050601

• Fatty acids and expression of adipokines.

  Biochimica et biophysica acta 20050530

• Selective PPARgamma modulators with improved pharmacological profiles.

  Bioorganic & medicinal chemistry letters 20050516

• Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.

  Molecular and cellular endocrinology 20050512

• DASH: a novel analysis method for molecular dynamics simulation data. Analysis of ligands of PPAR-gamma.

  Journal of medicinal chemistry 20050505

• Effectiveness and side effects of thiazolidinediones for type 2 diabetes.

  The Medical journal of Australia 20050502

• Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.

  American journal of physiology. Endocrinology and metabolism 20050501

• Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway.

  Molecular pharmacology 20050501

• Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.

  Cardiology clinics 20050501

• Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.

  Journal of clinical pharmacology 20050501

• Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance: does it really work? If yes, is it a novelty?

  Diabetic medicine : a journal of the British Diabetic Association 20050501

• Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma.

  Diabetes 20050501

• Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.

  Diabetes 20050501

• The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.

  Diabetes care 20050501

• Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARgamma ligand rosiglitazone.

  The Journal of nutrition 20050501

• Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.

  Metabolism: clinical and experimental 20050501

• Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet.

  Metabolism: clinical and experimental 20050501

• Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells.

  Thrombosis and haemostasis 20050501

• The Clinical Significance of PPAR Gamma Agonism.

  Current molecular medicine 20050501

• Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

  Pharmacotherapy 20050501

• [Rosiglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice].

  Zhonghua xin xue guan bing za zhi 20050501

• [A Markov model to access long-term effects of rosiglitazone natrium on the treatment of type 2 diabetes].

  Wei sheng yan jiu = Journal of hygiene research 20050501

• Identification and characterization of peroxisome proliferator response element in the mouse GLUT2 promoter.

  Experimental & molecular medicine 20050430

• [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].

  MMW Fortschritte der Medizin 20050428

• [Effects of rosiglitazone on aortic function in rats with insulin resistant-hypertension].

  Sheng li xue bao : [Acta physiologica Sinica] 20050425

• Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone.

  Circulation 20050419

• Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2.

  The Journal of biological chemistry 20050415

• Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.

  Journal of medicinal chemistry 20050407

• Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.

  Human reproduction (Oxford, England) 20050401

• Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells.

  American journal of respiratory cell and molecular biology 20050401

• Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation.

  Transplant international : official journal of the European Society for Organ Transplantation 20050401

• Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes.

  Diabetes care 20050401

• S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance.

  Diabetes 20050401

• Placental transfer of rosiglitazone in the first trimester of human pregnancy.

  Fertility and sterility 20050401

• PPARgamma in endothelial cells influences high fat diet-induced hypertension.

  American journal of hypertension 20050401

• Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.

  The American journal of managed care 20050401

• [Nonalcoholic steatohepatitis].

  Annales d'endocrinologie 20050401

• Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.

  Journal of medicinal chemistry 20050324

• HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo.

  Circulation 20050322

• Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2.

  Bioorganic & medicinal chemistry letters 20050315

• Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.

  Cancer research 20050315

• Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells.

  The Journal of biological chemistry 20050311

• PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.

  American journal of physiology. Heart and circulatory physiology 20050301

• Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.

  The Journal of clinical endocrinology and metabolism 20050301

• Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.

  Endocrinology 20050301

• Selective inhibition of human cytochrome P4502C8 by montelukast.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone.

  Journal of the American Society of Nephrology : JASN 20050301

• Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels.

  European heart journal 20050301

• Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?

  International journal of obesity (2005) 20050301

• Lessons from human mutations in PPARgamma.

  International journal of obesity (2005) 20050301

• Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.

  Diabetes, obesity & metabolism 20050301

• Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.

  Diabetes, obesity & metabolism 20050301

• Development of a complex scintillation proximity assay for high-throughput screening of PPARgamma modulators.

  Acta pharmacologica Sinica 20050301

• Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.

  Diabetologia 20050301

• Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients.

  Diabetes 20050301

• The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.

  Inflammatory bowel diseases 20050301

• The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20050301

• Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.

  Arthritis and rheumatism 20050301

• Risk reduction therapy for syndrome X: comparison of several treatments.

  American journal of hypertension 20050301

• [Effect of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development].

  Polskie Archiwum Medycyny Wewnetrznej 20050301

• Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6,7-dimethyl-1,2,3,4-tetrahydro-2-oxo-4-quinoxalinyl)ethoxy]phenyl]methylene]thiazolidine-2,4-dione derivatives as potent euglycemic and hypolipidemic agents.

  Bioorganic & medicinal chemistry letters 20050215

• c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes.

  Biochemical and biophysical research communications 20050211

• Characterization of recombinant long-chain rat acyl-CoA synthetase isoforms 3 and 6: identification of a novel variant of isoform 6.

  Biochemistry 20050208

• Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.

  Toxicological sciences : an official journal of the Society of Toxicology 20050201

• Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050201

• Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.

  Biochemistry 20050201

• Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome.

  Clinical endocrinology 20050201

• Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury.

  Diabetes 20050201

• Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.

  The European respiratory journal 20050201

• Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.

  Neuro endocrinology letters 20050201

• [Pexoxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20050201

• The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.

  American journal of hypertension 20050201

• Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects.

  Diabetes & vascular disease research 20050201

• Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy.

  European journal of pharmacology 20050131

• Intracellular mediators of procyanidin-induced lipolysis in 3T3-L1 adipocytes.

  Journal of agricultural and food chemistry 20050126

• Benzoyl 2-methyl indoles as selective PPARgamma modulators.

  Bioorganic & medicinal chemistry letters 20050117

• Pro-inflammatory properties for thiazolidinediones.

  Biochemical pharmacology 20050115

• Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver.

  The Journal of biological chemistry 20050114

• [Glucose-independent impact of the glitazones on the cardiovascular outcome].

  MMW Fortschritte der Medizin 20050113

• 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.

  Bioorganic & medicinal chemistry letters 20050103

• Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes.

  FEBS letters 20050103

• PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation.

  American journal of physiology. Heart and circulatory physiology 20050101

• Effects of PPAR-gamma ligands on vascular smooth muscle marker expression in hypertensive and normal arteries.

  American journal of physiology. Heart and circulatory physiology 20050101

• Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).

  Diabetes/metabolism research and reviews 20050101

• Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.

  The Journal of clinical endocrinology and metabolism 20050101

• Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster.

  Endocrinology 20050101

• Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program.

  Pharmacoepidemiology and drug safety 20050101

• The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.

  British journal of clinical pharmacology 20050101

• The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.

  Diabetologia 20050101

• Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus.

  Diabetes research and clinical practice 20050101

• Rosiglitazone and lipid metabolism.

  Diabetologia 20050101

• Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.

  Clinical endocrinology 20050101

• Rosiglitazone-induced proptosis.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20050101

• The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20050101

• A case of rosiglitazone exposure in the second trimester of pregnancy.

  Reproductive toxicology (Elmsford, N.Y.) 20050101

• Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.

  Antiviral therapy 20050101

• Enhancing islet engraftment with rosiglitazone.

  Transplantation proceedings 20050101

• Pituitary resistin gene expression is upregulated in vitro and in vivo by dexamethasone but is unaffected by rosiglitazone.

  Neuroendocrinology 20050101

• Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20050101

• Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial.

  The Journal of international medical research 20050101

• Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.

  Cardiology 20050101

• Rosiglitazone/Metformin.

  Drugs 20050101

• Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20050101

• Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone.

  Ethnicity & disease 20050101

• Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient.

  Skinmed 20050101

• Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes: evidence for PPARgamma-independent inhibition by 15-deoxy-Delta12,14prostaglandin J2.

  Arthritis research & therapy 20050101

• Drug interactions. Rosiglitazone and anti-HIV agents.

  TreatmentUpdate 20050101

• [Use of rosiglitazone in women with polycystic ovarian syndrome].

  Akusherstvo i ginekologiia 20050101

• Hyperhomocysteinemia exacerbates the development of intimal hyperplasia in Sprague-Dawley rats: Alleviation by rosiglitazone.

  Experimental and clinical cardiology 20050101

• [Rosiglitazone-metformin fixed dose combination for treatment of type 2 diabetes].

  Presse medicale (Paris, France : 1983) 20041218

• A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.

  Analytical biochemistry 20041215

• Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle.

  Endocrinology 20041201

• Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.

  World journal of gastroenterology 20041201

• GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.

  British journal of pharmacology 20041201

• Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulphonylurea agent: response to Roy et al.

  Diabetes care 20041201

• Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes.

  Metabolism: clinical and experimental 20041201

• Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20041201

• Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease.

  Neurobiology of disease 20041201

• Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20041201

• Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20041201

• Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes.

  The Canadian journal of cardiology 20041201

• Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.

  Nuclear medicine communications 20041201

• Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.

  Endocrine journal 20041201

• Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.

  Diabetologia 20041201

• Gene expression and adiposity are modified by soy protein in male Zucker diabetic fatty rats.

  Obesity research 20041201

• [Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].

  Zhonghua nei ke za zhi 20041201

• Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria.

  Endocrine 20041201

• Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.

  Clinical therapeutics 20041201

• [Effects of rosiglitazone on serum leptin and insulin resistance in patients with Type 2 diabetes].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20041201

• Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation.

  European journal of pharmacology 20041128

• Determination of rosiglitazone in coated tablets by MEKC and HPLC methods.

  Journal of pharmaceutical and biomedical analysis 20041119

• Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.

  The Medical journal of Australia 20041115

• Rosiglitazone for treatment of HIV lipodystrophy.

  Annals of internal medicine 20041102

• Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids.

  American journal of physiology. Regulatory, integrative and comparative physiology 20041101

• Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands.

  The Journal of pharmacology and experimental therapeutics 20041101

• Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.

  Journal of lipid research 20041101

• Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.

  Gut 20041101

• Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone.

  Diabetes 20041101

• Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.

  Diabetes care 20041101

• Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes.

  Diabetes care 20041101

• Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

  Diabetes care 20041101

• Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma.

  Anti-cancer drugs 20041101

• Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.

  The Journal of clinical investigation 20041101

• Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.

  Clinical therapeutics 20041101

• [Rosiglitazon in treatment of Type II diabetes mellitus--experience of diabetologists in the Czech Republic. Part I: compensation of diabetes, sugar metabolism].

  Vnitrni lekarstvi 20041101

• Revised vs original QUICKI index during diet + rosiglitazone treatment in obese subjects.

  Diabetes & metabolism 20041101

• A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

  Archives of internal medicine 20041025

• Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation.

  Biochemical and biophysical research communications 20041022

• Rosiglitazone improves contextual fear conditioning in aged rats.

  Neuroreport 20041005

• Integrated genomic and proteomic analyses of gene expression in Mammalian cells.

  Molecular & cellular proteomics : MCP 20041001

• Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.

  British journal of clinical pharmacology 20041001

• Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans.

  Biomedical chromatography : BMC 20041001

• Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products.

  Diabetes 20041001

• Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.

  Cancer 20041001

• Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.

  Fertility and sterility 20041001

• Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.

  Molecular cancer therapeutics 20041001

• Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.

  The British journal of dermatology 20041001

• Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.

  The Journal of endocrinology 20041001

• Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).

  Calcified tissue international 20041001

• Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.

  Pharmacotherapy 20041001

• A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects.

  The Journal of biological chemistry 20040924

• Generic, highly selective and robust capillary electrophoresis method for separation of a racemic mixture of glitazone compounds.

  Journal of chromatography. A 20040917

• [Inflammation and diabetes].

  MMW Fortschritte der Medizin 20040902

• Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes.

  Blood 20040901

• Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes.

  Diabetes, obesity & metabolism 20040901

• Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.

  Journal of hypertension 20040901

• Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

  Diabetologia 20040901

• Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.

  Diabetes care 20040901

• Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.

  Metabolism: clinical and experimental 20040901

• 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells.

  Cancer research 20040901

• Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.

  Human pathology 20040901

• 9th International Conference on AD and related disorders (ICAD).

  The Lancet. Neurology 20040901

• Expression of uncoupling protein-3 mRNA in rat skeletal muscle is acutely stimulated by thiazolidinediones: an exercise-like effect?

  Diabetologia 20040901

• Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone.

  The Journal of clinical endocrinology and metabolism 20040901

• Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats.

  American journal of hypertension 20040901

• Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-alpha induction of p38 and p42/p44 mitogen-activated protein kinases.

  Diabetologia 20040901

• Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.

  Clinical pharmacology and therapeutics 20040901

• Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells.

  Circulation 20040831

• Drug company pulls out of Chinese lawsuit over diabetes drug.

  BMJ (Clinical research ed.) 20040828

• Development of multiple lipomas during treatment with rosiglitazone in a patient with HIV-associated lipoatrophy.

  AIDS (London, England) 20040820

• PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.

  Regulatory peptides 20040815

• Chronic treatment with growth hormone stimulates adiponectin gene expression in 3T3-L1 adipocytes.

  FEBS letters 20040813

• AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms.

  Biochemical and biophysical research communications 20040813

• Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.

  Journal of medicinal chemistry 20040812

• NGF gene expression and secretion in white adipose tissue: regulation in 3T3-L1 adipocytes by hormones and inflammatory cytokines.

  American journal of physiology. Endocrinology and metabolism 20040801

• Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice.

  Journal of cellular physiology 20040801

• Expression and functional activity of PPARgamma in pancreatic beta cells.

  British journal of pharmacology 20040801

• Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.

  Journal of cardiovascular pharmacology 20040801

• The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.

  International journal of oncology 20040801

• Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

  Diabetes 20040801

• Effects of peroxisome proliferator activated receptors-alpha and -gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.

  The Journal of endocrinology 20040801

• Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease.

  European journal of endocrinology 20040801

• [Alcoholic and non-alcoholic steatohepatitis].

  Therapeutische Umschau. Revue therapeutique 20040801

• Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.

  The American journal of cardiology 20040715

• Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro.

  The Journal of biological chemistry 20040709

• A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes.

  European journal of pharmacology 20040708

• Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.

  Bioorganic & medicinal chemistry letters 20040705

• Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element.

  The Journal of biological chemistry 20040702

• Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.

  Diabetes, obesity & metabolism 20040701

• Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin.

  Biochemical pharmacology 20040701

• Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population.

  Diabetes care 20040701

• The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients: response to Poulsen et al.

  Diabetes care 20040701

• Twice-Daily NPH or mixture insulins versus triple therapy: apples versus oranges: response to Poulsen et al.

  Diabetes care 20040701

• Novel expression of resistin in rat testis: functional role and regulation by nutritional status and hormonal factors.

  Journal of cell science 20040701

• Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin.

  Diabetologia 20040701

• Defective enamel ultrastructure in diabetic rodents.

  International journal of paediatric dentistry 20040701

• PPAR-gamma agonists as therapy for diseases involving airway neutrophilia.

  The European respiratory journal 20040701

• Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20040701

• [Cardiovascular effects of rosiglitazone].

  Presse medicale (Paris, France : 1983) 20040619

• Gene expression profiling of potential PPARgamma target genes in mouse aorta.

  Physiological genomics 20040617

• Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.

  The Journal of biological chemistry 20040604

• (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.

  Journal of medicinal chemistry 20040603

• Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.

  American journal of physiology. Endocrinology and metabolism 20040601

• Visceral obesity without insulin resistance in late-onset obesity rats.

  Endocrinology 20040601

• Increased adipose tissue expression of Grb14 in several models of insulin resistance.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040601

• Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.

  Reproductive toxicology (Elmsford, N.Y.) 20040601

• Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed Syrian Golden hamster, an animal model of nutritionally-induced insulin resistance.

  Atherosclerosis 20040601

• Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

  Diabetes care 20040601

• Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.

  Expert opinion on pharmacotherapy 20040601

• Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.

  The American journal of cardiology 20040601

• Evidence for a potent antiinflammatory effect of rosiglitazone.

  The Journal of clinical endocrinology and metabolism 20040601

• PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.

  European journal of endocrinology 20040601

• Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.

  American heart journal 20040601

• Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea.

  Acta diabetologica 20040601

• Rosiglitazone for HIV-1 lipoatrophy.

  Lancet (London, England) 20040529

• Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.

  Annals of internal medicine 20040518

• Summaries for patients. Rosiglitazone treatment for fat redistribution and metabolic abnormalities caused by anti-HIV therapy.

  Annals of internal medicine 20040518

• Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model.

  Biochemical pharmacology 20040515

• Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer.

  Cancer research 20040515

• Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice.

  The Journal of biological chemistry 20040507

• C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.

  Circulation 20040504

• Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein.

  Intensive care medicine 20040501

• Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.

  Arteriosclerosis, thrombosis, and vascular biology 20040501

• Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

  Hypertension (Dallas, Tex. : 1979) 20040501

• Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway.

  Kidney international 20040501

• Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance.

  Diabetic medicine : a journal of the British Diabetic Association 20040501

• Stringent rosiglitazone-dependent gene switch in muscle cells without effect on myogenic differentiation.

  Molecular therapy : the journal of the American Society of Gene Therapy 20040501

• Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.

  American heart journal 20040501

• Fatty acid-mediated inhibition of IL-12 production by murine macrophages is independent of PPARgamma.

  The British journal of nutrition 20040501

• Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.

  DNA and cell biology 20040501

• Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

  Clinical therapeutics 20040501

• Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease.

  Journal of endocrinological investigation 20040501

• Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.

  Drugs of today (Barcelona, Spain : 1998) 20040501

• [Effects of salidroside on carbohydrate metabolism and differentiation of 3T3-L1 adipocytes].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20040501

• [Future targets in the treatment of type 2 diabetes].

  Wiener klinische Wochenschrift 20040430

• Simplified method for determination of rosiglitazone in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040425

• Rosiglitazone treatment of diabetes mellitus after solid organ transplantation.

  Transplantation 20040415

• Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

  American journal of physiology. Endocrinology and metabolism 20040401

• Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.

  Endocrinology 20040401

• Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20040401

• Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion.

  Cardiovascular research 20040401

• Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20040401

• Managing pediatric ingestions of the new antidiabetic agents.

  Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association 20040401

• Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.

  Thrombosis and haemostasis 20040401

• Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?

  Diabetes 20040401

• Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

  Diabetic medicine : a journal of the British Diabetic Association 20040401

• Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.

  Journal of molecular endocrinology 20040401

• Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20040401

• [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].

  Zhonghua nei ke za zhi 20040401

• [Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data].

  Annales d'endocrinologie 20040401

• Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner.

  Prostaglandins & other lipid mediators 20040401

• [Effect of rosiglitazone on level of serum TNF-alpha and its relation with insulin resistance in type 2 diabetes mellitus].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20040401

• Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.

  Circulation 20040323

• Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal.

  Circulation research 20040319

• Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040305

• Effects of insulin-sensitising agents in mice with hepatic insulin resistance.

  Diabetologia 20040301

• PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.

  Hypertension (Dallas, Tex. : 1979) 20040301

• Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.

  Diabetes research and clinical practice 20040301

• Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells.

  Gut 20040301

• The metabolic effects of insulin and rosiglitazone combination therapy in Chinese type 2 diabetic patients with nephropathy.

  Medical science monitor : international medical journal of experimental and clinical research 20040301

• Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.

  Drug metabolism and disposition: the biological fate of chemicals 20040301

• Increased CD36 protein as a response to defective insulin signaling in macrophages.

  The Journal of clinical investigation 20040301

• Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.

  Clinical pharmacology and therapeutics 20040301

• Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.

  Fertility and sterility 20040301

• Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.

  Harvard heart letter : from Harvard Medical School 20040301

• Rosiglitazone and heart failure: long-term vigilance.

  Journal of cardiovascular pharmacology and therapeutics 20040301

• Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

  Clinical therapeutics 20040301

• [Influence of peroxisome proliferator-activated receptor gamma on airway inflammation of guinea pigs with asthma].

  Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 20040301

• [Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome].

  Zhonghua fu chan ke za zhi 20040301

• Complications & side effects. Disappointing result for rosiglitazone and lipodystrophy.

  TreatmentUpdate 20040301

• Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism.

  The Journal of biological chemistry 20040227

• PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation.

  Circulation research 20040220

• Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.

  The American journal of medicine 20040215

• Managing HIV lipoatrophy.

  Lancet (London, England) 20040207

• No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

  Lancet (London, England) 20040207

• PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes.

  American journal of physiology. Heart and circulatory physiology 20040201

• Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats.

  The Journal of pharmacology and experimental therapeutics 20040201

• PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms.

  British journal of pharmacology 20040201

• Rosiglitazone restores G-protein coupling, recruitment, and function of renal dopamine D1A receptor in obese Zucker rats.

  Hypertension (Dallas, Tex. : 1979) 20040201

• Treatment of nonalcoholic steatohepatitis.

  Current gastroenterology reports 20040201

• In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.

  Diabetes care 20040201

• Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice.

  Critical care medicine 20040201

• Peroxisome proliferator-activated receptor-gamma ligands: a pluripotent class of pharmacological agents that may prove to be useful for adjuvant treatment of sepsis and multiple organ dysfunction syndrome.

  Critical care medicine 20040201

• Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

  The American journal of cardiology 20040201

• Simultaneous determination of metformin in combination with rosiglitazone by reversed-phase liquid chromatography.

  Journal of chromatographic science 20040201

• [Peroxisome poliferator-activated receptors and their modulators].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040201

• [Heart, diabetes and glitazones].

  Annales d'endocrinologie 20040201

• Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

  Biochemical and biophysical research communications 20040130

• Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

  The Biochemical journal 20040115

• Bone is a target for the antidiabetic compound rosiglitazone.

  Endocrinology 20040101

• Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.

  Annals of surgery 20040101

• Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma.

  The American journal of pathology 20040101

• Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model.

  Journal of medicinal chemistry 20040101

• Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.

  European journal of pharmacology 20040101

• Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPARgamma agonists and a structurally unrelated PPARgamma agonist.

  Toxicologic pathology 20040101

• The metabolic syndrome: an emerging health epidemic in women.

  Progress in cardiovascular diseases 20040101

• Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes.

  The Journal of investigative dermatology 20040101

• Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2.

  Arzneimittel-Forschung 20040101

• Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.

  Current medical research and opinion 20040101

• Effects of pioglitazone versus rosiglitazone on lipoprotein subclasses.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20040101

• Towards single-tablet therapy for type 2 diabetes mellitus. Rationale and recent developments.

  Treatments in endocrinology 20040101

• Effect of retinoic acid on leptin, glycerol, and glucose levels in mature rat adipocytes in vitro.

  Journal of medicinal food 20040101

• Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists.

  Anticancer research 20040101

• Induction of adipocyte-like phenotype in human mesenchymal stem cells by hypoxia.

  Stem cells (Dayton, Ohio) 20040101

• Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20040101

• 15-Deoxy-Delta12,14-prostaglandin J2 regulates endogenous Cot MAPK kinase kinase 1 activity induced by lipopolysaccharide.

  The Journal of biological chemistry 20031226

• Polymer-assisted solution phase synthesis of the antihyperglycemic agent Rosiglitazone (Avandia).

  Organic & biomolecular chemistry 20031221

• [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].

  MMW Fortschritte der Medizin 20031218

• Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.

  The Journal of clinical investigation 20031215

• Australian government tries to stop independent advice on diabetes drugs.

  BMJ (Clinical research ed.) 20031213

• [Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].

  MMW Fortschritte der Medizin 20031211

• [An overweight diabetic does not tolerate metformin. Insulin sensitizer can be prescribed alone, too].

  MMW Fortschritte der Medizin 20031204

• Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia.

  Circulation 20031202

• Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes.

  Diabetologia 20031201

• Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats.

  Diabetologia 20031201

• Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.

  Current opinion in lipidology 20031201

• Novel PPARgamma-dependent and independent effects for thiazolidinediones.

  Current opinion in lipidology 20031201

• The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.

  Diabetes care 20031201

• Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.

  The Journal of clinical endocrinology and metabolism 20031201

• Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma.

  Arthritis and rheumatism 20031201

• Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes.

  Biochimie 20031201

• Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.

  Journal of cardiovascular pharmacology and therapeutics 20031201

• Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.

  Clinical therapeutics 20031201

• Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.

  Clinical therapeutics 20031201

• The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.

  Journal of the American College of Cardiology 20031119

• Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling.

  Journal of immunology (Baltimore, Md. : 1950) 20031115

• Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone.

  Biochemical and biophysical research communications 20031114

• Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.

  Diabetes care 20031101

• Contrasting effects of nateglinide and rosiglitazone on insulin secretion and phospholipase C activation.

  Metabolism: clinical and experimental 20031101

• Diabetes drug may also benefit blood vessels.

  Mayo Clinic health letter (English ed.) 20031101

• Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis.

  Clinical therapeutics 20031101

• Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats.

  Canadian journal of physiology and pharmacology 20031101

• Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process.

  The Biochemical journal 20031101

• Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.

  Circulation 20031021

• Synthesis and insulin-sensitizing activity of a novel kind of benzopyran derivative.

  Bioorganic & medicinal chemistry letters 20031020

• A phase II trial with rosiglitazone in liposarcoma patients.

  British journal of cancer 20031020

• Induction of apoptosis by mono(2-ethylhexyl)phthalate (MEHP) in U937 cells.

  Toxicology letters 20031015

• Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.

  Hypertension (Dallas, Tex. : 1979) 20031001

• PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031001

• Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.

  Diabetologia 20031001

• Thiazolidinediones and blood lipids in type 2 diabetes.

  Arteriosclerosis, thrombosis, and vascular biology 20031001

• Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene.

  Diabetic medicine : a journal of the British Diabetic Association 20031001

• Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

  Hepatology (Baltimore, Md.) 20031001

• Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20031001

• The 'glitazones': rosiglitazone and pioglitazone.

  Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 20031001

• [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].

  MMW Fortschritte der Medizin 20030918

• Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil.

  European journal of pharmacology 20030912

• Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.

  Journal of medicinal chemistry 20030911

• Ascochlorin derivatives as ligands for nuclear hormone receptors.

  Journal of medicinal chemistry 20030911

• Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

  The Journal of biological chemistry 20030905

• Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.

  Endocrinology 20030901

• Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes.

  Diabetes, obesity & metabolism 20030901

• Unilateral edema due to a thiazolidinedione.

  Diabetes care 20030901

• Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.

  Diabetes 20030901

• Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells.

  Thorax 20030901

• Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

  British journal of pharmacology 20030901

• Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard.

  Biomedical chromatography : BMC 20030901

• [The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China].

  Zhonghua nei ke za zhi 20030901

• Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Metabolic update: better defining lipodystrophy and treating insulin resistance.

  AIDS clinical care 20030901

• Glitazones and heart failure: critical appraisal for the clinician.

  Circulation 20030826

• Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.

  Circulation research 20030822

• Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.

  Oncogene 20030821

• 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.

  Bioorganic & medicinal chemistry letters 20030818

• Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.

  The Journal of biological chemistry 20030815

• TNF-alpha induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes.

  Journal of cellular biochemistry 20030815

• Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.

  American journal of physiology. Endocrinology and metabolism 20030801

• PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.

  The Journal of pharmacology and experimental therapeutics 20030801

• Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPARgamma in cell invasion process.

  Carcinogenesis 20030801

• Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.

  American journal of hypertension 20030801

• Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.

  Diabetes 20030801

• Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

  Diabetes 20030801

• A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.

  Metabolism: clinical and experimental 20030801

• Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.

  Metabolism: clinical and experimental 20030801

• Peroxisome proliferator-activated receptor-gamma ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element.

  Fertility and sterility 20030801

• Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.

  The Journal of clinical endocrinology and metabolism 20030801

• Regulation of MMP-1 expression in vascular endothelial cells by insulin sensitizing thiazolidinediones.

  Atherosclerosis 20030801

• Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice.

  Proteomics 20030801

• Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.

  Surgery 20030801

• [Influence of rosiglitazone on the airway inflammation in guinea pigs with asthma].

  Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University 20030801

• PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner.

  Oncogene 20030703

• Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells.

  Journal of cellular physiology 20030701

• Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats.

  Diabetes, obesity & metabolism 20030701

• Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation.

  European journal of clinical investigation 20030701

• Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.

  Diabetes care 20030701

• A 'futile cycle' induced by thiazolidinediones in human adipose tissue?

  Nature medicine 20030701

• Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.

  Cancer research 20030701

• Pre-diabetes, insulin resistance, inflammation and CVD risk.

  Diabetes research and clinical practice 20030701

• Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.

  Pharmacotherapy 20030701

• Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.

  Pharmacotherapy 20030701

• Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.

  Oncogene 20030619

• Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha.

  Biochemical and biophysical research communications 20030606

• Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells.

  Molecular endocrinology (Baltimore, Md.) 20030601

• Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.

  Diabetes 20030601

• Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

  Diabetes care 20030601

• The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.

  Cardiovascular research 20030601

• The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20030601

• Combination agents for diabetes.

  Advance for nurse practitioners 20030601

• Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.

  Antiviral therapy 20030601

• Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.

  Circulation 20030527

• Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells.

  The Journal of biological chemistry 20030523

• 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.

  Bioorganic & medicinal chemistry letters 20030519

• Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response.

  Journal of immunology (Baltimore, Md. : 1950) 20030515

• AhR- and ERK-dependent pathways function synergistically to mediate 2,3,7,8-tetrachlorodibenzo-p-dioxin suppression of peroxisome proliferator-activated receptor-gamma1 expression and subsequent adipocyte differentiation.

  Toxicology and applied pharmacology 20030515

• [Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].

  MMW Fortschritte der Medizin 20030508

• Liquid chromatographic method for the determination of rosiglitazone in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030505

• c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones.

  Biochemical and biophysical research communications 20030502

• Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20030501

• Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway.

  Acta pharmacologica Sinica 20030501

• Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.

  Diabetic medicine : a journal of the British Diabetic Association 20030501

• PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro.

  Breast cancer research and treatment 20030501

• Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.

  Postgraduate medicine 20030501

• Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.

  Chinese medical journal 20030501

• Hepatotoxicity of the thiazolidinediones.

  Clinics in liver disease 20030501

• Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

  Circulation 20030429

• 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia.

  The Journal of biological chemistry 20030425

• Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.

  Circulation 20030422

• A peroxisome proliferator-activated receptor-gamma agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells.

  Cancer research 20030415

• PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation.

  Biochemical and biophysical research communications 20030411

• Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.

  Journal of medicinal chemistry 20030410

• Phenylacetic acid derivatives as hPPAR agonists.

  Bioorganic & medicinal chemistry letters 20030407

• Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.

  The Journal of biological chemistry 20030404

• Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma.

  The Journal of biological chemistry 20030404

• Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism.

  Biochemical and biophysical research communications 20030404

• Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.

  American journal of physiology. Endocrinology and metabolism 20030401

• Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.

  Arteriosclerosis, thrombosis, and vascular biology 20030401

• Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

  Drug metabolism and disposition: the biological fate of chemicals 20030401

• Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.

  Journal of hepatology 20030401

• Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

  Diabetes 20030401

• Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone.

  Journal of molecular and cellular cardiology 20030401

• Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.

  Toxicology letters 20030320

• Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.

  Bioorganic & medicinal chemistry letters 20030310

• [When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].

  MMW Fortschritte der Medizin 20030306

• PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.

  American journal of physiology. Endocrinology and metabolism 20030301

• Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20030301

• Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

  The Journal of clinical investigation 20030301

• Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.

  Fertility and sterility 20030301

• Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.

  Biochemical pharmacology 20030301

• Effects of rosiglitazone and oleic acid on UCP-3 expression in L6 myotubes.

  Diabetes, obesity & metabolism 20030301

• Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.

  Journal of clinical pharmacology 20030301

• Rosiglitazone: potential beneficial impact on cardiovascular disease.

  International journal of clinical practice 20030301

• Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22.

  The Journal of biological chemistry 20030227

• [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].

  MMW Fortschritte der Medizin 20030227

• Initial management of glycemia in type 2 diabetes.

  The New England journal of medicine 20030220

• Diminished production of nitric oxide synthase cofactor tetrahydrobiopterin by rosiglitazone in adipocytes.

  Biochemical pharmacology 20030215

• A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.

  Biochemical and biophysical research communications 20030207

• Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.

  Diabetes 20030201

• Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.

  Gastroenterology 20030201

• Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.

  Arteriosclerosis, thrombosis, and vascular biology 20030201

• Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy.

  Journal of the Society for Gynecologic Investigation 20030201

• Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation.

  Rheumatology (Oxford, England) 20030201

• Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.

  Metabolism: clinical and experimental 20030201

• Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone.

  Metabolism: clinical and experimental 20030201

• Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability.

  Diabetologia 20030201

• Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.

  Journal of the Indian Medical Association 20030201

• Did this drug cause my patient's hepatitis?

  Annals of internal medicine 20030121

• Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.

  Bioorganic & medicinal chemistry letters 20030120

• Rosiglitazone fails to improve hypertriglyceridemia and glucose tolerance in CD36-deficient BN.SHR4 congenic rat strain.

  Physiological genomics 20030115

• Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.

  Biochemical pharmacology 20030115

• Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators.

  Biochemical and biophysical research communications 20030110

• Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes.

  The Journal of biological chemistry 20030103

• Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.

  Archives of biochemistry and biophysics 20030101

• The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

  CNS drugs 20030101

• Differential regulation of lipogenesis and leptin production by independent signaling pathways and rosiglitazone during human adipocyte differentiation.

  Diabetes 20030101

• Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.

  Diabetes 20030101

• Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.

  Diabetes care 20030101

• Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.

  Arteriosclerosis, thrombosis, and vascular biology 20030101

• Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?

  European journal of endocrinology 20030101

• Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.

  Diabetes, obesity & metabolism 20030101

• Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.

  Journal of human hypertension 20030101

• Rosiglitazone reduces urinary albumin excretion in type II diabetes.

  Journal of human hypertension 20030101

• Diabetes medicine update. Old dogs, new tricks.

  Diabetes self-management 20030101

• Polycystic ovary syndrome and insulin resistance.

  Medicine and health, Rhode Island 20030101

• Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study.

  Dermatology (Basel, Switzerland) 20030101

• Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.

  Diabetes technology & therapeutics 20030101

• Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?

  Current medical research and opinion 20030101

• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  Drugs 20030101

• Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury.

  American journal of nephrology 20030101

• A retrospective review of thiazolidinediones with development of a troglitazone conversion protocol.

  TheScientificWorldJournal 20030101

• Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.

  PharmacoEconomics 20030101

• Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.

  The Cochrane database of systematic reviews 20030101

• Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with type 2 diabetes mellitus.

  Journal of diabetes and its complications 20030101

• Fat redistribution and bone abnormalities in HIV-infected patients.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20030101

• Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.

  Clinical therapeutics 20030101

• Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.

  Clinical therapeutics 20030101

• Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.

  Clinical therapeutics 20030101

• Crossover and double blind study with metformin and rosiglitazone in impaired glucose tolerance subjects.

  Proceedings of the Western Pharmacology Society 20030101

• Tissue-specific expression of two peroxisomal 3-ketoacyl-CoA thiolase genes in wild and PPAR alpha-null mice and induction by fenofibrate.

  Advances in experimental medicine and biology 20030101

• Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.

  Diabetes 20021201

• Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter.

  Molecular endocrinology (Baltimore, Md.) 20021201

• Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone.

  The Journal of clinical endocrinology and metabolism 20021201

• Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats.

  Hypertension (Dallas, Tex. : 1979) 20021201

• The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation.

  Developmental cell 20021201

• Repaglinide in combination therapy.

  Diabetes, nutrition & metabolism 20021201

• Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors.

  Chemico-biological interactions 20021110

• Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.

  The American journal of cardiology 20021101

• A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.

  Diabetes care 20021101

• Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone.

  Journal of lipid research 20021101

• AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.

  Journal of lipid research 20021101

• A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.

  Molecular endocrinology (Baltimore, Md.) 20021101

• Regulation of uncoupling protein-2 mRNA in L6 myotubules: I: Thiazolidinediones stimulate uncoupling protein-2 gene expression by a mechanism requiring ongoing protein synthesis and an active mitogen-activated protein kinase.

  Endocrine 20021101

• Lipopolysaccharide increases resistin gene expression in vivo and in vitro.

  FEBS letters 20021023

• [Meta-analysis shows: insulin sensitizer is safe for the liver].

  MMW Fortschritte der Medizin 20021003

• Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells.

  American journal of physiology. Endocrinology and metabolism 20021001

• A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

  Diabetes care 20021001

• Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

  Obesity research 20021001

• Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.

  Journal of acquired immune deficiency syndromes (1999) 20021001

• [Severe electrolyte imbalance and edema in therapy with rosiglitazone].

  Medizinische Klinik (Munich, Germany : 1983) 20020915

• Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.

  The Journal of investigative dermatology 20020901

• Rosiglitazone in the management of older patients with type 2 diabetes mellitus.

  International journal of clinical practice 20020901

• Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects.

  Journal of acquired immune deficiency syndromes (1999) 20020901

• [Insulin sensitizer drugs--review].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• [Rosiglitazone (BRL-49653)].

  Nihon rinsho. Japanese journal of clinical medicine 20020901

• Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.

  Inflammatory bowel diseases 20020901

• Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.

  The Journal of biological chemistry 20020830

• Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster.

  The Journal of biological chemistry 20020809

• Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy.

  Circulation research 20020809

• Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

  Circulation 20020806

• Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.

  Diabetes 20020801

• Efficient gene regulation by PPAR gamma and thiazolidinediones in skeletal muscle and heart.

  Molecular therapy : the journal of the American Society of Gene Therapy 20020801

• LC determination of rosiglitazone in bulk and pharmaceutical formulation.

  Journal of pharmaceutical and biomedical analysis 20020731

• The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents.

  The Journal of biological chemistry 20020726

• The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

  The Journal of biological chemistry 20020712

• Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes.

  Diabetes 20020701

• Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study.

  Diabetes 20020701

• Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.

  Diabetes care 20020701

• Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20020701

• Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20020701

• Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20020701

• Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.

  Digestive diseases and sciences 20020701

• Oral hypoglycaemics. When not to use what.

  Australian family physician 20020701

• The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.

  Clinical therapeutics 20020701

• Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep mice.

  Molecular & cellular proteomics : MCP 20020701

• Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma.

  Cytokine 20020621

• Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism.

  Journal of immunology (Baltimore, Md. : 1950) 20020615

• Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists.

  Endocrinology 20020601

• Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation.

  Endocrinology 20020601

• Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells.

  Cancer research 20020601

• Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone.

  Journal of clinical pharmacology 20020601

• Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

  Gastroenterology 20020601

• Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia.

  Inflammation 20020601

• The glitazones: a new treatment for type 2 diabetes mellitus.

  Intensive & critical care nursing 20020601

• Mechanisms regulating adipocyte expression of resistin.

  The Journal of biological chemistry 20020531

• Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.

  Circulation 20020514

• [Glinides and glitazones in diabetes treatment. Are they really effective?].

  MMW Fortschritte der Medizin 20020502

• Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes.

  Endocrinology 20020501

• Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro.

  Diabetes 20020501

• Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.

  Diabetes 20020501

• Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

  Diabetes care 20020501

• Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2.

  Molecular endocrinology (Baltimore, Md.) 20020501

• Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts.

  The Journal of clinical endocrinology and metabolism 20020501

• Induction of adipocyte differentiation by a thiazolidinedione in cultured, subepidermal, fibroblast-like cells of an infant with congenital generalized lipodystrophy.

  The Journal of clinical endocrinology and metabolism 20020501

• Thiazolidinediones in the treatment of type 2 diabetes.

  Expert opinion on pharmacotherapy 20020501

• [Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome].

  Zhonghua fu chan ke za zhi 20020501

• Thiazolidinediones and type 2 diabetes: new drugs for an old disease.

  The Medical journal of Australia 20020415

• Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein.

  The Journal of biological chemistry 20020412

• PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.

  Circulation research 20020405

• Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.

  Diabetes 20020401

• A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

  Diabetes 20020401

• Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.

  Diabetes 20020401

• A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.

  Diabetes care 20020401

• PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro.

  The Journal of clinical endocrinology and metabolism 20020401

• [Rosiglitazone: clinical data].

  Annales d'endocrinologie 20020401

• [Rosiglitazone: a clinical development focused on cardio-vascular prevention].

  Annales d'endocrinologie 20020401

• [Medication of the month. Rosiglitazone (Avandia)].

  Revue medicale de Liege 20020401

• Rosiglitazone--useful drug but has side effects.

  The Journal of the Association of Physicians of India 20020401

• Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.

  JAMA 20020320

• Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

  Circulation 20020312

• Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.

  Endocrinology 20020301

• Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists.

  Diabetes 20020301

• The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

  Diabetes 20020301

• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  Clinical therapeutics 20020301

• [Type 2 diabetes. How can the infarction risk be reduced?].

  MMW Fortschritte der Medizin 20020227

• Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.

  Journal of medicinal chemistry 20020214

• Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.

  Diabetes care 20020201

• Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1.

  Osteoarthritis and cartilage 20020201

• [A case report. Rosiglitazone treatment was highly effective yet had to be terminated].

  Lakartidningen 20020131

• [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].

  MMW Fortschritte der Medizin 20020124

• Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020122

• PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation.

  Biochemical and biophysical research communications 20020118

• Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons.

  Brain research 20020111

• Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.

  Biochemical and biophysical research communications 20020111

• PPARgamma-dependent and PPARgamma-independent effects on the development of adipose cells from embryonic stem cells.

  FEBS letters 20020102

• Thiazolidinediones influence plasma steroids of male obese Zucker rats.

  Endocrinology 20020101

• Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes.

  The Journal of pharmacology and experimental therapeutics 20020101

• Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling.

  Molecular pharmacology 20020101

• Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy.

  The Journal of clinical endocrinology and metabolism 20020101

• In vitro metabolite identification using fast gradient high performance liquid chromatography combined with tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20020101

• Study to investigate cognitive function in type 2 diabetes.

  AWHONN lifelines 20020101

• Are all glitazones the same?

  Diabetes/metabolism research and reviews 20020101

• Differentiating members of the thiazolidinedione class: a focus on efficacy.

  Diabetes/metabolism research and reviews 20020101

• Differentiating members of the thiazolidinedione class: a focus on safety.

  Diabetes/metabolism research and reviews 20020101

• Rosiglitazone-induced granulomatous hepatitis.

  Journal of clinical gastroenterology 20020101

• Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes.

  Diabetes/metabolism research and reviews 20020101

• Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes.

  Diabetes/metabolism research and reviews 20020101

• Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

  Drugs 20020101

• Glitazones: clinical effects and molecular mechanisms.

  Annals of medicine 20020101

• HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study.

  Arzneimittel-Forschung 20020101

• Pharmacokinetics of rosiglitazone in patients with end-stage renal disease.

  The Journal of international medical research 20020101

• Management of rosiglitazone-induced edema: two case reports and a review of the literature.

  Diabetes technology & therapeutics 20020101

• Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.

  Current medical research and opinion 20020101

• Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X.

  Folia biologica 20020101

• An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes.

  Current medical research and opinion 20020101

• Accelerated hypertension due to rosiglitazone therapy.

  Indian heart journal 20020101

• Effects of the thiazolidinediones on cardiovascular risk factors.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Lipoprotein effects of different thiazolidinediones in clinical practice.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101

• Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.

  Treatments in endocrinology 20020101

• Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.

  Bioorganic & medicinal chemistry letters 20011217

• Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.

  The Journal of biological chemistry 20011214

• Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.

  Life sciences 20011214

• Nonhypoglycemic effects of thiazolidinediones.

  Annals of internal medicine 20011204

• Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.

  Journal of cardiovascular pharmacology 20011201

• Glitazones, glycemia, and global health status.

  Diabetes care 20011201

• PPARgamma and atherosclerosis: effects on cell growth and movement.

  Arteriosclerosis, thrombosis, and vascular biology 20011201

• An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.

  The American journal of gastroenterology 20011201

• 15-deoxy-delta12,14-prostaglandin J2-induced apoptosis in amnion-like WISH cells.

  Prostaglandins & other lipid mediators 20011201

• Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.

  Diabetologia 20011201

• In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

  Circulation 20011120

• [Infarct prevention for diabetics. To lower blood sugar is not enough].

  MMW Fortschritte der Medizin 20011115

• Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway.

  Diabetes 20011101

• Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.

  Metabolism: clinical and experimental 20011101

• Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.

  Fertility and sterility 20011101

• Liver failure in a patient treated with long-term rosiglitazone therapy.

  The American journal of medicine 20011101

• [Rosiglitazone(BRL-49653)].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells.

  International journal of cancer 20011101

• Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism.

  Journal of internal medicine 20011101

• Rosiglitazone monotherapy and type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20011101

• Inhibition of myogenesis enables adipogenic trans-differentiation in the C2C12 myogenic cell line.

  FEBS letters 20011005

• Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.

  Molecular endocrinology (Baltimore, Md.) 20011001

• Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.

  The Journal of clinical investigation 20011001

• Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells.

  European journal of immunology 20011001

• A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.

  Molecular cell 20011001

• A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes.

  Biochimie 20011001

• [Glitazones--a new therapeutic principle in diabetes].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20010920

• Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-delta(12,14)-prostaglandin J(2).

  The Journal of biological chemistry 20010907

• Effects of retinoids and thiazolidinediones on proliferation, insulin release, insulin mRNA, GLUT 2 transporter protein and mRNA of INS-1 cells.

  Cell biochemistry and function 20010901

• A review of rosiglitazone in type 2 diabetes mellitus.

  Pharmacotherapy 20010901

• Pioglitazone and rosiglitazone for diabetes.

  Drug and therapeutics bulletin 20010901

• [News in oral antidiabetic therapy].

  Vnitrni lekarstvi 20010901

• Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice.

  Biochemical and biophysical research communications 20010831

• [Glitazone--a new class of drugs for the treatment of type 2 diabetes].

  Deutsche medizinische Wochenschrift (1946) 20010824

• Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells.

  The Journal of biological chemistry 20010817

• [The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].

  Nederlands tijdschrift voor geneeskunde 20010811

• RGS2 promotes adipocyte differentiation in the presence of ligand for peroxisome proliferator-activated receptor gamma.

  The Journal of biological chemistry 20010810

• (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.

  Journal of medicinal chemistry 20010802

• TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27.

  American journal of physiology. Endocrinology and metabolism 20010801

• How can anti-diabetics suppress tumours?

  Trends in pharmacological sciences 20010801

• PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease.

  Trends in molecular medicine 20010801

• Beta-cell deterioration--prospects for reversal or prevention.

  Diabetes, obesity & metabolism 20010801

• Insulin resistance and beta-cell function--a clinical perspective.

  Diabetes, obesity & metabolism 20010801

• PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.

  Diabetes, obesity & metabolism 20010801

• [ACE inhibitor plus glitazone. Insulin sensitizer, preventing diabetes?].

  MMW Fortschritte der Medizin 20010726

• [Thiazolidinediones--a new class of oral antidiabetic drugs].

  Orvosi hetilap 20010722

• Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists.

  The Journal of biological chemistry 20010713

• Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010710

• Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells.

  Experimental cell research 20010701

• A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes.

  Endocrinology 20010701

• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  Diabetes care 20010701

• Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.

  Journal of hepatology 20010701

• Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.

  European journal of pharmacology 20010629

• Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.

  Journal of medicinal chemistry 20010621

• Lessons from the glitazones: a story of drug development.

  Lancet (London, England) 20010609

• A high-capacity screen for adipogenic differentiation.

  Analytical biochemistry 20010601

• The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.

  Diabetes 20010601

• Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.

  Journal of clinical pharmacology 20010601

• Accurate mass liquid chromatography/mass spectrometry on quadrupole orthogonal acceleration time-of-flight mass analyzers using switching between separate sample and reference sprays. 2. Applications using the dual-electrospray ion source.

  Analytical chemistry 20010601

• Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat.

  Diabetes, obesity & metabolism 20010601

• Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.

  Diabetes, obesity & metabolism 20010601

• Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN.

  Current biology : CB 20010515

• Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists.

  The Journal of biological chemistry 20010511

• Rosiglitazone and type 2 diabetes mellitus.

  Lancet (London, England) 20010505

• Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages.

  FEBS letters 20010504

• Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.

  Diabetes 20010501

• Troglitazone induces GLUT4 translocation in L6 myotubes.

  Diabetes 20010501

• Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.

  Diabetes 20010501

• Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes.

  Diabetes 20010501

• Induction of CD36 by all-trans retinoic acid: retinoic acid receptor signaling in the pathogenesis of atherosclerosis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010501

• Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.

  The Journal of clinical endocrinology and metabolism 20010501

• Response of experimental retinal neovascularization to thiazolidinediones.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20010501

• The expression of the p85alpha subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor gamma in human adipocytes.

  Diabetologia 20010501

• Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.

  Hypertension research : official journal of the Japanese Society of Hypertension 20010501

• The effect of acarbose on the pharmacokinetics of rosiglitazone.

  European journal of clinical pharmacology 20010501

• Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.

  The Journal of biological chemistry 20010420

• Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats.

  Endocrinology 20010401

• Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.

  Molecular pharmacology 20010401

• Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation.

  Journal of leukocyte biology 20010401

• [Glitazones. Profile of a new class of substances].

  Der Internist 20010401

• [Thiazolidinediones: clinical data and perspectives].

  Diabetes & metabolism 20010401

• Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma.

  Journal of chromatography. B, Biomedical sciences and applications 20010305

• The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells.

  Molecular pharmacology 20010301

• Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.

  Arteriosclerosis, thrombosis, and vascular biology 20010301

• What caused this patient's sudden liver dysfunction?

  RN 20010301

• Rosiglitazone.

  Expert opinion on pharmacotherapy 20010301

• The failings of NICE. NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal.

  BMJ (Clinical research ed.) 20010224

• Guidance on rosiglitazone for type 2 diabetes mellitus.

  Lancet (London, England) 20010210

• Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010201

• Albumin regulates induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-delta(12-14)-prostaglandin J(2) in vitro and may be an important regulator of PPARgamma function in vivo.

  Endocrinology 20010201

• Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury.

  Gastroenterology 20010201

• Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

  Diabetes care 20010201

• Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway.

  Naunyn-Schmiedeberg's archives of pharmacology 20010201

• Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.

  Hypertension (Dallas, Tex. : 1979) 20010201

• Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20010201

• A comprehensive review of the antidiabetic agent rosiglitazone.

  Clinical therapeutics 20010201

• Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.

  BMJ (Clinical research ed.) 20010127

• New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).

  The Journal of the Association of Physicians of India 20010125

• The hormone resistin links obesity to diabetes.

  Nature 20010118

• Fatty-acyl-CoA thioesters inhibit recruitment of steroid receptor co-activator 1 to alpha and gamma isoforms of peroxisome-proliferator-activated receptors by competing with agonists.

  The Biochemical journal 20010115

• 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells.

  Cancer research 20010115

• New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.

  Annual review of medicine 20010101

• Diabetes in elderly adults.

  The journals of gerontology. Series A, Biological sciences and medical sciences 20010101

• Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.

  Diabetes care 20010101

• Pulmonary edema associated with rosiglitazone and troglitazone.

  The Annals of pharmacotherapy 20010101

• Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20010101

• Insulin resistance and its treatment by thiazolidinediones.

  Recent progress in hormone research 20010101

• Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20010101

• Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells.

  Journal of diabetes and its complications 20010101

• Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20010101

• Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101

• Conversion from troglitazone to rosiglitazone.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20010101

• Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione.

  Journal of molecular graphics & modelling 20010101

• Hepatotoxicity with thiazolidinediones: is it a class effect?

  Drug safety 20010101

• Rosiglitazone for lipodstrophy?

  TreatmentUpdate 20010101

• Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer.

  Pathobiology : journal of immunopathology, molecular and cellular biology 20010101

• The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.

  Metabolism: clinical and experimental 20001201

• Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

  Biochemical and biophysical research communications 20001130

• A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma.

  Molecular endocrinology (Baltimore, Md.) 20001001

• Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.

  Biochemical and biophysical research communications 20000510

• Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells.

  Journal of cardiovascular pharmacology 20000501

• Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.

  Diabetes 20000401

• v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats.

  Diabetes 20000401

• Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.

  Molecular cell 20000301

• The PPARs: from orphan receptors to drug discovery.

  Journal of medicinal chemistry 20000224

• A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation.

  The Journal of biological chemistry 20000121

• Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.

  Biochemical and biophysical research communications 19991101

• PPARalpha activation by Wy 14643 induces transactivation of the rat UCP-1 promoter without increasing UCP-1 mRNA levels and attenuates PPARgamma-mediated increases in UCP-1 mRNA levels induced by rosiglitazone in fetal rat brown adipocytes.

  Biochemical and biophysical research communications 19991022

• Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.

  Journal of lipid research 19990701

• Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth.

  Diabetes 19990601

• Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 19990601

• A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.

  Proceedings of the National Academy of Sciences of the United States of America 19990525

• Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.

  The Journal of biological chemistry 19990326

• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.

  Journal of medicinal chemistry 19981203

• A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.

  Diabetes 19981201

• Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain.

  Analytical biochemistry 19980315

• Glucocorticoids repress induction by thiazolidinediones, fibrates, and fatty acids of phosphoenolpyruvate carboxykinase gene expression in adipocytes.

  Journal of cellular biochemistry 19980301

• Induction of the nuclear orphan receptor RORgamma during adipocyte differentiation of D1 and 3T3-L1 cells.

  Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 19980301

• Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.

  The Journal of pharmacology and experimental therapeutics 19980201

• Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.

  The Journal of biological chemistry 19970207

• A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

  Cell 19951201

• Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress.

  Molecular endocrinology (Baltimore, Md.)

• PPARgamma-dependent regulation of adenylate cyclase 6 amplifies the stimulatory effect of cAMP on renin gene expression.

  Molecular endocrinology (Baltimore, Md.)